pyrroles has been researched along with simvastatin in 827 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 55 (6.65) | 18.2507 |
| 2000's | 531 (64.21) | 29.6817 |
| 2010's | 236 (28.54) | 24.3611 |
| 2020's | 5 (0.60) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, Y; Ballantyne, CM; Dunn, K; Gotto, AM; Hackman, A; Insull, W; Pownall, H; Smith, L | 1 |
| Firth, JC; Marais, AD; Mountney, J; Naoumova, RP; Rendell, NB; Taylor, GW; Thompson, GR | 1 |
| Best, J; Black, D; Bracs, P; d'Emden, M; Dart, A; Hamilton-Craig, I; Jerums, G; Nicholson, G; Sullivan, D; Tallis, G; West, M | 1 |
| Roberts, WC | 1 |
| Baetta, R; Calore, M; Comparato, C; Donetti, E; Fumagalli, R; Paoletti, R; Rossi, A; Soma, MR; Teruzzi, C | 1 |
| Calder, RA | 1 |
| Bergstrom, JD; Bostedor, RG; Chao, YS; Geissler, WM; Rew, DJ; Wright, SD | 1 |
| Hunninghake, D; Jones, P; Kafonek, S; Laurora, I | 1 |
| Lane, M; Laskarzewski, P; Stein, EA | 1 |
| Celermajer, DS; Simons, J; Simons, LA; Sullivan, D | 1 |
| Díaz, C; Hernández, G; Hernández-Perera, O; Lamas, S; Navarro-Antolín, J; Pérez-Sala, D; Sánchez-Pascuala, R | 1 |
| Black, DM; Mahla, G; Muller, D; Pentrup, A; Wolffenbuttel, BH | 1 |
| Adzet, T; Alegret, M; Díaz, C; Hernández, G; Laguna, JC; Sánchez, RM; Verd, JC | 1 |
| Crook, MA; Lumb, PJ; Semra, YK; Wierzbicki, AS | 1 |
| Wehmeier, T; Ziajka, PE | 1 |
| Simons, LA | 1 |
| de Bont, N; Demacker, PN; Netea, MG; Rovers, C; Smilde, T; Stalenhoef, AF; van der Meer, JW | 1 |
| Pincus, J | 1 |
| Bakker-Arkema, RG; Black, DM; Brown, AS; Campbell, CF; Guthrie, R; Henley, RW; Koren, M; McLain, R; Woo, W; Yellen, L | 1 |
| Ballantyne, CM; Jacobson, TA; Schein, JR; Williamson, A | 1 |
| D'Agostino, RB; Ellison, RC; Hartz, SC; Huse, DM; Kraemer, DF; Miller, JD; Russell, MW | 1 |
| Strandberg, TE; Tikkanen, MJ; Vanhanen, H | 2 |
| Dietz, BL; Oberg, KC | 1 |
| Hoogerbrugge, N | 1 |
| Geiss, HC; Parhofer, KG; Schwandt, P | 1 |
| Bakker-Arkema, RG; Black, DM; Davidson, MH; Henley, RW; Hunninghake, DB; Koren, MJ; McKenney, JM; McLain, RW; Schrott, HG; Smith, DG; Tresh, P; Weiss, SR | 1 |
| Assang, C; Baillie, TA; Lin, JH; Lu, P; Ma, B; Meng, Y; Prueksaritanont, T; Reider, PJ; Tang, C | 1 |
| Crouse, JR; Frohlich, J; Mercuri, M; Ose, L; Tobert, JA | 1 |
| Bataille, L; Hamoir, V; Horsmans, Y; Nakad, A; Sempoux, C | 1 |
| Barrett, PH; Huff, MW; Wilcox, LJ | 1 |
| Alfon, J; Badimon, L; Pueyo Palazon, C; Royo, T | 1 |
| Frane, AM; Gantner, SE; Joyce, DM; Kersten, ME; Murdock, AK; Murdock, DK; Murdock, RW; Olson, KJ | 1 |
| Klein, G; März, W; Neiss, A; Wehling, M; Wollschläger, H | 1 |
| Kostner, GM | 1 |
| Kostner, KM | 1 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
| Blanco-Colio, LM; Egido, J; Guijarro, C; Kasiske, BL; Keane, WF; Massy, ZA; O'Donnell, MP | 1 |
| Frohlich, BH; Gregg, RE; Tesfamariam, B | 1 |
| Dominiczak, MH; Murphy, MJ | 1 |
| Adzet, T; Alegret, M; Díaz, C; Hernández, G; Laguna, JC; Peris, C; Sánchez, RM; Vázquez, M; Verd, JC | 1 |
| Jonkers, GH | 1 |
| Conde, K; Fernandez, ML; Newton, RS; Pineda, G | 1 |
| Alfon, J; Badimon, L; Berrozpe, M; Guasch, JF | 1 |
| Branchi, A; Fiorenza, AM; Macor, S; Muzio, F; Rovellini, A; Sommariva, D; Torri, A | 1 |
| Barrett, PH; Burnett, JR; Huff, MW; Kleinstiver, SJ; Newton, RS; Telford, DE; Wilcox, LJ | 1 |
| Attanasio, E; Badia, X; Russo, P | 1 |
| Bäumer, AT; Böhm, M; Jockenhövel, F; Kebben, D; Nickenig, G; Temur, Y | 1 |
| Farnier, M | 1 |
| Joffe, BI; Kotze, MJ; Pilcher, GJ; Raal, FJ; Veller, MG | 1 |
| Elkin, RG; Yan, Z | 1 |
| Chik, G; Christ, ER; Crook, MA; Lumb, PJ; Semra, Y; Wierzbicki, AS | 1 |
| Hoshi, K; Ichihara, K; Satoh, K; Yamamoto, A | 1 |
| Conde, K; Fernandez, ML; Freake, HC; Newton, RS; Roy, S | 1 |
| Baetta, R; Bellosta, S; Bernini, F; Corsini, A; Fumagalli, R; Paoletti, R | 1 |
| Ichihara, K; Satoh, K | 1 |
| Farnier, M; Maigret, P; Portal, JJ | 1 |
| Chik, G; Crook, MA; Lumb, PJ; Wierzbicki, AS | 3 |
| Bakker-Arkema, RG; Black, DM; Nawrocki, JW | 1 |
| Barter, PJ; O'Brien, RC | 1 |
| Chan, M; Giannetti, N; Hayashi, S; Hunt, SA; Kato, T; Kobayashi, T; Morimoto, S; Namii, Y; Tokoro, T; Yokoyama, I | 1 |
| Auch-Schwelk, W; Elsner, M; Mach, S; Schächinger, V; Walter, DH; Zeiher, AM | 1 |
| Barbagallo, M; Barbieri, M; Giordano, M; Paolisso, G; Petrella, G; Ragno, E; Varricchio, M | 1 |
| Arikian, S | 1 |
| Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; van den Berkmortel, FW; van Langen, H; Wollersheim, H | 1 |
| Arnaboldi, L; Bellosta, S; Bernini, F; Corsini, A; Ferri, N; Paoletti, R | 1 |
| Blair, SN; Capuzzi, DM; Cater, NB; Gottlieb, SO; Morgan, JM; Nguyen, T | 1 |
| Mikhailidis, DP; Wierzbicki, AS | 2 |
| Donner, MG; Geiss, HC; Otto, C; Parhofer, KG; Schwandt, P | 1 |
| Crouse, JR; Davidson, MH; Dujovne, CA; Frohlich, J; Habib, R; Hunninghake, DB; Isaacsohn, JL; Kastelein, JJ; Liu, M; Melino, MR; Mercuri, M; Mitchel, YB; O'Grady, L; Ose, L | 1 |
| Dansette, PM; Jaoen, M; Pons, C | 1 |
| Huang, J; Kiener, PA; Knapp, AC; Starling, G | 1 |
| Acosta, S; Dobs, A; Recto, CS | 1 |
| Brown, WV | 1 |
| Cromwell, WC; Ziajka, PE | 1 |
| Dotani, MI; Elnicki, DM; Gibson, CM; Jain, AC | 1 |
| Ose, L; Risberg, K; Svilaas, A; Thoresen, M | 1 |
| Davidson, MH | 2 |
| Stein, EA | 2 |
| Black, DM | 1 |
| Aspichueta, P; Díaz, C; Hernández, G; Hernández, ML; Isusi, E; Liza, M; Martínez, MJ; Ochoa, B | 1 |
| Elisaf, M; Miltiadous, G; Tsimihodimos, V | 1 |
| Crouch, MA | 1 |
| Dorner, GT; Joukhadar, C; Klein, N; Prinz, M; Schmetterer, L; Schrolnberger, C; Vukovich, T; Wolzt, M | 1 |
| Harangi, M; Paragh, G | 1 |
| Celada Rodríguez, A; Cerdán Oliver, M; de Miguel Clavé, J; Ocaña López, JM; Solera Albero, J; Tárraga López, PJ | 1 |
| Agrusta, M; Amodio, M; Corigliano, G; De Simone, G; Gaeta, I; Gentile, S; Guarino, G; Magliano, P; Oliviero, B; Salvatore, T; Sasso, CF; Torella, R; Turco, S | 1 |
| Goldner, D; Insull, W; Kafonek, S; Zieve, F | 1 |
| Rosenson, RS; Schaefer, EJ; Tangney, CC | 1 |
| Allen, SE; Attanasio, E; Russo, P | 1 |
| Adams-Huet, B; Balis, D; Devaraj, S; Grundy, SM; Jialal, I; Stein, D | 1 |
| Hilleman, DE; Lenz, TL; Wurdeman, RL | 1 |
| Beinlich, CJ; Ichihara, K; Morgan, HE; Satoh, K; Shirota, F; Tsunajima, T | 1 |
| Bo, M; Fabris, F; Fiandra, U; Mercadante, G; Nicolello, MT; Piliego, T | 1 |
| Lupattelli, G; Palumbo, B; Sinzinger, H | 1 |
| Maclaine, GD; Patel, H | 1 |
| Farnier, M; Mercuri, M; Stein, EA; Waldstreicher, J | 1 |
| Berra, C; Branchi, A; Colombo, E; Dalla Valle, E; Fiorenza, AM; Muzio, F; Rovellini, A; Sommariva, D; Torri, A | 1 |
| Ito, MK | 1 |
| Crouse, JR; Davidson, MH; Escobar, ID; Hunninghake, DB; Illingworth, DR; Liu, M; Ma, PT; Melino, MR; Mercuri, M; Mitchel, YB; O'Grady, L; Paragh, G; Stalenhoef, AF | 1 |
| Wierzbicki, AS | 2 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, E | 1 |
| Hamakubo, T; Inoue, K; Kitahara, M; Kodama, T; Morikawa, S; Nakagawa, S; Saito, Y; Suganami, H; Umetani, M; Yamazaki, H | 1 |
| Susekov, AV | 1 |
| Young, JH | 1 |
| Crook, MA; Mikhalidis, DP; Reynolds, TM; Wierzbicki, AS | 1 |
| Andrews, TC; Ballantyne, CM; Hsia, JA; Kramer, JH | 1 |
| Durrington, PN | 1 |
| Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S; Wollersheim, H | 1 |
| Auer, J; Eber, B | 1 |
| Conradie, MM; Gopal, R; Hough, S; Hulley, PA; Maritz, FJ | 1 |
| Igel, M; Sudhop, T; von Bergmann, K | 1 |
| Keller, U; Mirsaidi, R; Miserez, AR | 1 |
| Griffin, BP; Lauer, MS; Novaro, GM; Pearce, GL; Sprecher, DL; Tiong, IY | 1 |
| Bazalo, GR | 1 |
| Hsyu, PH; Kerr, BM; Lewis, RH; Lillibridge, JH; Schultz-Smith, MD | 1 |
| Gierens, H; März, W; Nauck, M; Scharnagl, H; Schinker, R; Wieland, H | 1 |
| Bruegel, M; Stein, O; Stein, Y; Teupser, D; Thiery, J | 1 |
| Chen, HJ; Joseph, J; Li, DY; Mehta, JL; Romeo, F | 1 |
| Adams-Huet, B; Balis, D; Devaraj, S; Jialal, I; Stein, DT | 1 |
| Altamura, L; Chiariello, L; Crea, F; Gaspardone, A; Gioffrè, PA; Proietti, I; Tomai, F; Versaci, F | 1 |
| Castle, SS; Duncan, MC; Streetman, DS | 1 |
| Aberg, JA; Alston, B; Aweeka, F; Blaschke, T; Fang, F; Fichtenbaum, CJ; Gerber, JG; Kosel, B; Rosenkranz, SL; Segal, Y | 1 |
| Blanco-Colio, LM; Egido, J; Hernández-Presa, MA; Ortego, M; Pascual, A; Plaza, JJ; Villa, A | 1 |
| Karalis, DG; Ross, AM; Scott, R; Vacari, RM; Zarren, H | 1 |
| Bradley, M; Chong, C; Kelly, S | 1 |
| Böhm, M; Kilter, H; Konkol, C; Laufs, U; Nickenig, G; Wassmann, S | 1 |
| Arnesen, H; Hjermann, I; Seljeflot, I; Tonstad, S | 2 |
| Baillie, TA; Fang, X; Lin, JH; Ma, B; Pearson, PG; Prueksaritanont, T; Qiu, Y; Subramanian, R | 1 |
| Hurt-Camejo, E; Mattsson-Hultén, L; Oscarsson, J; Wiklund, O | 1 |
| Piliero, PJ | 1 |
| Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN | 1 |
| Moon, A; Smith, T | 1 |
| Abourjaily, HM; Alsheikh-Ali, AA; Karas, RH | 2 |
| Bruckert, E; Gagné, C; Gaudet, D | 1 |
| Auteri, A; Bova, G; Bruni, F; Cercignani, M; Console, E; Palazzuoli, A; Pasqui, AL; Puccetti, L | 1 |
| Hinman, J; Scanu, AM | 1 |
| Adzet, T; Alegret, M; Díaz, C; Hernández, G; Laguna, JC; Peris, C; Roglans, N; Sánchez, RM; Vázquez, M; Verd, JC | 1 |
| Chen, H; Li, D; Mehta, JL; Romeo, F; Saldeen, T; Sawamura, T | 1 |
| Blanco-Colio, LM; Bustos, C; Egido, J; Hernández, AG; Hernández-Presa, MA; Ortego, M; Tuñón, J | 1 |
| Chapman, MJ; Doucet, C; Gonbert, S; Laouenan, H; Malinsky, S; Sposito, AC; Thillet, J | 1 |
| Asztalos, BF; Horvath, KV; McNamara, JR; Roheim, PS; Rubinstein, JJ; Schaefer, EJ | 1 |
| Hin, AT; Lee, YT; Suyono, S; Sy, R; Tanphaichitr, V; Wu, CC | 1 |
| Bannykh, S; England, JD; Gray, NL; Haas, RH; Hathaway, S; Kimura, BJ; Phillips, PS; Vladutiu, GD | 1 |
| Jonasson, L; Linderfalk, C; Olsson, AG; Schwartz, GG | 1 |
| Lin, JH; Mu, L; Prueksaritanont, T; Qiu, Y; Subramanian, R; Tang, C | 1 |
| Ahmad, S; Ahmed, Z; Bhatia, V; Haskard, DO; Kinderlerer, A; Lidington, EA; Mankoff, R; Mason, JC; Randi, AM | 1 |
| Nordøy, A | 1 |
| Chmielewski, M; Rutkowski, B; Zdrojewski, Z | 1 |
| de Graaf, J; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S | 1 |
| Bavendiek, U; Ganz, P; Gerdes, N; Horton, DB; Kinlay, S; Libby, P; Reynolds, RS; Robbie, L; Schönbeck, U; Varo, N | 1 |
| Chasiotis, G; Elisaf, M; Miltiadous, G; Papakostas, J; Seferiadis, K | 1 |
| Frolkis, JP; Minor, S; Nambi, V; Pearce, GL; Sprecher, DL | 1 |
| Harman, SM; Hecht, HS | 1 |
| Alber, HF; Ares, MP; Dichtl, W; Dulak, J; Frick, M; Nilsson, J; Pachinger, O; Schwarzacher, SP; Weidinger, F | 1 |
| Sinzinger, H | 1 |
| Angori, P; Auteri, A; Bova, G; Bruni, F; Cercignani, M; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Puccetti, L | 1 |
| Aukrust, P; Frøland, SS; Gullestad, L; Kastelein, JJ; Pedersen, TR; Semb, AG; Smilde, T; Stalenhoef, AF; Tripp, MD; Ueland, T; van Wissen, S; Waehre, T | 1 |
| Derhaschnig, U; Dorner, GT; Jilma, B; Joukhadar, C; Petternel, V; Rassoul, F; Richter, V; Wagner, OF; Wolzt, M | 1 |
| Gylling, H; Lindbohm, N; Miettinen, TA; Miettinen, TE; Rajaratnam, RA; Relas, H | 1 |
| Brady, TJ; Derfler, K; Haas, M; Hoffmann, U; Kostner, K; Stadler, A | 1 |
| Krane, V; Wanner, C | 1 |
| Hutten, BA; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S | 1 |
| Bays, HE; Crouse, JR; Dujovne, CA; Hutcheson, AG; Kashyap, ML; McGovern, ME; White, TE | 1 |
| Eriksson, M; Johnson, O; Kjellström, T; Lanke, J; Larsen, ML; Olsson, AG; Pedersen, T; Tikkanen, MJ; Wiklund, O | 1 |
| Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M | 1 |
| Blasetto, JW; Brown, WV; Chitra, R; Raza, A; Stein, EA | 1 |
| Barter, P; Hunninghake, DB; Hutchinson, HG; McKenney, JM; Shepherd, J | 2 |
| Caplan, RJ; Davidson, MH; Pears, JS; Rader, DJ | 1 |
| Fuller, S; Gillen, D; Lacey, L; Marriott, J; Wilson, K | 1 |
| McBurney, CR; Smith, DG | 1 |
| Bolaman, Z; Kadikoylu, G; Yavasoglu, I; Yukselen, V | 1 |
| Clark, LT | 1 |
| Amano, Y; Imura, Y; Ishikawa, E; Nishimoto, T; Sugiyama, Y; Tozawa, Ri | 1 |
| Aoki, T; Kitahara, M; Saito, Y; Sato, F; Tamaki, T; Yamazaki, H | 1 |
| Arnesen, KE; Aukrust, P; Damås, JK; Frøland, SS; Gullestad, L; Holm, AM; Pedersen, TR; Semb, AG; Torsvik, H; Waehre, T | 1 |
| Oguogho, A; Sinzinger, H | 1 |
| Belowski, D; Herman, ZS; Kalina, Z; Kowalski, J; Madej, A; Okopień, B; Zieliński, M | 1 |
| Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL | 1 |
| Sudhop, T; von Bergmann, K | 1 |
| Aoki, T; Kitahara, M; Maejima, T; Saito, Y; Sato, F; Yamazaki, H | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Davidson, MH; Jones, PH; McKenney, JM; Miller, E; Stein, EA | 1 |
| Huang, Q; Parker, RA; Tesfamariam, B | 1 |
| Ballantyne, CM; Gumbiner, B; Hunninghake, DB; Maccubbin, DL; Mitchel, YB; Shah, AK | 1 |
| de Boo, T; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S | 1 |
| Khadipash, LA; Kiseleva, NV; Kosmatova, OV; Mamedov, MN; Oganov, RG; Perova, NV | 1 |
| Akhmedzhanov, NM; Metel'kaya, VA; Oganov, RG; Raszzivin, VA; Vasiutina, EI | 1 |
| Abud-Mendoza, C; Baranda, L; Cruz-Rizo, J; Cuevas-Orta, E; de la Fuente, H; González-Amaro, R | 1 |
| Blanco-Colio, LM; Díaz, C; Egido, J; Hernández, G; Lorz, C; Martín-Ventura, JL; Muñoz-García, B | 1 |
| Chasiotis, G; Elisaf, MS; Kakafika, A; Milionis, HJ; Papakostas, J; Seferiadis, K | 1 |
| Fink, LM; Hauer-Jensen, M; Joseph, J; Li, D; Lin, P; Ling, W; Mehta, JL; Ponnappan, U; Shi, J; Wang, J; Zheng, H | 1 |
| Burger, F; Graber, P; Kwak, BR; Lüscher, TF; Mach, F; Matter, CM; Mulhaupt, F; Pelli, G; Veillard, NR | 1 |
| Jones, JK | 1 |
| Ballantyne, CM; Blazing, MA; Davidson, MH; DeLucca, P; Hunninghake, DB; Hustad, CM; Palmisano, J; Ramsey, KE; Yuan, Z | 1 |
| Bays, HE; McGovern, ME | 2 |
| Alber, H; Cisowski, J; Dichtl, W; Dulak, J; Frick, M; Józkowicz, A; Pachinger, O; Schwarzacher, SP; Weidinger, F; Zwick, R | 1 |
| Bertolami, MC; Cihon, F; Davidson, MH; Dujovne, CA; Escobar, ID; Frohlich, J; Maccubbin, DL; Mercuri, M; Ose, L; Scott, RS | 1 |
| Isomustajärvi, M; Laakso, J; Laaksonen, R; Lakka, TA; Lehtimäki, T; Päivä, H; Ruokonen, I; Salonen, JT; Valkonen, VP | 1 |
| Bolaman, Z; Kadikoylu, G | 1 |
| de Groot, E; Hutten, BA; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; van Wissen, S | 1 |
| Antonini-Canterin, F; Cervesato, E; Granata, G; Nicolosi, GL; Pavan, D; Piazza, R; Popescu, BA; Zuppiroli, A | 1 |
| Aicher, A; Badorff, C; Dimmeler, S; Fichtlscherer, S; Koyanagi, M; Rupp, S; Urbich, C; Zeiher, AM | 1 |
| Adamczyk, MA; Blasetto, JW; Bryzinski, BS; Cain, VA; Jones, PH; McKenney, JM | 1 |
| Harrell, TK; Jones, DW; King, DS; Lindley, BJ; Wilburn, AJ; Wofford, MR | 1 |
| Aleo, E; Dmitrieva, A; Littarru, GP; Passi, S; Stancato, A | 1 |
| Daly, JA; Ferrari, A; Gleason, JL; McNamara, JR; Rubenstein, JJ; Schaefer, EJ; Seman, LJ; Tayler, T | 1 |
| Berger, T; Daniel, WG; Garlichs, CD; Ludwig, J; Raaz, D; Reiss, C; Steinkasserer, A; Stumpf, C; Tantawi, O; Weng, A; Yilmaz, A | 1 |
| Blasetto, J; Caplan, R; Dane, A; Hutchison, H; Strutt, K | 1 |
| Davalos, A; Fisher, M | 1 |
| März, W | 1 |
| Kröger, K; Wittlinger, T | 1 |
| Edwards, JE; Moore, RA | 1 |
| de Maat, MM; de Rooij, BJ; Kleemann, R; Kooistra, T; Lindeman, J; Princen, HM; Szalai, AJ; Verschuren, L | 1 |
| Mach, F | 1 |
| Andrus, MR | 1 |
| Blennow, K; Eikenberg, O; Höglund, K; Vanderstichele, H; Vanmechelen, E; Wiklund, O | 1 |
| Horiuchi, S; Iida, KT; Matsuzaka, K; Nakagawa, Y; Nakakuki, M; Okazaki, H; Sakai, M; Sakamoto, Y; Shimano, H; Shu, M; Sone, H; Suzuki, H; Takahashi, A; Toyoshima, H; Yamada, N; Yokoo, T | 1 |
| Fang, CH; Li, JJ | 1 |
| Aukrust, P; Damås, JK; Frøland, SS; Gullestad, L; Haug, T; Semb, AG; Smith, C; Tunheim, SH; Waehre, T; Yndestad, A | 1 |
| de Grooth, GJ; Fruchart, JC; Kastelein, JJ; Klerkx, AH; Kuivenhoven, JA; Smilde, TJ; Stalenhoef, AF; Van Wissen, S; Zwinderman, AH | 1 |
| Tellier, P | 1 |
| Cressman, MD; Harris, S; Hutchinson, HG; Pears, JS; Vidt, DG | 1 |
| Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C | 1 |
| Cording, SA; Newnham, HH; Rando, LP | 1 |
| Andreassen, AK; Aukrust, P; Gullestad, L; Hognestad, A; Holm, T; Kjekshus, JK; Semb, AG; Stokke, O; Wergeland, R | 1 |
| Clark, DS; Gerber, R; Ryan, JD | 1 |
| Mück, AO; Seeger, H; Wallwiener, D | 1 |
| Fujisaki, K; Itoh, Y; Kubota, T; Oishi, R; Sendo, T; Yano, T | 1 |
| Alsheikh-Ali, AA; Karas, RH | 3 |
| Berry, DC; Knapp, P; Raynor, DK | 1 |
| Bernier, L; Chamberland, A; Davignon, J; Dubuc, G; Prat, A; Seidah, NG; Wassef, H | 1 |
| Mason, P | 1 |
| Ammann, P; Fehr, T; Fierz, W; Joller-Jemelka, HI; Kahlert, C; Rickli, H; Riesen, WF; Wüthrich, RP | 1 |
| Ballantyne, CM; Blazing, MA; Brady, WE; King, TR; Palmisano, J | 1 |
| Bell, PR; Loftus, IM; Molloy, KJ; Naylor, AR; Schwalbe, EC; Thompson, MM | 1 |
| de Graaf, J; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; van Tits, LJ; van Wissen, S | 1 |
| Eichelbaum, M; Fromm, MF; Kivistö, KT; Niemi, M; Pitkälä, K; Schaeffeler, E; Schwab, M; Strandberg, T; Tilvis, R | 1 |
| Dimmeler, S; Haendeler, J; Hoffmann, J; Zeiher, AM | 1 |
| Levenson, D | 1 |
| Balogh, Z; Harangi, M; Illyés, L; Kovács, P; Paragh, G; Seres, I; Törocsik, D | 1 |
| Chan, WB; Chow, CC; Ko, GT; Ma, RC; Osaki, R; So, WY; Yeung, VT | 1 |
| Bendiksen, FS; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Palmer, G; Pedersen, TR; Tikkanen, MJ | 1 |
| Athyros, VG; Bairaktari, ET; Elisaf, MS; Kakafika, AI; Milionis, HJ; Seferiadis, KI; Tsouli, SG | 1 |
| Hochman, JH; Lin, JH; Prueksaritanont, T; Pudvah, N; Qiu, J; Tang, C; Yamazaki, M | 1 |
| Manolopoulos, VG; Tavridou, A | 1 |
| Jacobson, TA | 1 |
| Das, V; Shrivastava, R; Singh, S | 1 |
| Gawaz, M; Gorchakova, O; Joost, A; Kastrati, A; Mocz, A; Schömig, A; von Beckerath, N | 1 |
| Klose, G | 1 |
| Blasetto, JW; Caplan, RJ; Ferdinand, KC; Gold, A; Hunninghake, DB; Jones, PH; Stein, EA | 1 |
| Bhalodkar, NC; Brown, DL; Brown, EJ; Kaplan, RC; White, J | 1 |
| Laskowitz, DT; Lynch, JR; McGirt, MJ; Woodworth, GF | 1 |
| Couture, P; Lamarche, B; Mauger, JF; Paradis, ME | 1 |
| Busso, N; Chobaz, V; Gabay, C; Palmer, G; So, A; Talabot-Ayer, D; Taylor, S | 1 |
| Cartwright, MS; Donofrio, PD; Jeffery, DR; Nuss, GR | 1 |
| Deng, Y; DeRose, RA; Farber, SA; Ho, SY; Santana, E; Thorpe, JL | 1 |
| Adams, GJ; Ballantyne, CM; Greene, J; Harrist, R; Insull, W; Karmonik, C; Kimball, KT; Morrisett, JD; Vick, GW | 1 |
| Baghestanian, M; Bucek, RA; Minar, E; Pourazim, A; Reiter, M; Wirth, S | 1 |
| Campbell, SD; Chen, C; Lin, J; Mills, JB; Mireles, RJ; Smolarek, TA; Xu, JJ | 1 |
| Carter, TL; Ehrlich, ME; Gandy, S; Pedrini, S; Petanceska, S; Prendergast, G | 1 |
| Hasegawa, R; Hirata-Koizumi, M; Miyake, S; Saito, M; Urano, T | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Deedwania, PC; Hunninghake, DB; Jones, PH | 1 |
| Sawicki, PT; Weizel, A | 1 |
| Abe, K; Deguchi, K; Hayashi, T; Nagano, I; Nagotani, S; Sato, K; Shoji, M; Zhang, W | 1 |
| Ganda, OP | 1 |
| Hirsch, M; Jones, P; O'Donnell, JC | 1 |
| Amin-Hanjani, S; Asahi, M; Huang, PL; Huang, Z; Liao, JK; Lo, EH; Mori, T; Moskowitz, MA; Qiu, J; Sumii, T; Thomas, S; Yoshimura, S | 1 |
| Ahotupa, M; Nuotio, I; Strandberg, T; Tikkanen, MJ; Vanhanen, H; Vasankari, T; Viikari, J; Vuorenmaa, T | 1 |
| Hess, L; Krähenbühl, S; Krähenbühl-Melcher, A; Rätz Bravo, AE; Schlienger, RG; Tchambaz, L | 1 |
| Chan, JC; Cheng, CW; Tomlinson, B; Woo, KS; You, JH | 1 |
| Judge, HM; Peters, G; Smith, SM; Storey, RF | 1 |
| Ahotupa, M; Gylling, H; Miettinen, T; Nuotio, I; Strandberg, T; Tikkanen, MJ; Vanhanen, H; Vasankari, T; Viikari, J | 1 |
| Carmina, E; Castello, F; Di Fede, G; Mansueto, P; Rini, GB; Rizzo, M | 1 |
| Arnaud, C; Burger, F; Mach, F; Nguyen, TH; Steffens, S; Trono, D; Veillard, NR | 1 |
| Gibb, H; Scialli, AR | 1 |
| Geiss, HC; Hund-Wissner, E; Otto, C; Parhofer, KG | 1 |
| Cheung, RC; Kallend, D; Morrell, JM; Schuster, H; Watkins, C | 1 |
| Abrahamowicz, M; Austin, PC; Eisenberg, MJ; Humphries, K; Pilote, L; Rahme, E; Tu, JV; Zhou, Z | 1 |
| Bhatt, DL; Karha, J | 1 |
| Almeida, EA; Carneiro, A; Jorge, M; Jorge, PA; Ozaki, MR | 1 |
| Battisti, WP; Brady, WE; Denke, MA; McBride, PE; Palmisano, J; Pearson, TA | 1 |
| Jones, P; Miller, PS; Smith, DG | 1 |
| Iwano, C; Matsuyama, K; Matzno, S; Nishikata, M; Yasuda, N | 1 |
| Barter, P; Kallend, D; Schuster, H; Stender, S; Watkins, C | 1 |
| Chiba, K; Hosokawa, M; Kameyama, Y; Kobayashi, K; Yamashita, K | 1 |
| Aberg, JA; Alston, BL; Brobst, SW; Fichtenbaum, CJ; Gerber, JG; Rosenkranz, SL; Segal, Y; Vega, JM; Yang, A | 1 |
| De Paepe, B; Laakso, J; Laaksonen, R; Lehtimäki, T; Lütjohann, D; Mattila, KM; Päivä, H; Smet, J; Thelen, KM; Van Coster, R; von Bergmann, K | 1 |
| Braunwald, E; Cannon, CP; Murphy, SA | 1 |
| de Graaf, J; Lemmers, HL; Stalenhoef, AF; van Himbergen, TM; van Tits, LJ | 1 |
| Miyashita, Y; Murano, T; Oyama, T; Saiki, A; Shirai, K; Watanabe, F | 1 |
| Abildstrom, SZ; Buch, P; Friberg, J; Gislason, GH; Gustafsson, I; Køber, L; Madsen, M; Rasmussen, JN; Rasmussen, S; Stender, S; Torp-Pedersen, C | 1 |
| Bergman, M; Bessler, H; Djaldetti, M; Salman, H; Straussberg, R | 1 |
| Albertini, JP; Charniot, JC; Hantz, E; Le Moyec, L; Valensi, P | 1 |
| Elisaf, MS; Milionis, HJ | 1 |
| Corpataux, JM; London, NJ; Naik, J; Porter, KE | 1 |
| Asberg, A; Hermann, M; Holdaas, H; Lemahieu, WP; Maes, BD; Vanrenterghem, Y; Verbeke, K | 1 |
| McKenney, JM | 1 |
| Boehlen, F; Daali, Y; de Moerloose, P; Fontana, P; Mach, F; Reber, G; Senouf, D; Sigwart, U | 1 |
| Damkier, P; Hallas, J; Korsholm, L; Kristensen, SR; Mickley, H; Poulsen, TS; Vinholt, P | 1 |
| Crisby, M; Lindberg, C; Schultzberg, M; Winblad, B | 1 |
| Cannon, CP; Ray, KK | 1 |
| Waters, DD | 1 |
| Basha, SJ; Mullangi, R; Muzeeb, S; Pasha, MK; Shashikumar, D; Srinivas, NR | 1 |
| Chiou, KR; Huang, WC; Lin, SL; Liu, CP; Shiang, JC; Wu, SC; Wu, TL | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Kostka, B; Marczyk, I; Michalska, M; Sikora, J | 1 |
| Adinaro, J; Beck, R; Doeppenschmidt, D; Henry, JS; Krasuski, RA; Smith, PB; Thompson, CM | 1 |
| Field, KM | 1 |
| Baldassarre, S; Carpentier, YA; Deckelbaum, RJ; Ducobu, J; Dupont, IE; Scruel, O | 1 |
| Dieleman, JP; Dunselman, H; Straus, SM; Sturkenboom, MC; van Herpen, G; van Wijk, MA; van Wyk, JT | 1 |
| Aukrust, P; Boullier, A; Damås, JK; Green, S; Quehenberger, O; Sandberg, WJ; Smith, C; Waehre, T | 1 |
| Davidson, M | 1 |
| de Graaf, J; Himbergen, TM; Roest, M; Stalenhoef, AF; van Tits, LJ; Voorbij, HA | 1 |
| Ferns, GA; Ghayour-Mobarhan, M; Lamb, DJ; Livingstone, C; Taylor, A; Vaidya, N; Wang, T | 1 |
| Phillips, PS | 1 |
| Bergman, M; Bessler, H; Djaldetti, M; Salman, H | 3 |
| Ichihara, K; Kanda, M; Kasai, T; Keimatsu, N; Satoh, K; Sun, F; Takaguri, A | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Bendiksen, FS; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Szarek, M; Tikkanen, MJ; Tsai, J | 1 |
| Cannon, CP | 1 |
| Briestensky, J; Jamborova, G; Jaynes, R; Kopecky, M; Nachtigal, P; Pospechova, K; Pospisilova, N; Santar, I; Semecky, V; Smahelova, A; Solichova, D; Zdansky, P | 1 |
| Allen, C; Amabile, N; Barrios, V; Chen, JW; Johnson-Levonas, AO; Massaad, R; Paganelli, F; Vandormael, K | 1 |
| Bots, AF; Kastelein, JJ | 1 |
| Babkin, AA; Iliukhin, OV; Kalganova, EL; Lopatin, IuM | 1 |
| Ahumada, M; Arcas, R; Arribas, JM; Gomez-Plana, J; Marín, F; Martínez, P; Oliver, C; Pascual, DA; Tornel, PL; Valdes, M | 1 |
| Ballantyne, CM; Brady, WE; Davies, MJ; Feldman, TA; McKenney, J; Mitchel, YB; Palmisano, J; Shah, A | 1 |
| Graselli, U; Joukhadar, C; Kostner, K; Lackner, E; Thallinger, C; Urbauer, E; Wolzt, M | 1 |
| Jadhav, SB; Jain, GK | 1 |
| Borges, JL | 1 |
| Crespo, MJ; Quidgley, JA | 1 |
| Kilkki, E; Kivistö, KT; Niemi, M; Soininen, K; Strandberg, T | 1 |
| Aronow, WS; Babu, S; Kakar, P; Sandhu, R; Sukhija, R | 1 |
| Pilote, L; Rahme, E; Zhou, Z | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Franiak, I; Koter-Michalak, M | 1 |
| Auberger, P; Bouvet, S; Fromigué, O; Haÿ, E; Jacquel, A; Marie, PJ; Modrowski, D | 1 |
| de Bont, N; Demacker, PN; Hijmans, A; Netea, MG; Rovers, C; Smilde, T; Stalenhoef, AF; van der Meer, JW | 1 |
| Braun, SL; Guha-Ray, DK; Penn, R; Rains, KT; Sawyers, WG; Williams, RX | 1 |
| Scheen, AJ | 1 |
| Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V | 1 |
| Rosenson, RS | 1 |
| Haghfelt, TH | 1 |
| Dincer, I; Erol, C; Ertas, F; Ongun, A; Ozdol, C; Turhan, S | 1 |
| Bax, JJ; Boersma, E; Dunkelgrün, M; Feringa, HH; Koning, J; Poldermans, D; Schouten, O; van Laanen, JH; van Urk, H; Vidakovic, R | 1 |
| Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Demyanets, S; Hohensinner, PJ; Huber, K; Kaun, C; Maurer, G; Pammer, J; Pfaffenberger, S; Rega, G; Wojta, J | 1 |
| Brown, BG | 1 |
| Castilla-Guerra, L; Espino-Montoro, A; Fernandez Moreno, Mdel C; Jimérnez, MD; López-Chozas, JM | 1 |
| Boerma, M; Burton, GR; Fink, LM; Hauer-Jensen, M; McGehee, RE; Wang, J | 1 |
| Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Otsuka, Y | 1 |
| Chow, SC; Coward, WR; Marei, A; Vasa-Nicotera, MM; Yang, A | 1 |
| Galin, ID; Smith, DA | 1 |
| Ballantyne, CM; Bertolami, M; Cain, VA; Hernandez Garcia, HR; Nul, D; Raichlen, JS; Stein, EA; Theroux, P; Weiss, R | 1 |
| Bruckert, E; Carreau, V; Chauvenet, M; Faltaos, DW; Giral, P; Hulot, JS; Lechat, P; Urien, S | 1 |
| Celinska-Löwenhoff, M; Löwenhoff, T; Szczeklik, A; Undas, A | 1 |
| Fujita, T; Hirata, Y; Matsumoto, A; Matsumura, T; Nagai, R; Ohno, M; Ohta, M; Suzuki, E; Suzuki, S; Takenaka, K | 1 |
| Dörge, H; Grabedünkel, J; Liakopoulos, OJ; Nagorsnik, U; Schmitto, JD; Schoendube, FA | 1 |
| Cheah, JS; Ong, HT | 1 |
| Cayley, WE | 1 |
| Ravnskov, U; Rosch, PJ; Sutter, MC | 1 |
| Mann, SJ | 1 |
| Burns, MP; Duff, K; Igbavboa, U; Wang, L; Wood, WG | 1 |
| Berneis, K; Rizzo, M | 1 |
| Plans-Rubió, P | 1 |
| Buerke, M; Hennen, R; Keller, A; Müller-Werdan, U; Russ, M; Schmidt, H; Werdan, K | 1 |
| Bucek, RA; Minar, E; Pourazim, A; Reiter, M; Wirth, S | 1 |
| Allemann, C; Babiychuk, EB; Draeger, A; Hoppeler, H; Mohaupt, M; Monastyrskaya, K; Savolainen, H | 1 |
| Busser, E; de Kleijn, DP; de Vries, JP; Koekkoek, JA; Moll, FL; Pasterkamp, G; Schoneveld, A; van der Wal, AC; Velema, E; Verheijen, JH; Verhoeven, BA; Virmani, R | 1 |
| Laaksonen, R; Lehtimäki, T; Lütjohann, D; Päivä, H; Thelen, KM | 1 |
| Kalina, A | 2 |
| Lachaine, J; Merikle, EP; Rinfret, S; Tarride, JE | 1 |
| Johnson, G; Macreadie, IG; Macreadie, PI; Schlosser, T | 1 |
| Davidson, MH; Robinson, JG | 1 |
| Carod-Artal, FJ | 1 |
| Knopp, RH; Paramsothy, P | 1 |
| Adamovich, E; Allen, ZA; Butler, EG; Butler, WM; Galbreath, RW; Merrick, GS; Moyad, MA; Wallner, KE | 1 |
| Abraham, J; Alla, V; Bonkovsky, HL; Chalasani, NP; Raina, D; Siddiqui, J; Wu, GY | 1 |
| Guthrie, RM | 1 |
| Edwards, C; Gladding, PA; Kerr, A | 1 |
| Lloyd, K | 2 |
| Cheong, SS; Han, KH; Hong, MK; Jang, JS; Kim, JJ; Kim, YH; Lee, CW; Lee, SW; Park, CB; Park, DW; Park, SJ; Park, SW | 1 |
| März, P; Miserez, AR; Otten, U | 1 |
| Morais, MG; Pedrosa, R; Sena, A | 1 |
| Laaksonen, R; Lehtimäki, T; Luomala, M; Lütjohann, D; Päivä, H; Peltonen, N; Thelen, K | 1 |
| Gennimata, V; Ikonomidis, I; Kotsis, V; Lekakis, J; Pitiriga, V; Protogerou, A; Zakopoulos, N | 1 |
| Brecht, K; Kaufmann, P; Krähenbühl, S; Török, M; Waldhauser, KM; Zahno, A | 1 |
| Auteri, A; Bruni, F; Ciani, F; Ghezzi, A; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Pontani, A; Puccetti, L | 1 |
| Boyd, IW; O'Shea, JM; Ronaldson, KJ | 1 |
| Dellavalle, RP; Drake, AL; Freeman, SR; Graber, M; Heilig, LF; McNealy, K; Schilling, LM | 1 |
| Alemao, E; Jousilahti, P; Salomaa, V; Sintonen, H; Yin, D | 1 |
| Bartosová, L; Cermáková, E; Cibicek, N; Cibicková, L; Jun, D; Micuda, S; Palicka, V | 1 |
| Fox, KM; Gandhi, SK; McKenney, JM; Ohsfeldt, RL; Stacy, TA | 1 |
| Ho, W; Huo, Y; Liu, ZP; Meng, L | 1 |
| Evans, M; Golomb, B | 1 |
| Moriguchi, H; Sato, C; Uemura, T | 1 |
| Edwards, P; Goldberg, RB; Guyton, JR; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS | 1 |
| Aukrust, P; Boullier, A; Breland, U; Damås, JK; Fevang, B; Frøland, SS; Gullestad, L; Halvorsen, B; Hansson, GK; Kjekshus, J; Ovchinnikova, O; Quehenberger, O; Robertson, AK; Sandberg, WJ; Smith, C; Taskén, K; Waehre, T; Yndestad, A; Øie, E | 1 |
| Junni, P; Katajamaa, M; Laaksonen, R; Lehtimäki, T; Lütjohann, D; Oresic, M; Päivä, H; Saarinen, L; Seppänen-Laakso, T; Smet, J; Soini, J; Sysi-Aho, M; Van Coster, R | 1 |
| Inoue, N; Ishikawa, M; Kato, T; Motomura, K; Oikawa, S; Okajima, F; Shimano, H; Takahashi, A; Yamada, N | 1 |
| Hiatt, WH; Linnebur, SA | 1 |
| Butler, R; Wainwright, J | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, JA | 1 |
| Nesto, RW; Singh, PP | 1 |
| Bays, HE; Jones, PH; Kashyap, ML; Knopp, RH; McGovern, ME; McKenney, JM; Ruoff, GE | 1 |
| Fabian, V; Knezevic, W; Mastaglia, FL; Needham, M; Panegyres, P; Zilko, P | 1 |
| Balcells, S; Blanch, J; Carreras, R; Díez-Perez, A; Enjuanes, A; Grinberg, D; Mellibovsky, L; Monllau, JC; Nogues, X; Pedro-Botet, J; Ruiz-Gaspa, S | 1 |
| Galgóczy, L; Leiter, E; Lukács, G; Papp, T; Pócsi, I; Vágvölgyi, C | 1 |
| Molden, E; Westergren, T | 1 |
| Cangemi, R; Carnevale, R; Loffredo, L; Pignatelli, P; Violi, F | 1 |
| Janíková, L; Stanková, B; Stopka, P; Tvrzická, E; Vareka, T; Vecka, M; Zahin, M; Zák, A; Zeman, M | 1 |
| Côté, HC; Frohlich, JJ; Humphries, KH; Laaksonen, R; Lehtimäki, T; Päivä, H; Schick, BA | 1 |
| Gans, RO; May, JF; Mulder, DJ; Smit, AJ; Tervaert, JW; van Doormaal, JJ; van Haelst, PL; Wobbes, MH; Zijlstra, F | 1 |
| Choudhry, NK; Levin, R; Winkelmayer, WC | 1 |
| Delgado, O; Kaczmarek, I; Meiser, B; Reichart, B; Sadoni, S; Schmöckel, M | 1 |
| Berg, RL; Brown-Switzer, C; Ghebranious, N; McCarty, CA; Peissig, P; Sirohi, E; Wilke, RA | 1 |
| Graff, J; Jönsson, B; Lindgren, P; Olsson, AG; Pedersen, TJ | 1 |
| Huang, YC; Khan, S; Kim, MK; Li, P; Nguyen, T; Sanchez, J; Song, JC; Wang, CC | 1 |
| Bal, BS; Kant, R; Mahajan, M; Sharma, R; Singh, B | 1 |
| Hammervold, T; Howe, PR; Meyer, BJ; Rustan, AC | 1 |
| McMahon, DE | 1 |
| Furu, K; Karlstad, Ø; Rønning, M; Sakshaug, S; Skurtveit, S | 1 |
| Allen, C; Chung, N; Constance, C; Johnson-Levonas, AO; Lund, M; Massaad, R; McCrary Sisk, C; Westphal, S | 1 |
| Caballero, R; Delpón, E; Gómez, R; Núñez, L; Tamargo, J; Vaquero, M | 1 |
| Clarke, PJ; Grobler, MP; Levison, DB; Liew, D; Magliano, DJ; Rogers, SL; Webb, K | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Koter-Michalak, M | 1 |
| Hartung, HP; Neuhaus, O | 1 |
| Gandhi, SK; Ghali, JK; Hassman, DR; Insull, W; Miller, E; Y As, JW | 1 |
| Guyton, JR; Laskowitz, DT; Lynch, JR; Mace, B; Song, P; Wang, H; Warner, DS; Yang, HJ; Yates, RB | 1 |
| Botteman, MF; Damen, J; Koren, MJ; Kuntze, CE; Liu, LZ; Mamdani, M; Straka, RJ | 1 |
| Kaul, P | 1 |
| Frial, T; Miller, PS; Tran, YB | 1 |
| Ballantyne, C; Maccubbin, D; Pearson, T; Shah, A; Sisk, C; Veltri, E | 1 |
| Lachaine, J; Merikle, E; Montpetit, M; Rinfret, S; Tarride, JE | 1 |
| Hess, G; Hill, J; Liu, LZ; Sanders, KN | 1 |
| Dande, A; Holford, TR; Kocherla, M; Ruaño, G; Seip, RL; Smith, A; Sorokin, A; Thompson, PD; Windemuth, A; Wu, AH | 1 |
| Parle, M; Singh, N | 1 |
| Chen, J; Chopp, M; Goussev, A; Jiang, H; Li, Y; Lu, C; Lu, D; Mahmood, A; Qu, C; Schallert, T | 1 |
| Bax, JJ; Davignon, J; Dunkelgrun, M; Feringa, HH; Hoeks, SE; Kastelein, JJ; Poldermans, D; Schouten, O; van Domburg, RT; Vidakovic, R; Welten, GM | 1 |
| Kazis, LE; Lee, A; Lee, TA; Li, NC; Wang, SW; Wolozin, B | 1 |
| Chen, C; Lin, J; Smolarek, T; Tremaine, L | 1 |
| Hill, JS; Qiu, G | 1 |
| Archer, SL; Bonnet, S; Haromy, A; McMurtry, MS; Michelakis, ED | 1 |
| Coleman, CI; Dale, KM; Henyan, NN; Kluger, J; White, CM | 1 |
| Frudakis, TN; Gabriel, R; Ginjupalli, SN; Gomez, HJ; Handelin, B; Thomas, MJ | 1 |
| Deeg, MA; Johnson, C; Raikwar, NS; Williams, CD | 1 |
| Bassi, A; Caltagirone, C; Colivicchi, F; Santini, M | 1 |
| Azzellino, A; Balestri, G; Cazzaniga, M; Cerrito, MG; Cusa, EN; DeCarlini, C; Ferrari, AU; Garducci, S; Guerra, L; Lavitrano, ML; Loardi, C; Mancia, G; Menicanti, L; Paolini, G; Radaelli, A; Santo, D | 1 |
| Blazing, MA; Braunwald, E; Califf, RM; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Arnaboldi, L; Corsini, A; Guzzetta, M; Paoletti, R; Pazzucconi, F; Radaelli, G; Sirtori, CR | 1 |
| Bhasin, B; Malhotra, S; Pandhi, P; Pattanaik, S; Shafiq, N; Singh, M; Venkateshan, SP | 1 |
| Hostalek, U; Kassner, U; Steinhagen-Thiessen, E; Vogt, A | 1 |
| Blasetto, J; Gandhi, S; Harley, CR; Heien, H; Nelson, SP; Sasane, R | 1 |
| Macreadie, IG; Westermeyer, C; Wikhe, K | 1 |
| Cannon, CP; Kumar, A | 1 |
| Hassan, MK; Heeba, G; Khalifa, M; Malinski, T | 1 |
| Midgley, L; O'Regan, DJ; Porter, KE; Turner, NA | 1 |
| Eggen, AE; Engeland, A; Furu, K; Hartz, I; Njølstad, I; Sakshaug, S; Skurtveit, S | 1 |
| Bielinska, A; Gluszko, P | 1 |
| Davidson, MH; Fox, KM; Gandhi, SK; Ohsfeldt, RL | 1 |
| Dal Pan, G; McAdams, M; Staffa, J | 1 |
| Bała, A; Broncel, M; Chojnowska-Jezierska, J; Duchnowicz, P; Koter-Michalak, M; Wojsznis, W | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, J | 1 |
| Kanagarajan, N; Murthy, S; Nam, JH; Noah, ZA | 1 |
| Behlouli, H; Eisenberg, MJ; Humphries, K; Pilote, L; Rinfret, S; Tu, JV | 1 |
| Bestehorn, HP; Büttner, HJ; Frundi, D; Hochholzer, W; Neumann, FJ; Stratz, C; Trenk, D; Valina, CM | 1 |
| Dallinga-Thie, GM; Dunselman, PH; Jukema, JW; Liem, AH; Roeters van Lennep, HW; Zwinderman, AH | 1 |
| Chello, M; D'Ambrosio, A; Di Sciascio, G; Nusca, A; Pasceri, V; Patti, G; Vetrovec, GW | 1 |
| Cappelleri, JC; Dubois, RW; Messerli, FH; Pinto, L; Sichrovsky, T; Tang, SS; Thakker, KM | 1 |
| Birnbaum, Y; Lin, Y; Merla, R; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
| Asberg, A; Gedde-Dahl, A; Hejazifar, S; Hoel, K; Skottheim, IB | 1 |
| Jukema, JW; Liem, AH; van de Woestijne, AP; Visseren, FL; Zwinderman, AH | 1 |
| Aukrust, P; Breland, UM; Damås, JK; Fevang, B; Frøland, SS; Gullestad, L; Halvorsen, B; Oie, E; Otterdal, K; Sandberg, WJ; Smith, C; Waehre, T; Yndestad, A | 1 |
| Kumar, V; Shah, RP; Singh, S | 1 |
| Benner, JS; Foody, JM; Joyce, AT; Liu, LZ; Rudolph, AE | 2 |
| Gandhi, SK; Harley, CR; Heien, H; McDonough, K; Nelson, SP | 1 |
| Abe, Y; Furukado, S; Hori, M; Hoshi, T; Hougaku, H; Kitagawa, K; Sakaguchi, M; Yamagami, H | 1 |
| Brenner, H; Hahmann, H; Hoffmann, MM; Rothenbacher, D; Vossen, CY; Wüsten, B | 1 |
| Gawaz, M; Geisler, T; Paterok, M; Zürn, CS | 1 |
| Liew, TV; Ray, KK | 1 |
| Camm, J; De Souza, A; Jahangiri, M; Kourliouros, A; Marciniak, A; Roberts, N; Tsiouris, A; Valencia, O | 1 |
| Gratsianskii, NA; Vaulin, NA | 1 |
| Doggrell, SA | 1 |
| Hallinen, T; Martikainen, J; Niskanen, L; Peura, P; Soini, E | 1 |
| Fox, KM; Gandhi, SK; McKenney, JM; Ohsfeldt, RL | 1 |
| Derdak, Z; Harangi, M; Mirdamadi, HZ; Paragh, G; Seres, I; Sztanek, F | 1 |
| Fu, Q; Gao, Y; Zhang, LR | 1 |
| Xiao, H; Yang, CS | 1 |
| Braathen, P; Molden, E; Skovlund, E | 1 |
| Lóopez-Marure, R; Massó, FA; Montaño, LF; Páez, A; Rodríguez, E; Sánchez, CA; Varela, E; Zapata, E | 1 |
| Carvajal-González, G; Egido, J; Mezzano, S; Ortiz, A; Rodrigues Díez, R; Rodrigues-Díez, R; Rodríguez-Vita, J; Ruiz-Ortega, M; Sánchez-López, E; Selgas, R | 1 |
| Abe, M; Fujita, M; Hasegawa, K; Kawamura, T; Kita, T; Morimoto, T; Ono, K; Satoh, N; Shimatsu, A; Takaya, T; Wada, H | 1 |
| Bybee, KA; Lavie, CJ; O'Keefe, JH | 1 |
| Beamer, B; Costa-Scharplatz, M; Frial, T; Gandhi, S; Ramanathan, K | 1 |
| Berker, B; Cengiz, SD; Cesur, M; Demirtaş, S; Erdoğan, G; Kaya, C | 1 |
| Ballantyne, CM; Cain, VA; Raichlen, JS | 1 |
| Banerjee, S; Blazing, MA; Braunwald, E; Brilakis, ES; Califf, RM; Cannon, CP; de Lemos, JA; Morrow, DA; Murphy, SA; Sabatine, MS; Wiviott, SD | 1 |
| Bérard, A; Blais, L; Dragomir, A; Lalonde, L; Perreault, S; White, M | 1 |
| Vogel, RA; Willke, RJ; Zhou, S | 1 |
| Benner, JS; Foody, JM; Jeffers, BW; Joyce, AT; Liu, LZ | 1 |
| Bienvenu, AL; Picot, S | 1 |
| Bays, HE; Buttler, SM; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Bothwell, AL; Colangelo, CM; Cuchara, LA; Lorber, MI; Pober, JS; Rao, DA; Tang, PC; Tellides, G; Wang, Y; Yi, T | 1 |
| Gamie, Z; Graham, S; Linder, T; Tang, QO; Tran, GT; Tsialogiannis, E; Tsiridis, E | 1 |
| Alena, T; Brcakova, E; Cibicek, N; Cibickova, L; Daniel, J; Eva, B; Helena, Z; Hyspler, R; Jun, D; Micuda, S; Norbert, C; Palicka, V; Radomir, H; Stanislav, M; Ticha, A; Vladimir, P; Zivna, H | 1 |
| Barrios, V; Echarri, R; Escobar, C | 1 |
| Burke, JP; Dhonnchu, TN; Maher, BM; Soo, A; Watson, RW; Wood, AE | 1 |
| Freedland, SJ; Goldberg, KC; Hamilton, RJ; Platz, EA | 1 |
| Atkin, SL; Kilpatrick, ES; Sathyapalan, T | 4 |
| Basart, DC; Defesche, JC; Heeringa, J; Kastelein, JJ; Lansberg, PJ; Liem, AH; Oosterveer, DM; Sijbrands, EJ; Versmissen, J; Witteman, JC; Yazdanpanah, M | 1 |
| Pedersen, TR | 1 |
| Cziraky, M; Grochulski, D; Hoy, T; Jacobson, TA; Kuznik, A; Wertz, DA | 1 |
| Cermakova, E; Cibicek, N; Cibickova, L; Hyspler, R; Palicka, V; Ticha, A; Zadak, Z | 1 |
| Channer, KS; Jones, TH; Kapoor, D; Stanworth, RD | 1 |
| Glueck, CJ; Goldenberg, N; Khan, NA; Rawal, B; Wang, P; Yeramaneni, S | 1 |
| Cater, NB; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Tikkanen, MJ | 1 |
| Abel, T; Fehér, J | 1 |
| Lüscher, TF | 1 |
| Satoh, A; Satoh, M | 1 |
| Abramsky, O; Boimel, M; Grigoriadis, N; Lourbopoulos, A; Rosenmann, D; Rosenmann, H; Touloumi, O | 1 |
| Gryglewski, R; Hassan, M; Heeba, G; Khalifa, M; Malinski, T; Moselhy, ME | 1 |
| Kapoor, AS; Majumdar, SR; McAlister, FA; Mohamed, R; Norris, CM; Pretorius, V; Ross, DB | 1 |
| Cater, NB; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Szarek, M; Tikkanen, MJ | 3 |
| Keskitalo, JE; Kurkinen, KJ; Neuvoneni, PJ; Niemi, M | 1 |
| Erem, C; Ersoz, HO; Hacihasanoglu, AB; Karti, SS; Ukinc, K | 1 |
| Horna, A; Kulichová, B; Lopéz, SA; Nováková, L; Satínský, D; Solich, P; Solichová, D | 1 |
| Barbieri, M; Bertolini, S; Canonica, GW; Descalzi, D; Folli, C; Gamalero, C; Passalacqua, G; Riccio, AM; Scordamaglia, F | 1 |
| Bernstein, SJ; Bruhnsen, KD; Choe, HM; Kennedy, DM; Parsons, DM; Standiford, CJ; Stevenson, JG; Sy, FZ | 1 |
| Kanic, V; Naji, F; Sabovic, M; Suran, D; Vokac, D | 1 |
| Braga, MF; Gupta, M; Teoh, H; Tsigoulis, M; Verma, S | 1 |
| Inui, N; Kagawa, Y; Kokudai, M; Sakaeda, T; Takeuchi, K; Watanabe, H | 1 |
| Alcudia, JF; Badimon, L; Guadall, A; Martínez-González, J; Raposo, B; Rodríguez, C; Sánchez-Gómez, S | 1 |
| Falagas, ME; Kopterides, P | 1 |
| Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Strandberg, TE; Tikkanen, MJ | 1 |
| Frosch, DL; Grande, D; Kahn, BE; Perkins, AW | 1 |
| Halava, H; Helin-Salmivaara, A; Huupponen, R; Junnila, J | 1 |
| Baker, SP; Caselli, R; Evans, BA; Evans, JE; Hinerfeld, D; Kane, K; Moonis, M; Pollen, DA; Rogaeva, E; St George-Hyslop, P; Swearer, J | 1 |
| Goldberg, RB; Guyton, JR; Jensen, E; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS | 1 |
| Adewale, AJ; Ballantyne, CM; Grundy, SM; Hsueh, WA; Parving, HH; Polis, AB; Robinson, JG; Rosen, JB; Tershakovec, AM; Tomassini, JE | 1 |
| Bláha, M; Bláha, V; Nováková, L; Sadílek, P; Satínský, D; Solich, P; Solichová, D; Vlcková, H | 1 |
| Curi, R; Genvigir, FD; Hirata, MH; Hirata, RD; Rodrigues, AC | 1 |
| Coplan, N; Gintautas, J; Gupta, MP; Labana, SS; Polena, S; Shaikh, H; Soffer, D; Zazzali, K | 1 |
| Hjemdahl, P; Jørgensen, L; Malmström, RE; Ostergren, J | 1 |
| Hohenegger, M; Minichsdorfer, C | 1 |
| Cho, L; Jacob, M | 1 |
| Jin, D; Kim, DH; Kim, SK; Lee, KJ; Li, JH; Qi, XF; Teng, YC; Yoon, YS | 1 |
| Kitas, GD; Melas, N; Saratzis, A; Saratzis, N | 1 |
| Chopp, M; Han, Y; Karki, K; Knight, RA; Ledbetter, KA; Seyfried, DM; Yang, D; Zhang, J | 1 |
| Bate, A; Edwards, IR; Hägg, S; Strandell, J | 1 |
| Bi, S; Li, J; Li, YB; Liu, GD; Liu, XM; Su, Y; Sun, YM; Xu, Y | 1 |
| Becker, ML; Hofman, A; Stricker, BH; Uitterlinden, AG; van Schaik, RH; Visser, LE | 1 |
| Ali, S; Ginsburg, GS; Reed, CR; Salisbury, BA; Shah, SH; Spasojevic, I; Voora, D | 1 |
| Terland, O | 1 |
| Bailey, KM; Balmforth, AJ; Hall, AS; Romaine, SP | 1 |
| Goetghebeur, M; Jönsson, B; Lindgren, P; Merikle, E; Wagner, M | 1 |
| Frisbee, JC; Frisbee, SJ; Goodwill, AG; James, ME; Stapleton, PA | 1 |
| Abate, N; Ballantyne, CM; Catapano, AL; Davidson, MH; Polis, AB; Smugar, SS; Tershakovec, AM | 1 |
| Alha, P; Knuuttila, M; Saxlin, T; Suominen-Taipale, L; Ylöstalo, P | 1 |
| Hillyer, J; Kwon, BK; Lee, JH; Mann, CM; Stammers, AM; Tetzlaff, W | 1 |
| Carluccio, MA; De Caterina, R; Distante, A; Massaro, M; Scoditti, E; Storelli, C; Zampolli, A | 1 |
| Culler, SD; Weintraub, WS | 1 |
| Birnbaum, H; Connolly, C; Ivanova, J; Kidolezi, Y; Kuznik, A; Signorovitch, J; Simpson, RJ | 1 |
| Kelly, MT; Kipnes, MS; Lele, A; Rhyne, JM; Roth, EM; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Crosslin, DR; Ginsburg, GS; Messer, C; Reed, CR; Salisbury, BA; Shah, SH; Voora, D; Zhai, J | 1 |
| Barter, PJ; Brandrup-Wognsen, G; Nicholls, SJ; Palmer, M | 1 |
| Faergeman, O; Hyde, CL; Lira, M; Macinnes, A; Mazzarella, RA; Paciga, SA; Sanders, FA; Thompson, JF; van Wijk, DF; Wood, L | 1 |
| Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K | 1 |
| Faergeman, O; Fayyad, R; Holdaas, H; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Tikkanen, MJ | 1 |
| Cengiz, SD; Dünder, I; Kaya, C; Pabuccu, R | 1 |
| Choi, D; Chung, N; Her, AY; Jang, Y; Kang, SM; Kim, JY; Lee, SH; Manabe, I | 1 |
| Goldberg, RB; Guyton, JR; Mazzone, T; Polis, AB; Tershakovec, AM; Tipping, D; Tomassini, JE; Weinstock, RS | 1 |
| Buerke, M; Chen, L; Frister, A; Hofmann, B; Lautenschläger, M; Loppnow, H; Luther, T; Müller-Werdan, U; Rose-John, S; Schlitt, A; Silber, RE; Song, N; Werdan, K; Zhang, L | 1 |
| Näntö-Salonen, K; Niinikoski, H; Simell, O; Tanner, LM | 1 |
| Burke, JP; Rublee, DA | 1 |
| de Vries, JP; Hoefer, IE; Hurks, R; Kerver, M; Moll, FL; Pasterkamp, G; Schoneveld, A; Tangelder, MJ; Vink, A | 1 |
| Barber, MJ; Chasman, DI; Chatterjee, A; Hyde, CL; Krauss, RM; Li, X; Mangravite, LM; McCarty, CA; Nickerson, DA; Ridker, PM; Rieder, MJ; Rotter, JI; Smith, JD; Stephens, M; Wilke, RA; Williams, PT | 1 |
| Cao, HY; Li, J; Li, ZQ; Pan, W; Sun, YM; Wang, LF | 1 |
| Eckel, RH | 1 |
| Coban, AY; Durupinar, B; Güney, AK; Tekeli, HO | 1 |
| Foody, JM; Liu, LZ; Mendys, PM; Simpson, RJ | 1 |
| Allgar, V; Chipperfield, R; Gaunt, R; Harvey, P; McCormack, T; Robinson, P | 1 |
| Watson, KE | 1 |
| Boaz, M; Gilad, R; Lampl, Y; Lorberboym, M; Sadeh, M; Tikozky, A; Vysberg, I | 1 |
| Adámek, T; Alusik, S; Lejsková, M; Paluch, Z | 1 |
| Hu, XJ; Jia, M; Li, YP; Zhang, LR | 1 |
| Geleedst-De Vooght, M; Jansen, P; Maitland-van der Zee, AH; Mantel-Teeuwisse, A; Schalekamp, T | 1 |
| Asberg, A; Ellesat, KS; Hylland, K; Thomas, KV; Tollefsen, KE | 1 |
| Holford, TR; Kane, JP; Kocherla, M; Pullinger, CR; Ruaño, G; Seip, RL; Thompson, PD; Windemuth, A; Wu, AH | 1 |
| Agnew-Blais, J; Brookhart, MA; Choudhry, NK; Federman, AD; Fischer, MA; Kesselheim, AS; Liberman, JN; Liu, J; Shrank, WH | 1 |
| Wheelan, KR; Winter, FD | 1 |
| Bullock, R; Craig, D; Malouf, R; McGuinness, B; O'Hare, J; Passmore, P | 1 |
| Berk, M; Henry, MJ; Jacka, FN; Kotowicz, MA; Nicholson, GC; Pasco, JA; Williams, LJ | 1 |
| Kalonia, H; Kumar, A; Kumar, P | 1 |
| Araújo, LF; Duarte, AJ; Jabot, B; Nicolau, JC; Orii, NM; Rached, F; Ramires, JA; Serrano Júnior, CV; Soeiro, Ade M | 1 |
| Chopp, M; Ding, C; Han, Y; Karki, K; Knight, RA; Seyfried, DM; Yang, D; Zhang, J | 1 |
| Bodmer, M; Brecht, K; Bur, D; Krähenbühl, S; Tsakiris, DA; Zahno, A | 1 |
| Birnbaum, H; Ivanova, J; Kuznik, A; Ramakrishnan, K; Signorovitch, J; Simpson, RJ | 1 |
| Barary, MA; El-Kimary, EI; Hassan, EM; Maher, HM; Youssef, RM | 1 |
| Arazi, SS; Bernik, MM; Cerda, A; Curi, R; Dorea, EL; Genvigir, FD; Hirata, MH; Hirata, RD; Oliveira, R; Rodrigues, AC; Willrich, MA | 1 |
| Holme, I; Kvien, TK; Pedersen, TR; Semb, AG | 1 |
| Chen, YC; Hsieh, CH; Hsieh, MW; Jeng, JC; Jeng, SF; Lu, TH; Rau, CS | 1 |
| Anetseder, M; Hager, M; Metterlein, T; Roewer, N; Schuster, F; Tadda, L | 1 |
| Schunn, H | 1 |
| Adewale, AJ; Brown, WV; Flaim, D; Foody, JM; Jones-Burton, C; Lowe, RS; Tershakovec, AM; Zieve, F | 1 |
| Arranz Martínez, E; Gordillo López, FJ; Hermosa Hernán, JC; Ruiz García, A | 1 |
| Bláha, M; Bláha, V; Lánská, M; Malý, J; Nováková, L; Solich, P; Solichová, D; Vlcková, H | 1 |
| Bailey, C; Capps, N; Ramachandran, S; Saraf, S; Shetty, C | 1 |
| Benowitz, NL; Breazna, A; DeMicco, DA; Frey, P; Pipe, A; Samuels, L; Waters, DD; Wun, CC | 1 |
| Koh, KK; Quon, MJ; Sakuma, I | 1 |
| Wilke, RA | 1 |
| Civantos, E; Egido, J; Lavoz, C; Mezzano, S; Ortiz, A; Rayego-Mateos, S; Rodrigues Díez, R; Rodrigues-Díez, R; Rodríguez-Vita, J; Ruiz-Ortega, M | 1 |
| Insull, W; Jiang, P; Krause, S; Padley, RJ; Parreno, RA; Superko, HR; Thakkar, RB; Toth, PP | 1 |
| Betteridge, J | 1 |
| Meek, CL; Pathmanathan, H; Ramsbottom, T; Reston, JD; Viljoen, A | 1 |
| Brunham, LR; Carleton, BC; Carter, C; Hayden, MR; Hovingh, GK; Jukema, JW; Kastelein, JJ; Lansberg, PJ; Miao, F; Ross, CJ; Stalenhoef, AF; Visscher, H; Zhang, L | 1 |
| Crook, MA | 1 |
| Asuphol, O; Chaiyakunapruk, N; Dhippayom, T; Jeanpeerapong, N; Poowaruttanawiwit, P | 1 |
| Alanen, T; Helin-Salmivaara, A; Huupponen, R; Korhonen, MJ | 1 |
| Ballantyne, CM; Jones, PH; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Thakker, KM | 1 |
| Cerda, A; Curi, R; Genvigir, FD; Hirata, MH; Hirata, RD; Rodrigues, AC | 1 |
| Belo, VA; Gerlach, RF; Guimaraes, DA; Izidoro-Toledo, TC; Tanus-Santos, JE | 1 |
| Faergeman, O; Fayyad, R; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Tikkanen, MJ | 1 |
| Ara, R; Durrington, PN; Pandor, A; Rafia, R; Rees, A; Reynolds, TM; Stevens, J; Stevenson, M; Ward, SE; Wierzbicki, AS | 1 |
| Dean, IN; Rawal, SY; Stein, SH; Tipton, DA | 1 |
| DeFilippis, A; Eberlein, M; Girgis, RE; Iacono, A; Jones, S; Lechtzin, N; Reed, RM | 1 |
| D'Avolio, LW; Farwell, WR; Gaziano, JM; Lawler, EV; Scranton, RE | 1 |
| Abela, GS; Durga, S; Huang, R; Janoudi, A; Tamhane, U; Vedre, A | 1 |
| Arazi, SS; Bernik, MM; Cerda, Á; Dorea, EL; Genvigir, FD; Hirata, MH; Hirata, RD; Oliveira, Rd; Rodrigues, AC; Willrich, MA | 1 |
| Al Nuaimi, H; Al-Ani, B; Savage, C | 1 |
| Chen, G; Keyes, KT; Long, B; Qian, J; Ye, Y | 1 |
| Eeg-Olofsson, K; Eliasson, B; Gudbjörnsdóttir, S; Jonasson, JM; Miftaraj, M; Sundell, KA; Svensson, AM | 1 |
| Ferreira-Sae, MC; Franchini, KG; Geloneze, B; Grespan-Magossi, AM; Nadruz, W; Pio-Magalhães, JA; Schreiber, R; Souza, FA; Velloso, LA | 1 |
| Shi, J; Xue, Z | 1 |
| Alonso, R; Badimón, L; Barba, A; Díaz, JL; Fuentes, F; Guallar, E; Irigoyen, L; López-Miranda, J; Mata, N; Mata, P; Muñiz, O; Ordovas, JM; Padró, T; Perez-Jiménez, F; Piedecausa, M; Sanchez, JF; Vidal, JI | 1 |
| Al-Khateeb, A; Ibrahim, S; Imran, K; Mohamed, MS; Yusof, Z; Zilfalill, BA | 1 |
| Catapano, AL; Norata, GD; Pirillo, A | 1 |
| Barbosa, CP; Bersani-Amado, CA; Bracht, A; Bracht, L; Caparroz-Assef, SM; Cuman, RK; Ishii-Iwamoto, EL | 1 |
| Ageno, W; Dentali, F; Romualdi, E; Squizzato, A | 1 |
| Furman, A; Lopez, JR; Malmstrom, RA; Meier, JL; Schaefer, S | 1 |
| Björnsson, E; Jacobsen, EI; Kalaitzakis, E | 1 |
| de Mello, CF; de Oliveira, CV; Ferreira, J; Funck, VR; Furian, AF; Guerra, GP; Mallmann, CA; Oliveira, MS; Pereira, LM; Rambo, LM; Ribeiro, LR; Royes, LF | 1 |
| Azizova, OA; Baranova, OA; Blagodatskikh, KA; Koroleva, OS; Nosikov, VV; Pushkov, AA; Reznichenko, NE; Zateĭshchikov, DA | 1 |
| Karska-Basta, I; Kubicka-Trząska, A; Romanowska-Dixon, B; Undas, A | 1 |
| Abdulhalim, AM; Grabner, M; Johnson, W; Kuznik, A; Mullins, CD | 1 |
| Ellesat, KS; Holth, TF; Hylland, K; Yazdani, M | 1 |
| Hart, RJ; Hunter, T; Raval, AD; Stuckey, B | 1 |
| Ali, OF; Butrous, GS; Growcott, EJ; Wharton, J | 1 |
| Charlton-Menys, V; Dissanayake, S; Durrington, PN; France, MW; Kwok, S; Soran, H; Younis, NN | 1 |
| Fullerton, DA; Meng, X; Reece, TB; Reppert, AE; Sadaria, MR; Weyant, MJ; Yu, JA | 1 |
| Buikema, A; Kulakodlu, M; Kuznik, A; Potash, J; Swindle, JP | 1 |
| Akçalı, Z; Borlu, F; Namal, E; Oztekin, E; Sener, N; Ulaş, T | 1 |
| Brewer, HB; Hu, B; Kastelein, JJ; Krueger, KA; McErlean, E; Nicholls, SJ; Nissen, SE; Shao, M; Wang, MD | 1 |
| Burzynska, B; Gora, M; Hoser, G; Iwanicka-Nowicka, R; Kiliszek, M; Koblowska, M; Kotlinski, M; Leszczynska, A; Plochocka, D; Rawa, K; Szkopinska, A | 1 |
| Arsenault, BJ; Barter, P; Boekholdt, SM; Chatterjee, A; Deedwania, P; DeMicco, DA; Hovingh, GK; Hyde, CL; Kastelein, JJ; LaRosa, JC; Pedersen, TR; Waters, DD | 1 |
| Ghafourifar, P; Parihar, A; Parihar, MS; Zenebe, WJ | 1 |
| Chapman, MJ | 1 |
| Teramoto, T | 1 |
| Luo, H; Luo, M; Wang, J; Xiao, Y | 1 |
| DeGorter, MK; Gradhand, U; Kim, RB; Tirona, RG; Urquhart, BL | 1 |
| Becker, ML; Elens, LL; Hofman, A; Stricker, BH; Uitterlinden, AG; van Schaik, RH; Visser, LE | 1 |
| Chan, WC; Hopkins, R; Jackson, G; Lawes, CM; Marshall, R; Thornley, S; Young, R | 1 |
| Bakhai, A; Emmas, C; Hollis, S; Rigney, U | 1 |
| Bennie, M; Bishop, I; Campbell, S; Godman, B | 1 |
| de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ | 1 |
| Civeira, F; Dan, AG; De Tilleghem, Cle B; Hanson, ME; Hing Ling, PK; Massaad, R; Milardo, C; Triscari, J | 1 |
| Borggrefe, M; Elmas, E; Fischer, J; Kälsch, T; Lang, S; Nguyen, XD; Stach, K; Weiss, C | 1 |
| Blomqvist, P; Chen, E; Chen, F; Davidson, M; Maccubbin, D; McKenney, JM; Sirah, W; Sisk, CM; Yan, L | 1 |
| Jiang, P; Padley, RJ; Thakker, KM; Toth, PP | 1 |
| Pearson, M | 1 |
| Luzak, B; Rywaniak, J; Stanczyk, L; Watala, C | 1 |
| Gambassi, G; Lapane, KL; Motzkus-Feagans, CA; Pakyz, A; Polk, R | 1 |
| Vareka, T; Vecka, M; Vítková, D; Zák, A; Zeman, M | 1 |
| Boersma, E; Daemen, J; de Jaegere, PP; Eindhoven, JA; Oemrawsingh, RM; Onuma, Y; Serruys, PW; van Domburg, RT; van Nierop, JW | 1 |
| Colosi, LM; Ottmar, KJ; Smith, JA | 1 |
| Covelli, D; Crisanti, F; De Vuono, S; Lupattelli, G; Mannarino, E; Pirro, M; Roscini, AR; Siepi, D | 1 |
| Al-Azzam, S; Alnasser, Z; Alzoubi, K; Masadeh, M; Mhaidat, N | 1 |
| Betteridge, J; DeMicco, DA; Fayyad, R; Holme, I; Kvien, TK; LaRosa, JC; Pedersen, TR; Semb, AG; Wun, CC | 1 |
| Boussoula, E; Boutsikou, M; Giannakopoulou, V; Katsiki, N; Kollia, A; Kolovou, G; Kolovou, V; Mavrogeni, S; Mihas, C; Vasiliadis, I | 1 |
| Filippatos, TD | 1 |
| Bożentowicz-Wikarek, M; Chudek, J; Kocełak, P; Olszanecka-Glinianowicz, M; Smertka, M | 1 |
| Barter, PJ; Karlson, BW; Lundman, P; Nicholls, SJ; Palmer, MK | 2 |
| Dandri, M; Kah, J; Keller, AD; Montalbano, R; Ocker, M; Sass, G; Sirma, H; Tiegs, G; Volz, T; Wüstenberg, A | 1 |
| Bruckert, E; Dallongeville, J; Rosenbaum, D; Sabouret, P | 1 |
| Heintjes, EM; Herings, RM; Meerding, WJ; Penning-van Beest, FJ; Plat, AW; Sturkenboom, MC; Webb, K | 1 |
| Gupta, A; Kalonia, H; Kumar, A; Mishra, J; Sharma, N | 1 |
| Jin, J; Kim, BY; Kim, DE; Kim, EK; Kim, JS; Lee, DK; Lee, H; Park, EJ; Shin, IJ | 1 |
| Aukrust, P; Breland, UM; Hagelsteen, K; Halvorsen, B; Haraldsen, G; Hol, J; Kasprzycka, M; Otterdal, K; Pedersen, TM; Ranheim, T; Stang, E | 1 |
| Ballantyne, CM; Belmont, JW; Brautbar, A; Keinan, A; Ma, L | 1 |
| Erkoseoglu, I; Kadioglu, M; Kalyoncu, NI; Kesim, M; Muci, E; Okuyan, M; Yaris, E | 1 |
| Butler, KA; Mitchell, PD; Teng, R | 1 |
| Dimbil, M; Golomb, BA; Hoffman, KB; Kraus, C | 1 |
| Bosch, J; García-Cardeña, G; García-Pagán, JC; Gracia-Sancho, J; Hide, D; Marrone, G; Rosado, E; Russo, L | 1 |
| Bang, CN; Gislason, GH; Greve, AM; Køber, L; Torp-Pedersen, C; Wachtell, K | 1 |
| Andersen, K; Björnsdóttir, LR; Einarsdóttir, R; Gizurarson, S; Halldórsson, M | 1 |
| Andreasson, A; Andrén, L; Eggertsen, R | 1 |
| Hu, M; Mak, VW; Tomlinson, B | 1 |
| Adámkova, V; Ceska, R; Dlouha, D; Hubacek, JA; Lanska, V; Vrablik, M | 1 |
| Boekholdt, SM; Breazna, A; DeMicco, DA; Ho, JE; Kastelein, JJ; Messig, M; Pedersen, TR; Waters, DD | 1 |
| Armitage, J; Chen, F; Chen, YP; Chen, ZM; Feng, F; Gao, Y; Hopewell, JC; Hundei, WB; Jiang, LX; Landray, M; Li, J; Li, X; Liu, JM; Valdes-Marquez, E; Zhang, D; Zhang, HB | 1 |
| Bush, M; Collins, D; Generaux, G; Hussey, E; McMullen, S; Nunez, DJ; Polli, JW; Smith, G; Turner, N | 1 |
| Fu, Q; Gao, Y; Jia, M; Li, YP; Lu, PQ; Yang, SH; Zhang, LR | 1 |
| Dubas, K; Kersnik, J; Kijowska, V; Seifert, B; Tomasik, T; Windak, A | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; McPeters, G; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Kitzmiller, JP; Phelps, MA; Sadee, W; Sullivan, DM; Wang, D | 1 |
| Dingemanse, J; Hoch, M; Hoever, P; Theodor, R | 1 |
| Latorre, A; Madrid, I; Moscardó, A; Santos, MT; Vallés, J | 1 |
| Atkin, SL; Kilpatrick, ES; Sathyapalan, T; Shepherd, J | 1 |
| Bae, J; Kryzhanovski, VA; LeNarz, LA; Sponseller, CA; Zhao, Z; Zhu, Y | 1 |
| Cai, DQ; Kim, CS; Kim, DH; Kim, SK; Lee, KJ; Qi, XF; Qin, JW; Wu, Z; Yu, YH; Zheng, L | 1 |
| Kennedy, RL; Malabu, UH; Vangaveti, V | 1 |
| Koh, KK | 1 |
| Boekholdt, SM; Pedersen, TR; Waters, DD | 1 |
| Dormuth, CR; Ernst, P; Garg, AX; Hemmelgarn, BR; James, MT; Lafrance, JP; Levy, A; Paterson, JM; Raymond, CB; Teare, GF | 1 |
| Kalonia, H; Kumar, A; Mishra, J; Sharma, N | 1 |
| Filipiak, KJ; Mamcarz, A; Naruszewicz, M; Siebert, J; Sliż, D | 1 |
| Campbell, SM; Godman, B; Gustafsson, LL; Pichetti, S; Sermet, C | 1 |
| Balu, S; Montouchet, C; Ruff, L | 1 |
| Cziraky, M; Jacobson, TA; Kuznik, A; Wertz, DA | 1 |
| D'Ettorre, A; Macchia, A; Mariani, J; Romero, M; Tognoni, G | 1 |
| Govindan, R; Kavitha, M; Narasimhan, S; Varalakshmi, PR | 1 |
| Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR | 1 |
| Kang, HJ; Kim, HS; Lee, JH; Oh, BH; Park, YB; Sohn, DW | 1 |
| Gitirana, LB; Machado, MN; Magalhães, CB; Melo, AC; Porto, LC; Ribeiro, ML; Santos, JC; Valença, SS; Zin, WA | 1 |
| Abdoli, N; Azarmi, Y; Eghbal, MA; Heidari, R | 1 |
| Steurer, J | 1 |
| Chen, L; Song, W; Wang, W; Wang, Y; Yan, X | 1 |
| Farkouh, ME; Sethi, SS | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Ichinomiya, S; Iwata, H; Sato, H; Siddig, S; Suwa, E; Tuerdi, G; Ueno, K; Yano, T | 1 |
| Groenewoud, H; van der Wilt, GJ; Vermeulen, B; Woertman, W | 1 |
| Kang, S; Liu, XB; Liu, Y | 1 |
| Atochina-Vasserman, EN; Goncharov, DA; James, ML; Krymskaya, VP; Milavec, M; Volgina, AV | 1 |
| Reiner, Ž; Tedeschi-Reiner, E | 1 |
| Groenemeijer, M; Nanayakkara, PW; Scheffer, PG; Schindhelm, RK; Simsek, S; Smulders, YM; van Verschuer, VM | 1 |
| Catapano, AL; Corrao, G; Ibrahim, B; Mancia, G; Merlino, L; Nicotra, F; Pasini, TS; Zambon, A | 1 |
| Berg, RL; Davis, RL; Denny, JC; Feng, Q; Iwuchukwu, OF; Jiang, L; Jiang, M; Krauss, RM; McCarty, CA; Nickerson, DA; Peissig, PL; Roden, DM; Rotter, JI; Waitara, MS; Wei, WQ; Wilke, RA; Xu, H | 1 |
| Burzynska, B; Danikiewicz, W; Gora, M; Kaminska, J; Leszczynska, A; Maciejak, A; Odolczyk, N; Plochocka, D; Siedlecka, J; Sojka, M; Swiezewska, E; Sygitowicz, G; Szkopinska, A; Tulacz, D; Warchol, I; Wysocka-Kapcinska, M | 1 |
| Bao, JQ; Fallon, JK; Higgins, JW; Ke, AB; Manro, JR; Smith, PC; Zamek-Gliszczynski, MJ | 1 |
| Almeida, S; Bruxel, EM; Ferreira, ME; Fiegenbaum, M; Hutz, MH; Lima, LO; Pires, RC; Van der Sand, CR; Van der Sand, LC | 1 |
| Aukrust, P; Holven, KB; Nenseter, MS; Ose, L | 1 |
| Dinesh, N; Kaur, PK; Kishore Babu, N; Pallerla, DS; Singh, S | 1 |
| Becker, ML; de Keyser, CE; Hofman, A; Klungel, OH; Maitland-van der Zee, AH; Peters, BJ; Stricker, BH; Uitterlinden, AG; Verstuyft, C; Visser, LE | 1 |
| Foody, JM; Hu, H; Neff, D; Ramey, DR; Sajjan, S; Tershakovec, AM; Tomassini, JE; Toth, PP; Tunceli, K | 1 |
| Ashton, JC; Maggo, S | 1 |
| Ivanova, MV; Ragino, YI; Safronova, OG; Shintyapina, AB; Stakhneva, EM; Vavilin, VA | 1 |
| Aramin, H; Eslami, L; Malekzadeh, R; Merat, S; Nasseri-Moghaddam, S | 1 |
| Duleba, AJ; Ortega, I; Sokalska, A; Stanley, SD; Villanueva, JA | 1 |
| Elens, L; Elisaf, M; Kolovou, G; Kolovou, V; Manolopoulos, VG; Ragia, G; Tavridou, A; Tselepis, AD; Van Schaik, RH | 1 |
| Beckx, K; Dhar, M; Eyskens, F; Luyckx, E; Simons, A; Van West, D | 1 |
| Casiano, H; Crespo, MJ; Cruz, N; Hernandez, C; Quidgley, J; Rivera, K; Torres, H | 1 |
| Barroso, MV; Benjamim, CF; de Brito-Gitirana, L; Ferreira, TS; Lanzetti, M; Porto, LC; Rueff-Barroso, CR; Valença, SS | 1 |
| Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A | 1 |
| Bauer, I; Bertolotto, M; Dallegri, F; Fabre, M; Galan, K; Lenglet, S; Mach, F; Montecucco, F; Nencioni, A; Palombo, D; Pane, B; Pelli, G; Pende, A; Python, M; Quercioli, A; Spinella, G; Vuilleumier, N | 1 |
| Elisaf, M; Giannakopoulou, E; Kolovou, G; Kolovou, V; Manolopoulos, VG; Ragia, G; Tavridou, A; Tselepis, AD | 1 |
| Cho, DY; Hong, JH; Hyeon, SH; Kim, CJ; Kim, EY; Kim, H; Kim, SW; Kim, TH; Kwon, JE; Lee, WS; Mintz, GS; Senguttuvan, NB; Seo, JS; Seok, JW; Weissman, NJ | 1 |
| Dingemanse, J; Nicolas, LB; van Bortel, L | 1 |
| Anticoli, S; Gambardella, L; Malorni, W; Maselli, A; Matarrese, P; Panusa, A; Ruggieri, A; Vona, R | 1 |
| Fialkow, J; Legg, JC; Nedergaard, BS; Nelson, P; Neutel, JM; Ramstad, D; Robinson, JG; Rogers, WJ; Scott, R; Somaratne, R; Wasserman, SM; Weiss, R | 1 |
| Chang, YH; Lee, YJ; Lin, KD; Shin, SJ | 1 |
| Huang, XH; Hui, RT; Liu, G; Lu, J; Xu, YL; Zheng, XX | 1 |
| Bullock, R; Craig, D; Malouf, R; McGuinness, B; Passmore, P | 1 |
| Horoshko, OM; Zamors'kyĭ, II; Zeleniuk, VH | 1 |
| Adamson, J; Baracaia, S; Belatri, R; Cassell, J; Delaney, B; Dyson, L; Fox, R; Goldacre, B; Gulliford, M; Hunter, T; Mahmood, S; McCann, G; Padmanabhan, S; Pirmohamed, M; Ronaldson, S; Round, T; Smeeth, L; Taweel, A; Torgerson, D; van Staa, TP | 1 |
| da Silva, MG; do Nascimento, DC; Duarte, RS; Ferreira, Jda S; Hacker, MA; Lara, FA; Lobato, LS; Monteiro, CP; Moraes, MO; Neumann, Ada S; Oliveira, DS; Pedrini, SC; Pereira, GM; Pessolani, MC; Ribeiro-Alves, M; Rosa, PS; Soares, CT | 1 |
| Budoff, M; Folse, HJ; Goswami, D; Kahn, R; Rengarajan, B | 1 |
| Almeida, S; Ferreira, ME; Fiegenbaum, M; Hutz, MH; Lima, LO; Pires, RC; Smiderle, L; Van der Sand, CR; Van der Sand, LC | 1 |
| Aslani, P; Ayoub, R; Gelissen, IC; Moles, R; Nguyen, HL; Tiao, DK | 1 |
| Bińczak-Kuleta, A; Clark, JS; Hornowska, I; Kaczmarczyk, M; Safranow, K; Sałacka, A | 1 |
| Blaschke, F; Chemitz, J; Draube, A; Hallek, M; Holtick, U; Kochanek, M; Liebig, TM; Pallasch, C; Scheid, C; Shimabukuro-Vornhagen, A; Theurich, S; von Bergwelt-Baildon, MS; Wennhold, K; Zoghi, S | 1 |
| Ahn, CW; Cha, BS; Cho, Y; Choe, E; Choi, Y; Kang, ES; Lee, HC; Lee, YH; Seo, JW; Wang, HJ; Yun, Y | 1 |
| Duncan, BB; Polanczyk, CA; Restelatto, LM; Ribeiro, RA; Stella, SF; Vieira, JL; Ziegelmann, PK | 1 |
| Berk, M; Li, X; Redlich, C; Sundquist, J; Sundquist, K; Williams, LJ | 1 |
| Basso, RG; Cerda, A; Fajardo, CM; Hirata, MH; Hirata, RD | 1 |
| Boekholdt, SM; Fayyad, R; Hovingh, GK; Laskey, R; Pedersen, TR; Stoekenbroek, RM; Tikkanen, MJ | 1 |
| Einecke, D | 1 |
| Kitzmiller, JP; Luzum, JA; Phelps, MA; Wang, J | 1 |
| Stimac, D; Vojvodić, Z | 1 |
| Chotenimitkhun, R; D'Agostino, R; Hamilton, CA; Herrington, DM; Hundley, WG; Jordan, JH; Lash, TL; Lawrence, JA; Vasu, S; Yeboah, J | 1 |
| Lewicki, M; Ng, I; Schneider, AG | 1 |
| Phongtuntakul, B; Tungsubutra, W | 1 |
| Carr, AJ; Cornell, HR; Hulley, PA; Kuzma-Kuzniarska, M; Moneke, MC | 1 |
| Bonaca, MP; Creager, MA | 1 |
| Bredie, SJ; Kramers, C; Lobo, CM; van der Vlugt, MJ; Willemsen, AE | 1 |
| Sommer, M; Stoevesandt, J; Trautmann, A | 1 |
| Ballocca, F; Barbero, U; Biondi-Zoccai, G; Bonora, S; Calcagno, A; Cannillo, M; Cerrato, E; D'Ascenzo, F; DiNicolantonio, JJ; Gaita, F; Gasparini, M; Gili, S; Grosso Marra, W; Lavie, CJ; Lonni, E; Mancone, M; Montefusco, A; Moretti, C; Omedè, P; Pianelli, M | 1 |
| Kang, HT; Kim, HS; Kim, J; Lee, JW; Yang, W | 1 |
| Baye, J; Hajek, C; Larson, EA; McDermaid, A; Narayana Gowda, S; Nicole Myrmoe, A; Voora, D; Wilke, RA | 1 |
| Cai, JP; Dai, DP; Geng, PW; Hong, Y; Luo, QF; Shi, JH; Wang, SH; Wang, YR; Xu, X; Zhao, FL; Zhou, Q; Zhou, S; Zhou, YF | 1 |
| Cauthon, KAB; Hanson, K; Mattes, RG | 1 |
| Dautović, E; Halilčević, D; Hatkić, A; Husejnović, MŠ; Rustemović-Čorbić, M; Smajlović, A; Softić, A; Srabović, N | 1 |
101 review(s) available for pyrroles and simvastatin
| Article | Year |
|---|---|
Comparison of statins in hypertriglyceridemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 1998 |
Peripheral neuropathy and lipid-lowering therapy.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Naphthalenes; Niacin; Peripheral Nervous System Diseases; Pravastatin; Pyrroles; Simvastatin | 1998 |
Maximizing the cost-effectiveness of lipid-lowering therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1998 |
[Pharmacology of HMG CoA reductase inhibitors (statins)].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin | 1999 |
[Aggressive therapy and combination therapy in severe hyperlipidemia].
Topics: Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Simvastatin | 1999 |
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
[The hyperlipidemias. Role of various statins].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
New insights into the pharmacodynamic and pharmacokinetic properties of statins.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cell Division; Cytochrome P-450 Enzyme System; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Mevalonic Acid; Pyridines; Pyrroles; Simvastatin | 1999 |
Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Simvastatin; Treatment Outcome | 2000 |
HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Pyrroles; Simvastatin | 2000 |
Cholesterol lowering in atherosclerosis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Simvastatin | 2000 |
Statin trials in progress: unanswered questions.
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
New statins and new doses of older statins.
Topics: Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2001 |
Statins in children: what do we know and what do we need to do?
Topics: Atorvastatin; Bezafibrate; Child; Child Welfare; Cost-Benefit Analysis; Drug Approval; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Effective use of statins to prevent coronary heart disease.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin | 2001 |
[The role of HDL in the prevention of cardiovascular events].
Topics: Anticholesteremic Agents; Arteriosclerosis; Aryldialkylphosphatase; Atorvastatin; Cholesterol, HDL; Esterases; Fatty Acids, Monounsaturated; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipid Peroxidation; Lovastatin; Phosphatidylcholine-Sterol O-Acyltransferase; Pyrroles; Simvastatin | 2001 |
Statin therapy--what now?
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Patient Selection; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2001 |
Synthetic statins: more data on newer lipid-lowering agents.
Topics: Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipids; Pyridines; Pyrroles; Simvastatin | 2001 |
[Substantiation of increasing doses of statins in clinical practice].
Topics: Adult; Aged; Angiography; Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Colestipol; Coronary Disease; Dogs; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Primates; Prospective Studies; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors | 2001 |
A clinical focus on statins.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Down-Regulation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Multicenter Studies as Topic; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Simvastatin | 2001 |
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
Topics: Atorvastatin; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Managing dyslipidemia in the high-risk patient.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2002 |
Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diet; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Exercise; Fatty Acids, Omega-3; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2002 |
Benefits and menaces related to the use of statins in patients after renal transplantation.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin | 2002 |
Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Renal Dialysis; Simvastatin | 2003 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome | 2003 |
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Treating dyslipidemia with statins: the risk-benefit profile.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin; Stroke; Triglycerides; United States | 2003 |
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Simvastatin | 2003 |
More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Evaluation; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Pyrimidines; Pyrroles; Racial Groups; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2004 |
Emerging therapies for cerebrovascular disorders.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cerebrovascular Circulation; Cerebrovascular Disorders; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Intracranial Aneurysm; Pyrroles; Randomized Controlled Trials as Topic; Risk; Simvastatin; Therapeutics; Tissue Plasminogen Activator; Treatment Outcome | 2004 |
[LDL cholesterol in normal range. The lower the better? Implications of the GREACE study].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Placebos; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2003 |
[Role of lipid lowering therapy in patients with peripheral arterial occlusive disease].
Topics: Anticholesteremic Agents; Arterial Occlusive Diseases; Atorvastatin; Disease Progression; Exercise Test; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Jejunoileal Bypass; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2004 |
Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2003 |
Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature.
Topics: Acenocoumarol; Administration, Oral; Aged; Anticoagulants; Atorvastatin; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; International Normalized Ratio; Male; Patient Compliance; Pyrroles; Simvastatin; Venous Thrombosis; Warfarin | 2004 |
[Ezetimibe: from pharmacology to clinical trials].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Depression, Chemical; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Intestinal Absorption; Liver; Lovastatin; Pravastatin; Pyrroles; Safety; Simvastatin; Treatment Outcome | 2003 |
Rosuvastatin-induced arrest in progression of renal disease.
Topics: Aged; Atorvastatin; Controlled Clinical Trials as Topic; Creatine; Disease Progression; Drug Administration Schedule; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
The role of lipid management in diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus; Diabetic Angiopathies; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, HDL; Pyrroles; Simvastatin; Triglycerides | 2005 |
Statins and osteoporosis: myth or reality?
Topics: Anticholesteremic Agents; Atorvastatin; Bone Development; Female; Fractures, Bone; Heptanoic Acids; Humans; Osteoporosis; Pyrroles; Simvastatin | 2004 |
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
Topics: Allylamine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Colesevelam Hydrochloride; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Muscular Diseases; Niacin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2005 |
Safety of high-dose atorvastatin therapy.
Topics: Atorvastatin; Drug Administration Schedule; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2005 |
Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis a
Topics: Animals; Atorvastatin; Chromatography, High Pressure Liquid; Fluorobenzenes; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pharmaceutical Preparations; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Topics: Animals; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2005 |
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Topics: Atorvastatin; Comorbidity; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Failure, Chronic; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Statins and osteoporosis: new role for old drugs.
Topics: Animals; Atorvastatin; Bone and Bones; Clinical Trials as Topic; Drug Delivery Systems; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Fractures, Bone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Osteogenesis; Osteoporosis; Pharmacokinetics; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Topics: Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Therapeutic Equivalency; Treatment Outcome | 2006 |
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2006 |
The clinical relevance of low-density-lipoproteins size modulation by statins.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Particle Size; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
[Thoughts about the results of the "IDEAL" study].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Follow-Up Studies; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2006 |
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Lipoproteins, LDL; Phytosterols; Pravastatin; Pyrroles; Simvastatin | 2006 |
How safe is aggressive statin therapy?
Topics: Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.
Topics: Atorvastatin; Bezafibrate; Clofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Lovastatin; Melanoma; Odds Ratio; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin; Skin Neoplasms; United States | 2006 |
[Interaction risk with statin switch].
Topics: Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Diltiazem; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Hemorrhages; Muscular Diseases; Pyrroles; Risk Factors; Simvastatin; Warfarin | 2007 |
[Selection of statin considering the HDL cholesterol level].
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; PPAR alpha; Pyrroles; Simvastatin | 2006 |
A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2007 |
Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis.
Topics: Atorvastatin; Drug Evaluation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multiple Sclerosis; Pyrroles; Simvastatin | 2007 |
Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2007 |
Impact of statin dosing intensity on transaminase and creatine kinase.
Topics: Atorvastatin; Creatine Kinase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Transaminases | 2007 |
A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia.
Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Child; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 2007 |
Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study.
Topics: Atorvastatin; Azetidines; Cholesterol, HDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Niacin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2007 |
Biological consequences of statins in Candida species and possible implications for human health.
Topics: Antifungal Agents; Atorvastatin; Candida glabrata; DNA, Mitochondrial; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Pyrroles; Simvastatin | 2007 |
Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ultrasonography, Interventional | 2007 |
[Statins--are they potentially useful in rheumatology?].
Topics: Arthritis, Rheumatoid; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Osteoporosis; Pyrroles; Rheumatic Diseases; Simvastatin; Treatment Outcome | 2007 |
Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
Topics: Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Medical Records Systems, Computerized; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Impact of systemic hypertension on the cardiovascular benefits of statin therapy--a meta-analysis.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Therapeutics | 2008 |
Intensive statin therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Atorvastatin; Blood Platelets; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin | 2008 |
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac | 2008 |
Statins: under investigation for increasing bone mineral density and augmenting fracture healing.
Topics: Animals; Atorvastatin; Bone Density; Bone Morphogenetic Protein 2; Clinical Trials as Topic; Fracture Healing; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 9; Osteoclasts; Pravastatin; Pyrroles; Simvastatin; Vascular Endothelial Growth Factor A | 2008 |
Relative safety profiles of high dose statin regimens.
Topics: Acute Coronary Syndrome; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Muscle, Skeletal; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin | 2008 |
Statins for sepsis: a critical and updated review.
Topics: Anticholesteremic Agents; Atorvastatin; Bacterial Infections; Heptanoic Acids; Humans; Pyrroles; Sepsis; Simvastatin; Treatment Outcome | 2009 |
Lipid reduction in acute coronary syndrome: how much, when, and how?
Topics: Acute Coronary Syndrome; Atorvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Meta-Analysis as Topic; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Simvastatin | 2009 |
Can statins suppress the development of abdominal aortic aneurysms? A review of the current evidence.
Topics: Animals; Aortic Aneurysm, Abdominal; Atorvastatin; Blood Vessels; Cardiovascular Agents; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Matrix Metalloproteinases; Models, Animal; Pyrroles; Risk Assessment; Simvastatin | 2010 |
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.
Topics: Anticholesteremic Agents; Asian People; Atorvastatin; Fluorobenzenes; Gene Frequency; Haplotypes; HeLa Cells; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Statins for the treatment of dementia.
Topics: Alzheimer Disease; Atorvastatin; Dementia; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2010 |
Differential metabolic effects of distinct statins.
Topics: Adiponectin; Animals; Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mice; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Databases, Nucleic Acid; Dose-Response Relationship, Drug; Dyslipidemias; Electronic Health Records; Genetic Association Studies; Genetic Markers; Heptanoic Acids; Humans; Obesity; Pravastatin; Pyrroles; Risk Assessment; Simvastatin; Treatment Outcome | 2011 |
Pitavastatin - results from phase III & IV.
Topics: Atorvastatin; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Simvastatin | 2010 |
Statins for acute ischemic stroke.
Topics: Atorvastatin; Cause of Death; Clopidogrel; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Neuroprotective Agents; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Stroke; Ticlopidine | 2011 |
Statins for women with polycystic ovary syndrome not actively trying to conceive.
Topics: Adult; Atorvastatin; Female; Heptanoic Acids; Hirsutism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperandrogenism; Hypoglycemic Agents; Menstruation Disturbances; Metformin; Polycystic Ovary Syndrome; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Young Adult | 2011 |
Pitavastatin: novel effects on lipid parameters.
Topics: Apolipoprotein A-I; Apolipoproteins B; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Coronary Artery Disease; Double-Blind Method; Dyslipidemias; Europe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Russia; Simvastatin; Triglycerides | 2011 |
Pitavastatin: clinical effects from the LIVES Study.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Diseases; Multicenter Studies as Topic; Muscular Diseases; Prospective Studies; Pyrroles; Quinolines; Risk; Simvastatin; Treatment Outcome; Triglycerides | 2011 |
Statins for multiple sclerosis.
Topics: Atorvastatin; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-beta; Multiple Sclerosis; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Simvastatin | 2011 |
A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.
Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER.
Topics: Adolescent; Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Databases, Factual; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides; Young Adult | 2012 |
Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥ 50% reduction in high-risk patients: results from VOYAGER.
Topics: Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Risk Reduction Behavior; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2013 |
Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
Topics: Acute Kidney Injury; Adult; Aged; Atorvastatin; British Columbia; Cohort Studies; Confidence Intervals; Databases, Factual; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Logistic Models; Male; Middle Aged; Odds Ratio; Patient Safety; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Sulfonamides; United Kingdom; United States | 2013 |
Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Registries; Saphenous Vein; Simvastatin; Treatment Outcome; Young Adult | 2013 |
The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
Topics: Aged; Aging; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cytosine; Databases, Factual; Dose-Response Relationship, Drug; Female; Genetic Association Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Polymorphism, Single Nucleotide; Prospective Studies; Pyrroles; Risk Factors; Sex Characteristics; Simvastatin; Thymine | 2014 |
Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Topics: Alanine Transaminase; Atorvastatin; Fatty Liver; Fenofibrate; gamma-Glutamyltransferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Non-alcoholic Fatty Liver Disease; Pyrroles; Simvastatin | 2013 |
Changes in high-density-lipoprotein cholesterol upon statin treatment in type 2 diabetic patients: a meta-analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin; Triglycerides | 2014 |
Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials.
Topics: Atorvastatin; Cholesterol, LDL; Disease Progression; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Stroke Volume; Ventricular Dysfunction, Left | 2014 |
Statins for the treatment of dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Atorvastatin; Dementia; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2014 |
HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass.
Topics: Acute Kidney Injury; Adult; Atorvastatin; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Coronary Artery Bypass; Creatinine; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Length of Stay; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Replacement Therapy; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2015 |
Pharmacological treatment and current management of peripheral artery disease.
Topics: Atorvastatin; Exercise; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyrroles; Simvastatin; Smoking Cessation; Treatment Outcome | 2015 |
[Choosing wisely when prescribing statins].
Topics: Atorvastatin; Cardiovascular Diseases; Fluorobenzenes; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Quality of Health Care; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2015 |
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Primary Prevention; Pyrroles; Rosuvastatin Calcium; Simvastatin | 2016 |
228 trial(s) available for pyrroles and simvastatin
| Article | Year |
|---|---|
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Arthralgia; Atorvastatin; Cholesterol; Cholesterol, Dietary; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperhidrosis; Hyperlipidemias; Lovastatin; Male; Middle Aged; Patient Education as Topic; Pyrroles; Simvastatin; Triglycerides | 1997 |
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome | 1998 |
Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Arthralgia; Atorvastatin; Brachial Artery; Cholestyramine Resin; Drug Therapy, Combination; Endothelium, Vascular; Exanthema; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Ultrasonography | 1998 |
Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Drug Administration Schedule; Drug Combinations; Fenofibrate; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 1998 |
Comparison of atorvastatin alone versus simvastatin +/- cholestyramine in the management of severe primary hypercholesterolaemia (the six cities study).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; CD11 Antigens; Cohort Studies; Cytokines; Double-Blind Method; Heptanoic Acids; Heterozygote; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipopolysaccharide Receptors; Lipopolysaccharides; Mice; Monocytes; Pyrroles; Simvastatin | 1998 |
Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Colestipol; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lovastatin; Male; Pyrroles; Simvastatin; Treatment Outcome | 1998 |
Effect of statins on C-reactive protein in patients with coronary artery disease.
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 1999 |
Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Pyrroles; Simvastatin; Treatment Outcome | 1999 |
The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Female; Fluvastatin; Health Policy; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pyrroles; Simvastatin; United States | 1998 |
Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin; Triglycerides | 1999 |
Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial).
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Diet, Fat-Restricted; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Safety; Simvastatin; Time Factors | 1999 |
Lowering effects of four different statins on serum triglyceride level.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1999 |
A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cost-Benefit Analysis; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin | 1999 |
Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Single-Blind Method | 2000 |
Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia.
Topics: Adult; Aged; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin | 1999 |
Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholestyramine Resin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Family Practice; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Linear Models; Logistic Models; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2000 |
Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease.
Topics: Adolescent; Adult; Atorvastatin; Cholesterol; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Graft Rejection; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lovastatin; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.
Topics: Aged; Atorvastatin; Calorimetry, Indirect; Carbon Dioxide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Oxygen Consumption; Pyrroles; Simvastatin; Single-Blind Method; Triglycerides | 2000 |
The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Blood Pressure; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Elasticity; Family Health; Female; Femoral Artery; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides; Tunica Intima | 2000 |
Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Margarine; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Sitosterols; Treatment Outcome; Triglycerides | 2000 |
Influence of atorvastatin versus simvastatin on fibrinogen and other hemorheological parameters in patients with severe hypercholesterolemia treated with regular low-density lipoprotein immunoadsorption apheresis.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Blood Viscosity; Combined Modality Therapy; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Fibrinogen; Hemorheology; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Immunosorbent Techniques; Lipoproteins, LDL; Male; Middle Aged; Plasma Volume; Pyrroles; Simvastatin | 2000 |
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Pyrroles; Simvastatin | 2000 |
High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Regression Analysis; Simvastatin; Triglycerides | 2000 |
Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Statistics, Nonparametric | 2000 |
Associations between change in C-reactive protein and serum lipids during statin treatment.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Time Factors | 2000 |
Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin | 2001 |
Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Therapeutic Equivalency; Thrombophilia; Treatment Outcome | 2001 |
[Cost-effectiveness of atorvastatin against simvastatin as hypolipemic treatment in hypercholesterolemic patients in primary care].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Triglycerides | 2001 |
Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Lovastatin; Male; Middle Aged; Placebos; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2001 |
Comparative study of HMG-CoA reductase inhibitors on fibrinogen.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Cross-Over Studies; Fatty Acids, Monounsaturated; Female; Fibrinogen; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 2001 |
Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost Control; Drug Costs; Europe; Heptanoic Acids; Humans; Hypercholesterolemia; Peripheral Vascular Diseases; Pyrroles; Simvastatin | 2001 |
Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Interleukin-6; Male; Middle Aged; Pravastatin; Pyrroles; Receptors, Interleukin-6; Simvastatin; Treatment Outcome; Triglycerides | 2001 |
Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
Topics: Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Cost-Benefit Analysis; Cross-Over Studies; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome | 2001 |
Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs simvastatin.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fibrinogen; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Time Factors; Treatment Outcome; Triglycerides | 2001 |
Effects of statins on biomarkers of bone metabolism: a randomised trial.
Topics: Adult; Aged; Alkaline Phosphatase; Anticholesteremic Agents; Atorvastatin; Biomarkers; Bone and Bones; Bone Development; Bone Resorption; Collagen; Collagen Type I; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Peptides; Pyrroles; Simvastatin | 2001 |
Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin | 2001 |
The effects of converting from simvastatin to atorvastatin on plasminogen activator inhibitor type-1.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Serine Proteinase Inhibitors; Simvastatin | 2001 |
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; United States | 2001 |
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Education as Topic; Pravastatin; Pyrroles; Risk; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; United States | 2001 |
Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Middle Aged; Pyrroles; Simvastatin; Tunica Intima | 2001 |
Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Atorvastatin; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Nelfinavir; Pyrroles; Simvastatin | 2001 |
Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2001 |
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Drug Interactions; Heptanoic Acids; HIV Protease Inhibitors; HIV Seronegativity; Human Experimentation; Humans; Pravastatin; Pyrroles; Ritonavir; Saquinavir; Simvastatin | 2002 |
Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Patient Compliance; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2002 |
Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease.
Topics: Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Evaluation; E-Selectin; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Male; Norway; P-Selectin; Pyrroles; Simvastatin; Statistics as Topic; Thrombomodulin; Tissue Plasminogen Activator; Treatment Outcome; Triglycerides; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 2002 |
Effects of simvastatin and atorvastatin on inflammation markers in plasma.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Middle Aged; Pyrroles; Simvastatin | 2002 |
Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
Topics: Adult; Aged; Atorvastatin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors | 2002 |
A preliminary evaluation of neural network analysis for pharmacodynamic modeling of the dosing of the hydroxymethylglutaryl coenzyme A-reductase inhibitors simvastatin and atorvastatin.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Models, Biological; Neural Networks, Computer; Pyrroles; Simvastatin | 2002 |
Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease.
Topics: Atorvastatin; Blood Coagulation; Coronary Disease; Double-Blind Method; Female; Fibrinolysis; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Pyrroles; Simvastatin; Time Factors | 2002 |
Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Azetidines; Blood Component Removal; Child; Cholesterol, LDL; Creatine Kinase; Diet Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Liver Function Tests; Male; Pyrroles; Simvastatin; Treatment Outcome | 2002 |
Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Simvastatin; Thrombin; Treatment Outcome | 2001 |
Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoprotein(a); Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2002 |
Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk.
Topics: Adult; Aged; Apolipoproteins A; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoprotein(a); Logistic Models; Male; Middle Aged; Probability; Pyrroles; Reference Values; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Simvastatin; Statistics, Nonparametric; Treatment Outcome | 2002 |
Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients.
Topics: Adult; Aged; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Maximum Tolerated Dose; Middle Aged; Pravastatin; Probability; Pyrroles; Reference Values; Severity of Illness Index; Simvastatin; Single-Blind Method; Treatment Outcome | 2002 |
Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin | 2002 |
Statin-associated myopathy with normal creatine kinase levels.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biopsy; Creatine Kinase; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Muscular Diseases; Pain; Pyrroles; Simvastatin | 2002 |
Are early clinical effects of cholesterol lowering mediated through effects on inflammation?
Topics: Angina Pectoris; Anticholesteremic Agents; Atorvastatin; Cholesterol; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Simvastatin; T-Lymphocytes | 2002 |
Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy.
Topics: Adult; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2002 |
Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells.
Topics: Animals; Atorvastatin; Blood Coagulation; CD40 Antigens; CD40 Ligand; Cells, Cultured; Cohort Studies; Coronary Stenosis; Cytokines; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Lipoproteins, LDL; Male; Mice; Middle Aged; Muscle, Smooth, Vascular; Phagocytes; Pyridines; Pyrroles; RNA, Messenger; Simvastatin | 2002 |
Time-dependent effect of statins on platelet function in hypercholesterolaemia.
Topics: Adult; Analysis of Variance; Antiporters; Atorvastatin; Blood Platelets; Case-Control Studies; Cholesterol; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Linear Models; Lipoproteins, LDL; Male; Middle Aged; Nitric Oxide Synthase; P-Selectin; Platelet Activation; Pravastatin; Pyrroles; Simvastatin; Time Factors | 2002 |
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy.
Topics: Atorvastatin; CD40 Ligand; Coronary Artery Disease; Double-Blind Method; Down-Regulation; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2003 |
Levels of adhesion molecules do not decrease after 3 months of statin therapy in moderate hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cell Adhesion Molecules; Cholesterol; Cross-Sectional Studies; Double-Blind Method; E-Selectin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Intercellular Adhesion Molecule-1; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Vascular Cell Adhesion Molecule-1 | 2003 |
Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestanol; Cholesterol; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Phytosterols; Pyrroles; Simvastatin; Sitosterols; Squalene; Sterols | 2003 |
Effects of combined low-density lipoprotein apheresis and aggressive statin therapy on coronary calcified plaque as measured by computed tomography.
Topics: Administration, Oral; Aged; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Calcinosis; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease; Drug Monitoring; Female; Follow-Up Studies; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Severity of Illness Index; Simvastatin; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Effect of atorvastatin (80 mg) and simvastatin (40 mg) on plasma fibrinogen levels and on carotid intima media thickness in patients with familial hypercholesterolemia.
Topics: Administration, Oral; Adult; Atorvastatin; Biomarkers; Carotid Arteries; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Probability; Pyrroles; Reference Values; Severity of Illness Index; Simvastatin; Treatment Outcome; Tunica Media | 2003 |
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Time Factors | 2003 |
A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 2003 |
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2003 |
Hemostatic effects of atorvastatin versus simvastatin.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemostasis; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin | 2003 |
Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease.
Topics: Adult; Aged; Atorvastatin; Chemokines; Coronary Artery Disease; Dose-Response Relationship, Drug; Down-Regulation; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Male; Middle Aged; Pyrroles; Receptors, Chemokine; RNA, Messenger; Simvastatin; Time Factors | 2003 |
Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.
Topics: Atorvastatin; Cells, Cultured; Chemokine CCL2; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Monocytes; Pyrroles; Simvastatin | 2003 |
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2003 |
Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Time Factors; Triglycerides | 2003 |
Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia.
Topics: Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoprotein(a); Male; Middle Aged; Pyrroles; Simvastatin | 2003 |
Therapy with statins in patients with refractory rheumatic diseases: a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Atorvastatin; Biomarkers; Blood Sedimentation; C-Reactive Protein; Child; Chloroquine; Dose-Response Relationship, Drug; Granulomatosis with Polyangiitis; Heptanoic Acids; HLA-DR Antigens; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Lupus Erythematosus, Systemic; Middle Aged; Proteinuria; Pyrroles; Rheumatic Diseases; Rheumatic Fever; Simvastatin; Treatment Outcome | 2003 |
Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.
Topics: Analysis of Variance; Atorvastatin; Blood Glucose; Female; Fenofibrate; Heptanoic Acids; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Simvastatin; Uric Acid | 2003 |
Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).
Topics: Adult; Aged; Alkaline Phosphatase; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Diarrhea; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Musculoskeletal Diseases; Nausea; Pyrroles; Simvastatin | 2003 |
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Simvastatin | 2003 |
Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels?
Topics: Acute Disease; Adult; Aged; Arginine; Atorvastatin; Biomarkers; Blood Glucose; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Female; Finland; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Statistics as Topic; Triglycerides | 2003 |
The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Double-Blind Method; Female; Femoral Artery; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Tunica Intima; Tunica Media | 2003 |
Statin therapy in patients with coronary artery disease improves the impaired endothelial progenitor cell differentiation into cardiomyogenic cells.
Topics: Adult; Animals; Anticholesteremic Agents; Atorvastatin; Cell Differentiation; Cells, Cultured; Coronary Artery Disease; Endothelial Cells; Female; Heptanoic Acids; Humans; Lovastatin; Male; Myocytes, Cardiac; Pyrroles; Rats; Simvastatin | 2004 |
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North America; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2003 |
Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Fasting; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lipoproteins; Lovastatin; Male; Middle Aged; Postprandial Period; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2004 |
Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins.
Topics: Adult; Aged; Amyloid beta-Peptides; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Peptide Fragments; Prospective Studies; Pyrroles; Simvastatin; Time Factors | 2004 |
Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors.
Topics: Angina Pectoris; Angina, Unstable; Atorvastatin; Coronary Artery Disease; Cross-Sectional Studies; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1; Leukocytes, Mononuclear; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Pyrroles; Simvastatin; Tumor Necrosis Factor-alpha | 2004 |
The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia.
Topics: Administration, Oral; Analysis of Variance; Arteriosclerosis; Atorvastatin; Carrier Proteins; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Glycoproteins; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Linear Models; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Probability; Prognosis; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Simvastatin; Treatment Outcome; Tunica Media | 2004 |
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2004 |
Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation.
Topics: Arteriosclerosis; Atorvastatin; C-Reactive Protein; Chronic Disease; Coronary Artery Disease; E-Selectin; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Nitric Oxide; Pyrroles; Simvastatin; Treatment Outcome | 2004 |
Comparison of two methods of presenting risk information to patients about the side effects of medicines.
Topics: Adult; Aged; Atorvastatin; Cardiac Surgical Procedures; Communication; Comprehension; Constipation; Drug Information Services; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Likelihood Functions; Male; Middle Aged; Myocardial Infarction; Pancreatitis; Patient Education as Topic; Physician-Patient Relations; Pyrroles; Risk Assessment; Simvastatin; Terminology as Topic | 2004 |
Statin-induced immunomodulatory effects on human T cells in vivo.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Adult; Antigens, CD; Atorvastatin; Cytokines; Down-Regulation; Enterotoxins; Female; Flow Cytometry; Heptanoic Acids; HLA-DR Antigens; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interferon-gamma; Lipids; Lymphocyte Activation; Major Histocompatibility Complex; Male; Membrane Glycoproteins; Pyrroles; Simvastatin; Superantigens; T-Lymphocytes | 2004 |
Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Azetidines; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2004 |
Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemi
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipid Peroxidation; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Simvastatin; Tunica Media; Ultrasonography | 2004 |
Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia.
Topics: Adult; Aged; Aryldialkylphosphatase; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipid Metabolism; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin | 2004 |
A comparative study of atorvastatin and simvastatin as monotherapy for mixed hyperlipidaemia in Type 2 diabetic patients.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2004 |
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Research Design; Simvastatin; Treatment Outcome | 2004 |
Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia.
Topics: Atorvastatin; Female; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Logistic Models; Male; Middle Aged; Pyrroles; Simvastatin; Uric Acid | 2004 |
Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Topics: Adolescent; Adult; Anticholesteremic Agents; Antiprotozoal Agents; Area Under Curve; Atorvastatin; Biomarkers; Calcium Channel Blockers; Clarithromycin; Creatine Kinase; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Male; Mibefradil; Middle Aged; Pravastatin; Protein Synthesis Inhibitors; Pyrroles; Simvastatin; Verapamil | 2004 |
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2004 |
Comparison of the impact of atorvastatin and simvastatin on apoA-I kinetics in men.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kinetics; Lipids; Male; Middle Aged; Pyrroles; Simvastatin | 2005 |
Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging.
Topics: Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Observer Variation; Pilot Projects; Pravastatin; Pyrroles; Reproducibility of Results; Simvastatin | 2004 |
Statin therapy has no significant effect on skin tissue cholesterol: results from a prospective randomized trial.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Skin | 2005 |
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Effects of statin therapy on circulating conjugated dienes, a measure of LDL oxidation.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Simvastatin | 2005 |
Effect of 12-month statin therapy on antioxidant potential of LDL and serum antioxidant vitamin concentrations.
Topics: alpha-Tocopherol; Atorvastatin; beta Carotene; Cholesterol, LDL; Chromatography, High Pressure Liquid; Female; gamma-Tocopherol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Simvastatin | 2004 |
Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Combined Modality Therapy; Cross-Over Studies; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2005 |
Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
Topics: Analysis of Variance; Apolipoproteins; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Nephelometry and Turbidimetry; Practice Guidelines as Topic; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2005 |
Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
Topics: Adolescent; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atorvastatin; Benzoxazines; Cholesterol, LDL; Cyclopropanes; Drug Interactions; Female; Heptanoic Acids; HIV Infections; HIV Seronegativity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Oxazines; Pravastatin; Pyrroles; Simvastatin | 2005 |
High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
Topics: Adult; Age Factors; Aged; Atorvastatin; Biopsy; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Citrate (si)-Synthase; Dose-Response Relationship, Drug; Double-Blind Method; Electron Transport; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscles; Patient Selection; Phytosterols; Pyrroles; Sex Factors; Simvastatin; Sitosterols; Succinate Cytochrome c Oxidoreductase; Time Factors; Ubiquinone | 2005 |
Serum 1H-nuclear magnetic spectroscopy followed by principal component analysis and hierarchical cluster analysis to demonstrate effects of statins on hyperlipidemic patients.
Topics: Aged; Atorvastatin; Cholesterol; Cluster Analysis; Coronary Disease; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Nuclear Magnetic Resonance, Biomolecular; Principal Component Analysis; Pyrroles; Reproducibility of Results; Simvastatin | 2005 |
Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
Topics: Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcineurin Inhibitors; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Lactones; Liver; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pravastatin; Pyrroles; Simvastatin; Tacrolimus; Time Factors | 2005 |
Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Pyrroles; Simvastatin; Statistics, Nonparametric; Treatment Outcome | 2005 |
[The comparison of simvastatin and atorvastatin effects on hemostatic parameters in patients with hyperlipidemia type II].
Topics: Aged; Antithrombin III; Atorvastatin; Factor X; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2005 |
Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 2005 |
Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy.
Topics: Angina, Unstable; Atorvastatin; Cell Adhesion; Cells, Cultured; Chemokine CX3CL1; Chemokines, CX3C; Chemotaxis; Cholesterol, LDL; Coronary Artery Disease; CX3C Chemokine Receptor 1; Endothelium, Vascular; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-8; Leukocytes, Mononuclear; Membrane Proteins; Myocardial Infarction; Pyrroles; Receptors, Chemokine; Simvastatin; Umbilical Veins | 2005 |
The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia.
Topics: Anticholesteremic Agents; Aryldialkylphosphatase; Atorvastatin; Carboxylic Ester Hydrolases; Cholesterol, HDL; Double-Blind Method; Female; Genotype; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Simvastatin; Treatment Outcome | 2005 |
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Prospective Studies; Pyrroles; Risk; Simvastatin | 2005 |
Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Europe; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Taiwan; Treatment Outcome | 2005 |
Achieving lipid goals in real life: the Dutch DISCOVERY study.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Netherlands; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
[Changes of elastic properties of magistral arteries in patients with ischemic heart disease during treatment with atorvastatin and simvastatin].
Topics: Anticholesteremic Agents; Arteries; Atorvastatin; Carotid Arteries; Cholesterol; Data Interpretation, Statistical; Elasticity; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperemia; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Myocardial Ischemia; Pyrroles; Radial Artery; Simvastatin; Time Factors; Triglycerides | 2005 |
Preoperative statin therapy and troponin T predict early complications of coronary artery surgery.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Comorbidity; Coronary Artery Bypass; Creatine Kinase, MB Form; Female; Heptanoic Acids; Hospital Mortality; Hospitals, University; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Interleukin-6; Lipids; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Premedication; Preoperative Care; Prospective Studies; Pyrroles; Risk Assessment; Simvastatin; Systemic Inflammatory Response Syndrome; Troponin T | 2006 |
LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin | 2005 |
The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Pyrroles; Simvastatin; Thiobarbituric Acid Reactive Substances | 2005 |
[Erythrocyte fluidity in patients with hyperlipidemia during statins therapy].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Erythrocyte Membrane; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipid Peroxidation; Male; Membrane Fluidity; Membrane Lipids; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Statistics, Nonparametric; Triglycerides | 2005 |
An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Atorvastatin; Cross-Over Studies; Delayed-Action Preparations; Drug Carriers; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Niacin; Pyrroles; Reference Values; Simvastatin; Treatment Outcome | 2006 |
[The IDEAL study comparing simvastatin 20-40 mg versus atorvastatin 80 mg for secondary prevention after myocardial infarction: between two ideas of the ideal].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Single-Blind Method; Treatment Outcome | 2006 |
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2006 |
Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Fenofibrate; Fibrinolysis; Genotype; Heptanoic Acids; Humans; Male; Permeability; Pyrroles; Quinapril; Simvastatin; Tetrahydroisoquinolines; Thrombin; Thrombosis | 2006 |
Treatment of hypercholesterolemia in patients with metabolic syndrome: how do different statins compare?
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Metabolic Syndrome; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Beneficial effect of statins in multiple sclerosis: is it dose-dependent?
Topics: Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Lovastatin; Multiple Sclerosis; Pyrroles; Simvastatin; Treatment Outcome | 2007 |
Plasma-soluble CD40 is related to cholesterol metabolism in patients with moderate hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; CD40 Antigens; Cholesterol; Cholesterol, Dietary; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles; Severity of Illness Index; Simvastatin; Solubility | 2006 |
Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin | 2006 |
A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle.
Topics: Atorvastatin; Biomarkers; Computational Biology; Gene Expression; Gene Expression Profiling; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Muscle, Skeletal; Muscular Diseases; Pyrroles; Simvastatin; Systems Biology | 2006 |
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
Topics: Adult; Atorvastatin; Cholesterol, LDL; Delayed-Action Preparations; Drug Combinations; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Niacin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
[Oxidation stress, insulin resistance and endothelial dysfunction during the treatment of hyperlipidaemia].
Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Endothelium, Vascular; Fatty Acids, Omega-3; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Oxidative Stress; Pyrroles; Simvastatin | 2006 |
Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin.
Topics: Adult; Aged; Atorvastatin; DNA, Mitochondrial; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Mitochondria, Muscle; Pyrroles; Retrospective Studies; Simvastatin; Ubiquinone | 2007 |
The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress.
Topics: Adult; Aged; Antibodies; Atorvastatin; Biomarkers; C-Reactive Protein; Cell Adhesion Molecules; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipoproteins, LDL; Male; Middle Aged; Neopterin; Oxidative Stress; Pyrroles; Simvastatin; von Willebrand Factor | 2007 |
Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
Topics: Adult; Apolipoproteins B; Atorvastatin; Biomarkers; Coronary Disease; Drug Administration Schedule; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Nephelometry and Turbidimetry; Pyrroles; Simvastatin; Treatment Outcome | 2006 |
Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects.
Topics: Animals; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Dietary Fats; Dietary Fats, Unsaturated; Dietary Supplements; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fish Oils; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lipid Metabolism; Lipids; Lipoproteins, IDL; Lipoproteins, VLDL; Male; Middle Aged; Pyridines; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 2007 |
Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Body Mass Index; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2007 |
[The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia].
Topics: Adult; Aged; Antioxidants; Atorvastatin; Catalase; Dyslipidemias; Erythrocyte Membrane; Female; Glutathione Peroxidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Superoxide Dismutase; Treatment Outcome | 2006 |
Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Disease; Creatinine; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Managed Care Programs; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2007 |
Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
Topics: Adult; Atorvastatin; Canada; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance, Pharmaceutical Services; Male; Models, Economic; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Statin therapy reduces serum levels of glycosylphosphatidylinositol-specific phospholipase D.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cell Line, Tumor; Cells, Cultured; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Liver; Male; Middle Aged; Phospholipase D; Pyrroles; Simvastatin; Triglycerides | 2007 |
Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Atorvastatin; Coronary Artery Bypass; Coronary Artery Disease; Coronary Circulation; Creatine Kinase; Dose-Response Relationship, Drug; E-Selectin; Enalapril; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Interleukin-6; Leukocyte Count; Male; Middle Aged; Platelet Count; Pyrroles; Ramipril; Simvastatin; Stroke Volume; Time Factors; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 2007 |
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Serum from hypercholesterolemic patients treated with atorvastatin or simvastatin inhibits cultured human smooth muscle cell proliferation.
Topics: Adult; Aged; Atorvastatin; Cell Line; Cell Proliferation; Cholesterol; Cross-Over Studies; Double-Blind Method; Female; Femoral Artery; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocytes, Smooth Muscle; Pyrroles; Serum; Simvastatin | 2007 |
Physicochemical modifications induced by statins therapy on human erythrocytes membranes.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Erythrocyte Membrane; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Peroxidation; Male; Membrane Fluidity; Membrane Lipids; Middle Aged; Pyrroles; Simvastatin; Sodium-Potassium-Exchanging ATPase; Triglycerides | 2007 |
Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Coronary Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Pyrroles; Simvastatin; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2008 |
Statin therapy increases carotid plaque echogenicity in hypercholesterolemic patients.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Arteries; Carotid Stenosis; Cholesterol; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-18; Interleukin-6; Male; Middle Aged; Pravastatin; Probability; Prospective Studies; Pyrroles; Simvastatin; Triglycerides; Tunica Intima; Ultrasonography | 2008 |
Use of lipid-modulating drugs in complicated course of coronary heart disease.
Topics: Antithrombin III; Atorvastatin; Cholesterol, LDL; Coronary Disease; Echocardiography; Female; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Peptide Hydrolases; Pravastatin; Prothrombin; Pyrroles; Simvastatin; von Willebrand Factor | 2007 |
Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Homocysteine; Humans; Hyperhomocysteinemia; Metabolic Clearance Rate; Polycystic Ovary Syndrome; Pyrroles; Retrospective Studies; Simvastatin; Treatment Outcome | 2009 |
Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvas
Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
Topics: Atorvastatin; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Syndrome; Thrombolytic Therapy; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Prospective Studies; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome | 2008 |
Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
Topics: Atorvastatin; Cholesterol, LDL; Creatine Kinase; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rhabdomyolysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Predictive Value of Tests; Pyrroles; Simvastatin; Treatment Outcome | 2008 |
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Myocardial Infarction; Pyrroles; Simvastatin | 2009 |
Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients.
Topics: Acute-Phase Proteins; Adult; Anticholesteremic Agents; Atorvastatin; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Ferritins; Fibrinogen; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Time Factors | 2009 |
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study.
Topics: Aged; Atorvastatin; Confounding Factors, Epidemiologic; Drug Prescriptions; Europe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Odds Ratio; Proportional Hazards Models; Prospective Studies; Pyrroles; Research Design; Risk Assessment; Risk Factors; Simvastatin; Time Factors; Treatment Outcome | 2009 |
Effects of statins on the pharmacokinetics of midazolam in healthy volunteers.
Topics: Adult; Area Under Curve; Atorvastatin; Cross-Over Studies; Cytochrome P-450 CYP3A; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypnotics and Sedatives; Japan; Male; Midazolam; Pyrroles; Quinolines; Simvastatin | 2009 |
Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction.
Topics: Atorvastatin; Female; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2009 |
Effect of exposure to small pharmaceutical promotional items on treatment preferences.
Topics: Adult; Atorvastatin; Attitude of Health Personnel; Clinical Competence; Drug Industry; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Marketing of Health Services; Organizational Policy; Pyrroles; Simvastatin; Students, Medical; Young Adult | 2009 |
Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Young Adult | 2009 |
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
Topics: Adolescent; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Young Adult | 2009 |
Platelet aggregation inhibition in patients receiving statins either fully or partially metabolized by CYP3A4.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Clopidogrel; Cytochrome P-450 CYP3A; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Simvastatin; Thrombosis; Ticlopidine | 2008 |
Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ticlopidine | 2009 |
The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
Topics: Aged; Atorvastatin; Creatine Kinase; Female; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Simvastatin | 2009 |
Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Atorvastatin; Canada; Cardiovascular Diseases; Confidence Intervals; Cost of Illness; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Health Care Costs; Heptanoic Acids; Hospitalization; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Markov Chains; Middle Aged; Myocardial Infarction; Probability; Pyrroles; Risk Assessment; Simvastatin; Survival Rate; Treatment Outcome | 2009 |
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Dual effect of statin medication on the periodontium.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Dental Plaque; Female; Gingivitis; Heptanoic Acids; Humans; Immunomodulation; Male; Middle Aged; Periodontal Index; Periodontal Pocket; Periodontium; Pyrroles; Regression Analysis; Risk Factors; Simvastatin | 2009 |
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, VLDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.
Topics: Adolescent; Adult; Aged; Alleles; Anticholesteremic Agents; Apolipoprotein E3; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Regression Analysis; Simvastatin | 2008 |
Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Chromosomes, Human, Pair 3; Female; Gene Deletion; Gene Frequency; Genotype; Heptanoic Acids; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Receptors, CCR; Receptors, CCR5; Retrospective Studies; Risk Factors; Simvastatin; Triglycerides | 2010 |
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cardiovascular Diseases; Female; Glomerular Filtration Rate; Heart Arrest; Heptanoic Acids; Humans; Kidney Failure, Chronic; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Pyrroles; Regression Analysis; Simvastatin | 2010 |
Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study.
Topics: Adult; Atorvastatin; C-Reactive Protein; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperandrogenism; Inflammation; Insulin; Insulin Resistance; Luteinizing Hormone; Oxidative Stress; Polycystic Ovary Syndrome; Prospective Studies; Pyrroles; Simvastatin; Testosterone; Young Adult | 2010 |
Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Azetidines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, LDL; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Glucose; Glycated Hemoglobin; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Black People; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Heptanoic Acids; Hispanic or Latino; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2010 |
Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures.
Topics: Aspirin; Atorvastatin; Cell Separation; Coculture Techniques; Dose-Response Relationship, Drug; Drug Synergism; Heptanoic Acids; HMGB1 Protein; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indomethacin; Interleukin-1; Interleukin-6; Leukocytes, Mononuclear; Lipopolysaccharides; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Pyrroles; Recombinant Proteins; Simvastatin; STAT3 Transcription Factor; Time Factors; Tumor Necrosis Factor-alpha | 2011 |
Genome-wide association of lipid-lowering response to statins in combined study populations.
Topics: Adult; Aged; Atorvastatin; Bayes Theorem; Cholesterol; Female; Genome-Wide Association Study; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Phenotype; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Simvastatin | 2010 |
Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease.
Topics: Aged; Analysis of Variance; Atorvastatin; Biomarkers; Chi-Square Distribution; Coronary Disease; Diet, Fat-Restricted; Female; Glutathione; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Simvastatin; Superoxide Dismutase; Treatment Outcome | 2010 |
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; General Practice; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Treatment Outcome | 2010 |
CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women.
Topics: Alleles; Asian People; Atorvastatin; China; Cytochrome P-450 CYP3A; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Prospective Studies; Pyrroles; Sex Factors; Simvastatin | 2011 |
Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial)
Topics: Aged; Atorvastatin; Denmark; Female; Finland; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Netherlands; Norway; Proportional Hazards Models; Prospective Studies; Pyrroles; Secondary Prevention; Simvastatin; Sweden; Treatment Outcome | 2010 |
Lack of clopidogrel-statin interaction in patients undergoing coronary stent implantation.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Simvastatin; Ticlopidine | 2010 |
Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Pyrroles; Simvastatin | 2010 |
Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Logistic Models; Male; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2010 |
Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heart Rate; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Smoking; Survival Rate; Treatment Outcome; United States | 2011 |
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome; United States | 2010 |
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2011 |
LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Secondary Prevention; Simvastatin; Treatment Outcome | 2011 |
[Effects of different statins, ezetimibe/simvastatin combination on hsCRP levels in unstable angina pectoris and non-ST elevation myocardial infarction patients: a randomized trial].
Topics: Angina, Unstable; Atorvastatin; Azetidines; C-Reactive Protein; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Single-Blind Method; Sulfonamides; Treatment Outcome | 2011 |
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Topics: Aged; Atorvastatin; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies.
Topics: Aged; Alleles; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Follow-Up Studies; Genotype; Heptanoic Acids; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2012 |
Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects.
Topics: Adult; Animals; Area Under Curve; Atorvastatin; Cross-Over Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver-Specific Organic Anion Transporter 1; Male; Mice; Mice, Knockout; Middle Aged; Organic Anion Transporters, Sodium-Independent; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Young Adult | 2012 |
Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.
Topics: Adenine; Androstenes; Anti-HIV Agents; Atazanavir Sulfate; Atorvastatin; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Interactions; Emtricitabine; Ethinyl Estradiol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Least-Squares Analysis; Linear Models; Lopinavir; Male; Oligopeptides; Organophosphonates; Patient Safety; Phosphinic Acids; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tenofovir | 2012 |
Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2012 |
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome | 2013 |
Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy.
Topics: Atorvastatin; Biomarkers; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Particle Size; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome; United States | 2012 |
Cholesterol metabolism differs after statin therapy according to the type of hyperlipemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; Lipids; Male; Middle Aged; Phytosterols; Pyrroles; Simvastatin; Sitosterols | 2012 |
Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease.
Topics: Adult; Aged; Anticholesteremic Agents; Arthritis; Atorvastatin; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2012 |
Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Angiopoietins; Apolipoproteins; Apolipoproteins B; Atorvastatin; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers.
Topics: Adenosine; Adult; Area Under Curve; Atorvastatin; Biotransformation; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Least-Squares Analysis; Linear Models; Male; Metabolic Clearance Rate; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyrroles; Simvastatin; Ticagrelor | 2013 |
No changes of cholesterol levels with a commercially available glucosamine product in patients treated with lipid lowering drugs: a controlled, randomised, open cross-over trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cross-Over Studies; Drug Interactions; Female; Glucosamine; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2012 |
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Simvastatin; Stroke | 2013 |
Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.
Topics: Adolescent; Adult; Aged; Animals; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Demography; Dogs; Dose-Response Relationship, Drug; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Madin Darby Canine Kidney Cells; Male; Mesylates; Middle Aged; Oxadiazoles; Piperidines; Pyrimidines; Pyrroles; Reference Standards; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Troleandomycin; Young Adult | 2013 |
The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Blood Glucose; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Fasting; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Complications; Diabetic Angiopathies; Double-Blind Method; Drug Combinations; Drug Monitoring; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin; Sulfonamides | 2013 |
Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.
Topics: Acetamides; Administration, Oral; Adult; Area Under Curve; Atorvastatin; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Germany; Half-Life; Heptanoic Acids; Humans; Hydroxylation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypnotics and Sedatives; Intestines; Isoquinolines; Liver; Male; Metabolic Clearance Rate; Pyrroles; Simvastatin; Young Adult | 2013 |
Effects of ezetimibe/simvastatin 10/20 mg vs. atorvastatin 20 mg on apolipoprotein B/apolipoprotein A1 in Korean patients with type 2 diabetes mellitus: results of a randomized controlled trial.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Asian People; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Combinations; Dyslipidemias; Ezetimibe, Simvastatin Drug Combination; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Pyrroles; Republic of Korea; Simvastatin; Treatment Outcome | 2013 |
Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Obesity; Peptide Fragments; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
No effect of atorvastatin and simvastatin on oxidative stress in patients at high risk for cardiovascular disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Deoxyguanosine; F2-Isoprostanes; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Peroxidase; Pyrroles; Simvastatin; Ubiquinone | 2013 |
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
Topics: Aged; Apolipoprotein B-100; Atorvastatin; Bilirubin; Biomarkers; Dinoprost; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Middle Aged; Niacin; Oxidative Stress; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Uric Acid | 2014 |
Investigation of combined CYP3A4 inductive/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882.
Topics: Adolescent; Adult; Atorvastatin; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyridines; Pyrroles; Simvastatin; Substrate Specificity; Young Adult | 2014 |
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Azetidines; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2014 |
High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Netherlands; Peripheral Arterial Disease; Prospective Studies; Pyrroles; Scandinavian and Nordic Countries; Simvastatin | 2015 |
[IMPROVE-IT Study proves effectiveness of ezetimib. The Higgs particle of lipidologists].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Simvastatin | 2014 |
Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Neoplasms; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2015 |
502 other study(ies) available for pyrroles and simvastatin
| Article | Year |
|---|---|
Levels of soluble cell adhesion molecules in patients with dyslipidemia.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cell Adhesion Molecules; Colestipol; Drug Therapy, Combination; E-Selectin; Endothelium, Vascular; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Lovastatin; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Solubility; Vascular Cell Adhesion Molecule-1 | 1996 |
Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Enzyme Inhibitors; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins, LDL; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1996 |
The rule of 5 and the rule of 7 in lipid-lowering by statin drugs.
Topics: Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1997 |
Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells.
Topics: Animals; Apoptosis; Atorvastatin; Carotid Stenosis; Cell Division; Cells, Cultured; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Muscle, Smooth, Vascular; Pravastatin; Pyrroles; Rabbits; Simvastatin | 1997 |
Atorvastatin versus simvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin | 1997 |
Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Carcinoma, Hepatocellular; Cholesterol; Enzyme Induction; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Liver; Liver Neoplasms; Male; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Simvastatin; Transcription, Genetic; Tumor Cells, Cultured | 1998 |
Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.
Topics: Animals; Atorvastatin; Cattle; Cells, Cultured; Endothelin-1; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pyrroles; RNA, Messenger; Simvastatin | 1998 |
Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits.
Topics: Acyltransferases; Animals; Atorvastatin; Bezafibrate; Cholesterol; Diacylglycerol O-Acyltransferase; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hypolipidemic Agents; Lipids; Liver; Male; Phospholipids; Pyrroles; Rabbits; Simvastatin; Triglycerides | 1998 |
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 1998 |
Cost-effectiveness of statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Markov Chains; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1998 |
Judicious evaluation of adverse drug reactions: inaccurate assessment of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced muscle injury.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Atorvastatin; Diagnostic Errors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pyrroles; Rhabdomyolysis; Simvastatin | 1999 |
Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Benzimidazoles; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Ketoconazole; Kinetics; Lovastatin; Mibefradil; Microsomes, Liver; Oxidoreductases, N-Demethylating; Pyridines; Pyrroles; Simvastatin; Tetrahydronaphthalenes | 1999 |
Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin | 1999 |
Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin.
Topics: Apolipoproteins B; Atorvastatin; Carrier Proteins; Cell Line; Cholesterol Esters; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lipoproteins; Liver; Pyrroles; Receptors, LDL; RNA, Messenger; Simvastatin | 1999 |
Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model.
Topics: Animals; Aorta; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Male; Platelet Adhesiveness; Platelet Aggregation; Pyrroles; Rabbits; Simvastatin; Thrombosis | 1999 |
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 1999 |
Lipophilic statins induce apoptosis of human vascular smooth muscle cells.
Topics: Animals; Anticholesteremic Agents; Apoptosis; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth, Vascular; Pravastatin; Protein Prenylation; Pyrroles; Rats; Simvastatin | 1999 |
Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity.
Topics: Animals; Anticholesteremic Agents; Aorta; Atorvastatin; Calcium; Cells, Cultured; Chelating Agents; Dose-Response Relationship, Drug; Drug Interactions; Fura-2; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Mevalonic Acid; Muscle Contraction; Muscle, Smooth, Vascular; Phenylephrine; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Vasoconstrictor Agents | 1999 |
Efficacy of statin therapy: possible effect of phenytoin.
Topics: Anticholesteremic Agents; Atorvastatin; Cytochrome P-450 Enzyme System; Drug Interactions; Epilepsy; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Middle Aged; Phenytoin; Pyrroles; Simvastatin | 1999 |
Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits.
Topics: Acyl Coenzyme A; Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol, Dietary; Choline-Phosphate Cytidylyltransferase; Enzymes; Heptanoic Acids; Lipids; Lipoprotein Lipase; Lipoproteins, VLDL; Liver; Male; Phospholipids; Pyrroles; Rabbits; Simvastatin; Sterol O-Acyltransferase; Triglycerides | 1999 |
Tamoxifen and hypertriglyceridemia.
Topics: Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Atorvastatin; Breast Neoplasms; Clofibrate; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Middle Aged; Pyrroles; Simvastatin; Tamoxifen; Treatment Outcome | 1999 |
Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
Topics: Analysis of Variance; Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Guinea Pigs; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Lipoproteins, LDL; Liver; Male; Pyrroles; Simvastatin | 1999 |
Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors.
Topics: Animals; Arteriosclerosis; Atorvastatin; Chemokine CCL2; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; DNA; Down-Regulation; Fibrinogen; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Polymerase Chain Reaction; Pyrroles; Rabbits; Simvastatin; Tunica Intima | 1999 |
The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
Topics: Animals; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, LDL; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Liver; Microsomes, Liver; Pyrroles; Simvastatin; Swine; Swine, Miniature; Triglycerides | 1999 |
Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men.
Topics: Adult; Angiotensin Receptor Antagonists; Atorvastatin; Blood Pressure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Reactive Oxygen Species; Receptors, Angiotensin; Simvastatin | 1999 |
Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; DNA; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Male; Mutation; Pyrroles; Receptors, LDL; Simvastatin; Treatment Outcome; Triglycerides; Tunica Intima; Vitamin E | 1999 |
Relationship between inhibition of mevalonate biosynthesis and reduced fertility in laying hens.
Topics: Animals; Atorvastatin; Chickens; Enzyme Inhibitors; Female; Fertility; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insemination, Artificial; Lovastatin; Mevalonic Acid; Oviposition; Pyrroles; Simvastatin | 1999 |
Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Prospective Studies; Pyrroles; Rhabdomyolysis; Simvastatin; Triglycerides | 1999 |
[Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?].
Topics: Adenosine Triphosphate; Animals; Atorvastatin; Dogs; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myocardial Contraction; Myocardial Ischemia; Myocardial Stunning; Myocardium; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
Atorvastatin and simvastatin have distinct effects on hydroxy methylglutaryl-CoA reductase activity and mRNA abundance in the guinea pig.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Enzyme Inhibitors; Fasting; Gene Expression Regulation, Enzymologic; Guinea Pigs; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Lipids; Male; Microsomes, Liver; Pyrroles; RNA, Messenger; Simvastatin | 1999 |
Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs.
Topics: Adenosine Triphosphate; Animals; Atorvastatin; Cholesterol; Dogs; Fatty Acids, Monounsaturated; Female; Fluvastatin; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Myocardial Reperfusion Injury; Myocardial Stunning; Perfusion; Pyridines; Pyrroles; Random Allocation; Simvastatin; Solubility; Time Factors | 2000 |
Effect of statin therapy on restenosis after coronary stent implantation.
Topics: Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Coronary Angiography; Coronary Disease; Disease-Free Survival; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hyperplasia; Indoles; Lovastatin; Male; Middle Aged; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Stents; Time Factors; Tunica Intima | 2000 |
A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study.
Topics: Anticholesteremic Agents; Atorvastatin; Costs and Cost Analysis; Heptanoic Acids; Humans; Pyrroles; Simvastatin | 2000 |
Pleiotropic effects of statins in atherosclerosis and diabetes.
Topics: Animals; Arteriosclerosis; Atorvastatin; Cell Division; Cell Movement; Cells, Cultured; Cholesterol; Cholesterol Esters; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endocytosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins; Lovastatin; Macrophages; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Muscle, Smooth; Pyridines; Pyrroles; Simvastatin | 2000 |
HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
Topics: Animals; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Microsomes, Liver; Pravastatin; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Species Specificity | 2000 |
Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death.
Topics: Apoptosis; Atorvastatin; Cell Survival; Cells, Cultured; Coronary Vessels; Cytokines; Dose-Response Relationship, Drug; Endothelium, Vascular; Fas Ligand Protein; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Membrane Glycoproteins; Muscle, Smooth, Vascular; Pravastatin; Pyrroles; Reference Values; Sensitivity and Specificity; Simvastatin | 2000 |
Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.
Topics: Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Least-Squares Analysis; Linear Models; Lovastatin; Nonlinear Dynamics; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Tachyphylaxis; Time Factors | 2000 |
Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting.
Topics: Aged; Anticholesteremic Agents; Arrhythmias, Cardiac; Atorvastatin; Cause of Death; Coronary Artery Bypass; Coronary Disease; Female; Heart Failure; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Preoperative Care; Pyrroles; Recurrence; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2000 |
Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipids; Male; Middle Aged; Norway; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Simvastatin; Surveys and Questionnaires | 2000 |
Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Cholesterol Esters; Female; Heptanoic Acids; Lipoproteins, VLDL; Liver; Lovastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin | 2000 |
ICAAC: nelfinavir interacts with statins and an antiseizure drug.
Topics: Anticholesteremic Agents; Anticonvulsants; Atorvastatin; Drug Interactions; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nelfinavir; Phenytoin; Pyrroles; Simvastatin | 2000 |
Therapy with statins is effective in some patients with homozygous familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Pyrroles; Simvastatin | 2000 |
Limitation of heart growth in neonatal piglets by simvastatin and atorvastatin: comparison with pravastatin.
Topics: Administration, Oral; Animals; Animals, Newborn; Atorvastatin; Blood Pressure; Body Weight; DNA; Heart; Heart Rate; Heart Ventricles; Heptanoic Acids; Mitogen-Activated Protein Kinases; Myocardium; Organ Size; Pravastatin; Proteins; Pyrroles; RNA; Simvastatin; Swine; Water | 2001 |
Statin induced myopathy does not show up in MIBI scintigraphy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi | 2001 |
A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Models, Economic; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
Topics: 3T3 Cells; Adenosine Triphosphate; Animals; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Pravastatin; Pyrroles; Simvastatin | 2001 |
Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
Topics: Atorvastatin; Cell Line; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; Pravastatin; Pyrroles; Quinolines; Receptors, LDL; RNA, Messenger; Simvastatin | 2000 |
Measurement of atherosclerosis progression.
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Artery Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Pyrroles; Simvastatin | 2001 |
Measurement of atherosclerosis progression.
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Pyrroles; Simvastatin | 2001 |
Rigorous detection and vigorous treatment of familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Tunica Intima; Ultrasonography | 2001 |
Effect of statins on bone mineral density and bone histomorphometry in rodents.
Topics: Animals; Atorvastatin; Bone Density; Bone Development; Bone Resorption; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ovariectomy; Pravastatin; Pyrroles; Radiography; Rats; Rats, Sprague-Dawley; Simvastatin | 2001 |
Development of tachyphylaxis on statin treatment.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pyrroles; Research Design; Simvastatin; Tachyphylaxis | 2001 |
Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.
Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Calcinosis; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Echocardiography; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Multivariate Analysis; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; Vascular Patency | 2001 |
Managed care trends in statin usage.
Topics: Anticholesteremic Agents; Atorvastatin; Databases, Factual; Drug Costs; Drug Utilization Review; Fatty Acids, Monounsaturated; Fluvastatin; Health Care Sector; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Managed Care Programs; Pravastatin; Pyridines; Pyrroles; Simvastatin; United States | 2001 |
Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells.
Topics: Anticholesteremic Agents; Atorvastatin; CCAAT-Enhancer-Binding Proteins; Cholesterol; DNA-Binding Proteins; fas Receptor; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lovastatin; Pyrroles; Receptors, LDL; Simvastatin; Sterol Regulatory Element Binding Protein 1; Transcription Factors; Triglycerides; Tumor Cells, Cultured | 2001 |
HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells.
Topics: Anticholesteremic Agents; Atorvastatin; Cell Adhesion; Cells, Cultured; Endothelium, Vascular; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lipopolysaccharide Receptors; Monocytes; NF-kappa B; Pyridines; Pyrroles; Receptors, LDL; RNA, Messenger; Simvastatin; Tetradecanoylphorbol Acetate; U937 Cells; Vascular Cell Adhesion Molecule-1 | 2001 |
Inhibition of LOX-1 by statins may relate to upregulation of eNOS.
Topics: Atorvastatin; Cells, Cultured; Coronary Vessels; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Mitogen-Activated Protein Kinases; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pyrroles; Receptors, LDL; Receptors, Oxidized LDL; RNA, Messenger; Scavenger Receptors, Class E; Simvastatin; Up-Regulation | 2001 |
The use over time of statins in coronary patients in an Italian tertiary referral center.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Drug Utilization Review; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Italy; Male; Middle Aged; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2001 |
Effect of tablet splitting on serum cholesterol concentrations.
Topics: Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Drug Costs; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Retrospective Studies; Simvastatin; Tablets; West Virginia | 2002 |
3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation.
Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Atorvastatin; Caspase Inhibitors; Caspases; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Flow Cytometry; Fluorescent Antibody Technique, Indirect; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Muscle, Smooth, Vascular; Polyisoprenyl Phosphates; Protein Prenylation; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Rabbits; Rats; rhoA GTP-Binding Protein; Sesquiterpenes; Simvastatin; Time Factors | 2002 |
Effectiveness of low doses of simvastatin versus atorvastatin: resolving conflicting evidence.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Evidence-Based Medicine; Heptanoic Acids; Humans; Pyrroles; Simvastatin | 2002 |
Impact of HMG CoA reductase inhibition on small GTPases in the heart.
Topics: Angiotensin II; Animals; Atorvastatin; Atrial Natriuretic Factor; Cardiac Myosins; Cardiomegaly; Cell Membrane; Cells, Cultured; Gene Expression Regulation; GTP Phosphohydrolases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Myocardium; Myosin Light Chains; Pyrroles; rac1 GTP-Binding Protein; Rats; Rats, Sprague-Dawley; rhoA GTP-Binding Protein; RNA, Messenger; Simvastatin | 2002 |
Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization.
Topics: Animals; Atorvastatin; Bile; Dogs; Glucuronides; Glucuronosyltransferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Magnetic Resonance Spectroscopy; Microsomes, Liver; Protein Isoforms; Pyridines; Pyrroles; Rats; Recombinant Proteins; Simvastatin; Uridine Diphosphate Glucuronic Acid | 2002 |
Interaction between ritonavir and statins.
Topics: Atorvastatin; Cytochrome P-450 Enzyme System; Drug Interactions; Heptanoic Acids; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Ritonavir; Simvastatin | 2002 |
Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose).
Topics: Acarbose; Adverse Drug Reaction Reporting Systems; Anticholesteremic Agents; Atorvastatin; Chromans; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrroles; Simvastatin; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
Topics: Acetyl-CoA Carboxylase; Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cricetinae; DNA-Binding Proteins; Enzyme Activation; Fatty Acid Synthases; Fatty Acids; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, VLDL; Liver; Male; Mesocricetus; Phospholipids; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Simvastatin; Sterol Regulatory Element Binding Protein 2; Transcription Factors; Triglycerides | 2002 |
Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Clinical Trials as Topic; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2002 |
Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1.
Topics: Atorvastatin; Cell Adhesion; Cell Adhesion Molecules; Coronary Vessels; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; NF-kappa B; Pyrroles; Receptors, LDL; Receptors, Oxidized LDL; Scavenger Receptors, Class E; Simvastatin | 2002 |
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase the binding activity and nuclear level of Oct-1 in mononuclear cells.
Topics: Atorvastatin; Cell Line; Cell Nucleus; DNA-Binding Proteins; Dose-Response Relationship, Drug; Heptanoic Acids; Host Cell Factor C1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Monocytes; Octamer Transcription Factor-1; Protein Binding; Pyrroles; Simvastatin; Transcription Factors; Up-Regulation | 2002 |
The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Muscular Diseases; Myositis; Pravastatin; Pyrroles; Rhabdomyolysis; Simvastatin | 2002 |
Summaries for patients. Muscle abnormalities in four patients taking statins to treat unfavorable cholesterol levels.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biopsy; Creatine Kinase; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Muscular Diseases; Pain; Pyrroles; Simvastatin | 2002 |
Effects of fibrates on metabolism of statins in human hepatocytes.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cytochrome P-450 CYP2C8; Fenofibrate; Fluorobenzenes; Gemfibrozil; Glucuronosyltransferase; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; In Vitro Techniques; Microsomes, Liver; Oxidation-Reduction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2002 |
Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury.
Topics: Atorvastatin; CD55 Antigens; Cell Line; Cells, Cultured; Complement Activation; Complement C3; Cytoprotection; Diterpenes; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Nitric Oxide; Phosphatidylinositol 3-Kinases; Polyisoprenyl Phosphates; Protein Kinase C; Pyrroles; rho GTP-Binding Proteins; RNA, Messenger; Simvastatin; Up-Regulation | 2002 |
Statins and homocysteine.
Topics: Atorvastatin; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperhomocysteinemia; Pyrroles; Risk Factors; Simvastatin | 2003 |
Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice.
Topics: Aged; Atorvastatin; Cardiology; Cholesterol, LDL; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Observer Variation; Patient Compliance; Pravastatin; Probability; Prospective Studies; Pyrroles; Reference Values; Simvastatin; Treatment Failure; Treatment Outcome | 2002 |
Comparison of the effects of atorvastatin versus simvastatin on subclinical atherosclerosis in primary preventionas determined by electronbeam tomography.
Topics: Analysis of Variance; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Chi-Square Distribution; Disease Progression; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Niacin; Primary Prevention; Pyrroles; Risk Factors; Simvastatin; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells.
Topics: Atorvastatin; Cell Line; Cell Survival; Down-Regulation; Endothelial Growth Factors; Endothelium, Vascular; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia-Inducible Factor 1, alpha Subunit; I-kappa B Proteins; Inflammation; Lovastatin; Muscle, Smooth, Vascular; NF-kappa B; NF-KappaB Inhibitor alpha; Plasminogen Activator Inhibitor 1; Protein Binding; Proto-Oncogene Proteins c-jun; Pyrroles; RNA, Messenger; Simvastatin; Transcription Factor AP-1; Transcription Factors; Vascular Endothelial Growth Factor A | 2003 |
Statin-induced myositis migrans.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Myositis; Pravastatin; Pyrroles; Simvastatin; Time Factors | 2002 |
[Ezetimib plus statin combination. A strong duo].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Risk Factors; Simvastatin | 2002 |
Muscular adverse effects of statins.
Topics: Anticholesteremic Agents; Fatty Acids, Monounsaturated; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Pyridines; Pyrroles; Rhabdomyolysis; Simvastatin | 2003 |
A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
Topics: Atorvastatin; Cholesterol; Clinical Trials as Topic; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Models, Economic; Pravastatin; Pyrroles; Simvastatin; United Kingdom | 2003 |
Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia.
Topics: Administration, Oral; Animals; Atorvastatin; Cholesterol, HDL; Disease Models, Animal; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Mice; Mice, Knockout; Oxazepines; Piperidines; Pyrroles; Rabbits; Receptors, LDL; Simvastatin; Species Specificity; Time Factors; Triglycerides | 2003 |
Comparison of the frequency of adverse events in patients treated with atorvastatin or simvastatin.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscles; Pyrroles; Simvastatin | 2003 |
Triglyceride-lowering effect of pitavastatin in a guinea pig model of postprandial lipemia.
Topics: Animals; Anticoagulants; Atorvastatin; Carrier Proteins; Guinea Pigs; Heparin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Intestinal Mucosa; Lipids; Lipoproteins; Male; Postprandial Period; Pyrroles; Quinolines; Simvastatin; Triglycerides | 2003 |
Variable influence of statins on isoprostanes in hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Dinoprost; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Isoprostanes; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Smoking | 2003 |
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States | 2003 |
[Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Meta-Analysis as Topic; Placebos; Pravastatin; Primary Prevention; Pyrroles; Simvastatin; Time Factors | 2003 |
Effect of pitavastatin on sterol and bile acid excretion in guinea pigs.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol 7-alpha-Hydroxylase; Cholesterol, HDL; Feces; Guinea Pigs; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Quinolines; RNA, Messenger; Simvastatin; Sterols | 2003 |
Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature.
Topics: Animals; Aorta; Atorvastatin; Bradykinin; Calcimycin; Cells, Cultured; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; In Vitro Techniques; Lipids; Microscopy, Fluorescence; NAD; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Oxidation-Reduction; Oxygen; Pyrroles; Rats; Rats, Sprague-Dawley; Rhodamines; Simvastatin; Subcellular Fractions; Superoxide Dismutase; Up-Regulation; Vasodilation | 2003 |
[Effect of combined antihypertensive and lipid lowering therapy on the level of coronary risk and tissue insulin resistance in patients with metabolic syndrome].
Topics: Adult; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Indapamide; Male; Metabolic Syndrome; Middle Aged; Perindopril; Pyrroles; Simvastatin; Treatment Outcome | 2003 |
Statins: new data in secondary prevention and diabetes. Pravastatin and simvastatin are the best-assessed statins.
Topics: Aged; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus; Drug Evaluation; Heptanoic Acids; Humans; Hypertension; Pravastatin; Pyrroles; Rhabdomyolysis; Simvastatin; Stroke; Treatment Outcome | 2003 |
[Comparative study of lipid lowering effect and influence on platelet aggregation of atorvastatin and simvastatin in patients ischemic heart disease with type II diabetes and combined hyperlipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation; Pyrroles; Simvastatin | 2003 |
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes.
Topics: ADP Ribose Transferases; Animals; Atorvastatin; Botulinum Toxins; Cells, Cultured; Cytotoxicity Tests, Immunologic; Enzyme Inhibitors; Fas Ligand Protein; Genes, Dominant; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ionophores; Jurkat Cells; Leukocytes, Mononuclear; Lymphocyte Activation; Membrane Glycoproteins; Mevalonic Acid; Mice; Phorbol Esters; Protein Prenylation; Pyrroles; rhoA GTP-Binding Protein; Simvastatin; T-Lymphocytes; Transfection | 2003 |
Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation.
Topics: Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Nitric Oxide; Polyisoprenyl Phosphates; Pyrroles; Simvastatin; Thrombomodulin; Tumor Necrosis Factor-alpha | 2003 |
Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
Topics: Animals; Arteriosclerosis; Atorvastatin; Blotting, Western; CD40 Antigens; Cells, Cultured; Depression, Chemical; Dose-Response Relationship, Drug; Endothelial Cells; Fibroblasts; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interferon-gamma; Lovastatin; Macrophages; Mevalonic Acid; Mice; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Pravastatin; Pyrroles; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Simvastatin; Transcription Factors | 2003 |
Spontaneous reports cannot serve as a basis for comparison of two drugs.
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin; United States; United States Food and Drug Administration | 2003 |
Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Niacin; Particle Size; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2003 |
Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells.
Topics: Atorvastatin; Cells, Cultured; Coronary Vessels; Dose-Response Relationship, Drug; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth, Vascular; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Simvastatin; Umbilical Veins; Vascular Endothelial Growth Factor A | 2003 |
Effects of simvastatin and atorvastatin in hypercholesterolemic patients.
Topics: Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin; Triglycerides | 2003 |
Effect of statins on the progression of bioprosthetic aortic valve degeneration.
Topics: Aged; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Atorvastatin; Bioprosthesis; Coronary Artery Bypass; Coronary Artery Disease; Female; Heart Valve Prosthesis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pravastatin; Prosthesis Failure; Pyrroles; Retrospective Studies; Simvastatin; Treatment Outcome; Ultrasonography | 2003 |
Cognitive impairment associated with atorvastatin and simvastatin.
Topics: Aged; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Memory Disorders; Pyrroles; Simvastatin | 2003 |
Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA.
Topics: Antioxidants; Atorvastatin; Catalase; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coenzymes; Erythrocytes; Fatty Acids, Unsaturated; Glutathione; Glutathione Peroxidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lymphocytes; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Superoxide Dismutase; Ubiquinone; Vitamin E | 2003 |
HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis.
Topics: Adjuvants, Immunologic; Antigens, CD; Arteriosclerosis; Atorvastatin; B7-2 Antigen; Bone Marrow Cells; CD83 Antigen; Cell Survival; Cells, Cultured; Dendritic Cells; Flow Cytometry; Heptanoic Acids; HLA-DR Antigens; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulins; Lymphocyte Culture Test, Mixed; Membrane Glycoproteins; Pyrroles; Receptors, CCR7; Receptors, Chemokine; Simvastatin; Time Factors; Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2004 |
Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro.
Topics: Animals; Atorvastatin; C-Reactive Protein; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Cholesterol; Down-Regulation; Gene Expression; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; I-kappa B Proteins; In Vitro Techniques; Interleukin-1; Male; Mice; Mice, Transgenic; NF-kappa B; NF-kappa B p50 Subunit; NF-KappaB Inhibitor alpha; Pyrroles; Receptors, Cytoplasmic and Nuclear; Simvastatin; Transcription Factors; Up-Regulation | 2004 |
Is there a "best" statin drug?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heptanoic Acids; Humans; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Toward a role for statins in immunomodulation.
Topics: Adjuvants, Immunologic; Animals; Atorvastatin; Autoimmune Diseases; Cytokines; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Genes, MHC Class II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Lovastatin; Mice; Pravastatin; Pyrroles; Simvastatin | 2002 |
Statins downregulate ATP-binding-cassette transporter A1 gene expression in macrophages.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Biological Transport; Blotting, Northern; Cell Line; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Luciferases; Macrophages; Mice; Oxygen; Promoter Regions, Genetic; Pyrroles; RNA, Messenger; Simvastatin; Swiss 3T3 Cells; Time Factors; Transcription, Genetic | 2004 |
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Incidence; Inflammation; Interleukin-6; Lovastatin; Pravastatin; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2004 |
Successful reintroduction of statin therapy after myositis: was there another cause?
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypothyroidism; Male; Myositis; Pyrroles; Simvastatin | 2004 |
Cell-based screen of HMG-CoA reductase inhibitors and expression regulators using LC-MS.
Topics: Atorvastatin; Biological Assay; Calibration; Cell Line; Chromatography, Liquid; Enzyme Induction; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mass Spectrometry; Mevalonic Acid; Pyrroles; Simvastatin | 2004 |
Class-specific pro-apoptotic effect of statins on human vascular endothelial cells.
Topics: Apoptosis; Atorvastatin; Cell Division; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Fas Ligand Protein; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Membrane Glycoproteins; Metabolic Clearance Rate; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Simvastatin; Umbilical Veins | 2004 |
Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors.
Topics: Adult; Annexin A5; Apoptosis; Atorvastatin; Caspase 3; Caspases; Cholesterol; Enzyme Inhibitors; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Pravastatin; Proto-Oncogene Proteins c-bcl-2; Pyrroles; RNA, Messenger; Simvastatin | 2004 |
Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Atorvastatin; Databases, Factual; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrroles; Rosiglitazone; Simvastatin; Thiazolidinediones; United States; United States Food and Drug Administration | 2004 |
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.
Topics: Alitretinoin; Animals; Atorvastatin; Base Sequence; Cell Line; Cholesterol; Consensus Sequence; DNA-Binding Proteins; Gene Expression Regulation; Hepatocytes; Heptanoic Acids; Homeostasis; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver X Receptors; Lovastatin; Mevalonic Acid; Mice; Orphan Nuclear Receptors; Promoter Regions, Genetic; Proprotein Convertase 9; Proprotein Convertases; Pyridines; Pyrroles; Quinolines; Rats; Receptors, Cytoplasmic and Nuclear; Regulatory Sequences, Nucleic Acid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Alignment; Sequence Homology, Nucleic Acid; Serine Endopeptidases; Simvastatin; Sp1 Transcription Factor; Species Specificity; Sterol Regulatory Element Binding Protein 2; Transcription Factors; Tretinoin | 2004 |
Update on statins.
Topics: Atorvastatin; Coronary Disease; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively.
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Carotid Artery Diseases; Endarterectomy, Carotid; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukins; Male; Matrix Metalloproteinases; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Tissue Inhibitor of Metalloproteinases; Tumor Necrosis Factor-alpha; Ultrasonography | 2004 |
Lipid-lowering response to statins is affected by CYP3A5 polymorphism.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genotype; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Polymorphism, Genetic; Pyrroles; Simvastatin | 2004 |
Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins.
Topics: Amino Acid Substitution; Antioxidants; Atorvastatin; Cells, Cultured; Cysteine; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mutagenesis, Site-Directed; Nitric Oxide; Oxidation-Reduction; Oxidative Stress; Protein Processing, Post-Translational; Pyrroles; Reactive Oxygen Species; Recombinant Fusion Proteins; S-Nitrosothiols; Simvastatin; Thioredoxins; Transfection; Umbilical Veins | 2004 |
Updated guidelines support even lower cholesterol levels for at-risk patients.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Risk Factors; Risk Reduction Behavior; Simvastatin; Triglycerides; United States | 2004 |
Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Cell Line; Drug Interactions; Heptanoic Acids; Humans; Hypolipidemic Agents; Pyrroles; Ritonavir; Simvastatin; Time Factors | 2004 |
Atorvastatin and simvastatin decrease the uptake of acetylated low-density lipoprotein by human monocytes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Calcium Channel Blockers; Dose-Response Relationship, Drug; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Monocytes; Pyrroles; Simvastatin; U937 Cells | 2005 |
Formulary conversion programs: the need for patient-specific risk assessment.
Topics: Aged; Atorvastatin; Cyclosporine; Drug Interactions; Female; Formularies as Topic; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Postoperative Care; Pyrroles; Rhabdomyolysis; Risk Assessment; Simvastatin | 2004 |
Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting.
Topics: Aged; Atorvastatin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation Inhibitors; Preoperative Care; Prospective Studies; Pyrroles; Simvastatin; Stents; Ticlopidine | 2004 |
[Sequelae of the CARDS Study. LDL of 110 mg/dl still too high?].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Long-Term Care; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2004 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003.
Topics: Atorvastatin; Coronary Disease; Fluorobenzenes; Goals; Heptanoic Acids; History, 20th Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Race, ethnicity, and sociocultural characteristics predict noncompliance with lipid-lowering medications.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Female; Health Status; Heptanoic Acids; Humans; Interviews as Topic; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Pyrroles; Simvastatin; Socioeconomic Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Urban Population | 2004 |
[Target values are more often attainable. Almost doubly so many patients with values under 100mg/dl].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Randomized Controlled Trials as Topic; Reference Values; Simvastatin; Time Factors | 2004 |
Synthes Award for Resident Research in Spinal Cord & Spinal Column Injury: Statins for the treatment of neurological injury: a role beyond cholesterol lowering.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Awards and Prizes; Brain Injuries; Heptanoic Acids; Hypercholesterolemia; Immunoblotting; Interleukin-6; Internship and Residency; Mice; Pyrroles; Research; RNA, Messenger; Simvastatin; Spinal Cord Injuries; Subarachnoid Hemorrhage | 2004 |
Assessment of the efficacy of different statins in murine collagen-induced arthritis.
Topics: Animals; Arthritis, Experimental; Atorvastatin; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lymph Nodes; Male; Mice; Mice, Inbred DBA; Nuclear Proteins; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Trans-Activators; Treatment Outcome | 2004 |
Statin-associated exacerbation of myasthenia gravis.
Topics: Atorvastatin; Cytokines; Dysarthria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lovastatin; Male; Middle Aged; Mitochondria; Models, Neurological; Muscular Diseases; Myasthenia Gravis; Neural Conduction; Pravastatin; Pyridostigmine Bromide; Pyrroles; Simvastatin; Th2 Cells; Ubiquinone | 2004 |
Lipid metabolism in zebrafish.
Topics: 4-Chloro-7-nitrobenzofurazan; Alkyl and Aryl Transferases; Animals; Annexin A2; Atorvastatin; Azetidines; Boron Compounds; Caveolin 1; Caveolins; Cell Movement; Cholesterol; Diterpenes; DNA; Embryo, Nonmammalian; Ethylnitrosourea; Ezetimibe; Farnesol; Farnesyltranstransferase; Geranyltranstransferase; Germ Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lovastatin; Mevalonic Acid; Microscopy, Fluorescence; Mutagenesis, Site-Directed; Mutation; Phosphatidylethanolamines; Protein Binding; Protein Prenylation; Pyrroles; Simvastatin; Zebrafish | 2004 |
Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.
Topics: Adenosine Triphosphate; Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Dogs; Estradiol; Fluoresceins; Heptanoic Acids; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Permeability; Pyrroles; Simvastatin; Structure-Activity Relationship | 2005 |
High-dose statins in acute coronary syndromes.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Myocardial Ischemia; Pyrroles; Risk; Simvastatin | 2005 |
Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Protein Precursor; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracellular Signaling Peptides and Proteins; Molecular Sequence Data; Neuroblastoma; Phosphorylation; Protein Serine-Threonine Kinases; Pyrroles; rho-Associated Kinases; Simvastatin; Tumor Cells, Cultured | 2005 |
A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
Topics: Area Under Curve; Atorvastatin; Biomedical Research; Databases, Bibliographic; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Japan; Pharmacology, Clinical; Pravastatin; Product Labeling; Pyrroles; Quinolines; Simvastatin; United States; United States Food and Drug Administration | 2005 |
[Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Cost Control; Drug Costs; Ezetimibe; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance Coverage; Male; Middle Aged; National Health Programs; Pyrroles; Simvastatin | 2004 |
Reduction of cerebral infarction in stroke-prone spontaneously hypertensive rats by statins associated with amelioration of oxidative stress.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldehydes; Animals; Atorvastatin; Blood Pressure; Body Weight; Deoxyguanosine; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Infarction, Middle Cerebral Artery; Lipids; Lysine; Oxidative Stress; Pyrroles; Quinolines; Rats; Rats, Inbred SHR; Simvastatin; Survival Analysis | 2005 |
Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia.
Topics: Animals; Atorvastatin; Brain Ischemia; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Embolism; Male; Mice; Mice, Inbred Strains; Mice, Knockout; Neuroprotective Agents; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrroles; Simvastatin; Stroke; Tissue Plasminogen Activator | 2005 |
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Topics: Aged; Ambulatory Care; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Comorbidity; Cross-Sectional Studies; Cyclosporine; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Male; Niacin; Oxidoreductases, N-Demethylating; Physicians; Pravastatin; Prevalence; Product Surveillance, Postmarketing; Pyrroles; Simvastatin; Time Factors | 2005 |
Assessing adherence to statin therapy using patient report, pill count, and an electronic monitoring device.
Topics: Atorvastatin; Cohort Studies; Data Collection; Electronics, Medical; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Compliance; Prospective Studies; Pyrroles; Research Design; Simvastatin | 2005 |
Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Ticlopidine | 2004 |
Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.
Topics: Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Carcinoma, Hepatocellular; Cell Line, Tumor; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Liver Neoplasms; Phosphorylation; Pravastatin; Protein Prenylation; Pyrroles; RNA, Messenger; Simvastatin; STAT3 Transcription Factor | 2005 |
Statin drugs and congenital anomalies.
Topics: Abnormalities, Drug-Induced; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant, Newborn; Lovastatin; Pregnancy; Pregnancy Outcome; Pyrroles; Simvastatin | 2005 |
Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
Topics: Aged; Atorvastatin; Cohort Studies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Mortality; Myocardial Infarction; Patient Compliance; Pravastatin; Proportional Hazards Models; Pyrroles; Retrospective Studies; Secondary Prevention; Simvastatin; Survival Analysis | 2005 |
Adverse events with concomitant amiodarone and statin therapy.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Amiodarone; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Simvastatin; United States; United States Food and Drug Administration | 2005 |
Plaque regression--a new target for antiatherosclerotic therapy.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Premedication; Pyrroles; Radiography; Remission Induction; Risk Reduction Behavior; Simvastatin; Ultrasonography | 2005 |
[Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits].
Topics: Animals; Anticholesteremic Agents; Aortic Diseases; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, LDL; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hypercholesterolemia; Indoles; Lipid Peroxidation; Male; Malondialdehyde; Pravastatin; Pyrroles; Rabbits; Simvastatin | 2005 |
Evaluation of apoptosis and necrosis induced by statins using fluorescence-enhanced flow cytometry.
Topics: Apoptosis; Atorvastatin; Avidin; Biotin; Cell Line; Cell Separation; Cells, Cultured; Drug Industry; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Flow Cytometry; Fluorescein-5-isothiocyanate; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Leukemia; Microscopy, Fluorescence; Necrosis; Pharmaceutical Preparations; Pravastatin; Propidium; Pyridines; Pyrroles; Simvastatin; Time Factors | 2005 |
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.
Topics: Alleles; Atorvastatin; Biological Transport; Cells, Cultured; Genetic Variation; HeLa Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Liver-Specific Organic Anion Transporter 1; Mutagenesis, Site-Directed; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pravastatin; Pyridines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin; Substrate Specificity; Transfection | 2005 |
Intensive lipid lowering with atorvastatin in coronary disease.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mortality; Pyrroles; Simvastatin | 2005 |
Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; C-Reactive Protein; Carotid Arteries; Cholesterol, LDL; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pyrroles; Simvastatin; Tunica Intima; Tunica Media | 2006 |
Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes.
Topics: 3T3-L1 Cells; Animals; Atorvastatin; Cell Culture Techniques; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Mevalonic Acid; Mice; Pioglitazone; PPAR gamma; Pravastatin; Pyrroles; Quinolines; RNA, Messenger; Simvastatin; Thiazolidinediones | 2005 |
Statin use after acute myocardial infarction: a nationwide study in Denmark.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Ambulatory Care; Atorvastatin; Denmark; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Population Surveillance; Pravastatin; Pyrroles; Registries; Sex Distribution; Simvastatin | 2005 |
In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells.
Topics: Atorvastatin; Cell Proliferation; Cytokines; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Leukocytes, Mononuclear; Lovastatin; Mitogens; Pravastatin; Pyrroles; Simvastatin | 2005 |
Reply to Al-Shaer, is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (Am Heart J 2005;149:e17.).
Topics: Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Pyrroles; Simvastatin | 2005 |
The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells.
Topics: Atorvastatin; Cell Division; Cell Movement; Chemotaxis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Myocytes, Smooth Muscle; Pravastatin; Pyridines; Pyrroles; Saphenous Vein; Simvastatin | 2005 |
Not all statins interfere with clopidogrel during antiplatelet therapy.
Topics: Adult; Atorvastatin; Chromatography, High Pressure Liquid; Clopidogrel; Drug Interactions; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ticlopidine | 2005 |
The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease.
Topics: Aged; Atorvastatin; Blood Platelets; Cholesterol, LDL; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Ticlopidine; Time Factors; Wound Healing | 2005 |
Effects of statins on microglia.
Topics: Amyloid beta-Peptides; Animals; Atorvastatin; Cell Death; Cell Line; Cell Survival; Cytokines; Dose-Response Relationship, Drug; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; L-Lactate Dehydrogenase; Lipopolysaccharides; Microglia; Peptide Fragments; Pyrroles; Rats; Simvastatin; Statistics, Nonparametric; Tetrazolium Salts; Thiazoles | 2005 |
Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: the CAPISH study.
Topics: Aged; Atorvastatin; Cholesterol; Cohort Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Retrospective Studies; Simvastatin; Treatment Failure; Triglycerides | 2005 |
New light on statin side effects. What recent research on the cholesterol drugs means to you.
Topics: Atorvastatin; Biomedical Research; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Differences between statins on clinical endpoints: a population-based cohort study.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Endpoint Determination; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Netherlands; Pravastatin; Pyridines; Pyrroles; Simvastatin; Treatment Outcome | 2005 |
Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Niacin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2005 |
Effect of statin therapy on serum trace element status in dyslipidaemic subjects.
Topics: Adult; Antioxidants; Atorvastatin; Blood Chemical Analysis; Ceruloplasmin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Trace Elements | 2005 |
How common is rhabdomyolysis in patients receiving lipid-lowering therapy?
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Creatine Kinase; Drug Therapy, Combination; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Middle Aged; Pravastatin; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States | 2005 |
Effect of pravastatin, simvastatin and atorvastatin on the phagocytic activity of mouse peritoneal macrophages.
Topics: Animals; Atorvastatin; Cell Proliferation; Concanavalin A; Heptanoic Acids; Lectins; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Microspheres; Mitogens; Phagocytosis; Pravastatin; Pyrroles; Simvastatin; Spleen | 2006 |
HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Pravastatin; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2005 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
The IDEAL cholesterol: lower is better.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin | 2005 |
MDOC and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoE-/- mouse model of atherosclerosis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cellulose, Oxidized; Diet; Disease Models, Animal; Endothelium, Vascular; Heptanoic Acids; Hyperlipidemias; Intercellular Adhesion Molecule-1; Lipoproteins; Male; Mice; Mice, Knockout; Pyrroles; Simvastatin; Triglycerides; Vascular Cell Adhesion Molecule-1 | 2006 |
[Cholesterol goals are now easier to reach. Half LDL cholesterol with only one tablet daily].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Controlled Clinical Trials as Topic; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin; Time Factors | 2005 |
Statins for high-risk patients without heart disease or high cholesterol.
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pravastatin; Pyrroles; Simvastatin; Stroke | 2006 |
[Drug combinations: statins and niacin].
Topics: Age Distribution; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Niacin; Pyrroles; Sex Factors; Simvastatin | 2005 |
Statins decrease serotonin-induced contractions in coronary arteries of swine in vitro.
Topics: Animals; Atorvastatin; Coronary Vessels; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Pravastatin; Pyrroles; Serotonin; Simvastatin; Swine; Time Factors; Vasoconstriction | 2006 |
Muscle symptoms associated with statins: a series of twenty patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Creatine Kinase; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pravastatin; Pyrroles; Simvastatin | 2006 |
Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins.
Topics: Aged; Aortic Aneurysm, Abdominal; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin | 2006 |
I'm taking Zocor to help lower my cholesterol. The directions say to take it at night. My friend takes Lipitor, but doesn't have to take it at night. Why the difference?
Topics: Anticholesteremic Agents; Atorvastatin; Chronotherapy; Heptanoic Acids; Humans; Pyrroles; Simvastatin | 2005 |
RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation.
Topics: Anticholesteremic Agents; Apoptosis; Atorvastatin; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Caspases; Cell Differentiation; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Humans; Osteosarcoma; Phenotype; Phosphorylation; Polyisoprenyl Phosphates; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Pyridines; Pyrroles; rhoA GTP-Binding Protein; RNA, Messenger; Signal Transduction; Simvastatin; Transforming Growth Factor beta | 2006 |
LPS-induced release of IL-1 beta, IL-1Ra, IL-6, and TNF-alpha in whole blood from patients with familial hypercholesterolemia: no effect of cholesterol-lowering treatment.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Female; Genetic Carrier Screening; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Interleukin-6; Lipopolysaccharides; Male; Middle Aged; Pyrroles; Simvastatin; Tumor Necrosis Factor-alpha | 2006 |
Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Particle Size; Polymorphism, Genetic; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2006 |
[Treatment of hypercholesterolemia--lower is better].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Evidence-Based Medicine; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin | 2006 |
Effect of statin treatment on coronary collateral development in patients with diabetes mellitus.
Topics: Angina Pectoris; Atorvastatin; Cholesterol, LDL; Collateral Circulation; Coronary Angiography; Coronary Disease; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth.
Topics: Aged; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Atorvastatin; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Netherlands; Population Surveillance; Pyrroles; Retrospective Studies; Simvastatin; Time Factors; Ultrasonography | 2006 |
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro.
Topics: Adult; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Cells, Cultured; DNA Fragmentation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Histones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myeloid Cell Leukemia Sequence 1 Protein; Myocytes, Cardiac; Neoplasm Proteins; Pravastatin; Proto-Oncogene Proteins c-bcl-2; Pyrroles; RNA, Messenger; Simvastatin | 2006 |
Direct comparison of the A to Z and PROVE IT trials: a second chance to gain a first impression.
Topics: Africa; Angioplasty, Balloon, Coronary; Asia; Atorvastatin; Australia; Canada; Case Management; Cholesterol, LDL; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Europe; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Ischemia; New Zealand; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Simvastatin; South America; Stents; Tirofiban; Treatment Outcome; Tyrosine; United States | 2006 |
Statins and stroke: current clinical practice.
Topics: Age Factors; Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Pyrroles; Secondary Prevention; Simvastatin; Stroke | 2006 |
Comparative expression profiling in primary and immortalized endothelial cells: changes in gene expression in response to hydroxy methylglutaryl-coenzyme A reductase inhibition.
Topics: Apoptosis; Atorvastatin; Cell Cycle; Cell Line, Transformed; Cells, Cultured; Endothelial Cells; Gene Expression Profiling; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Oligonucleotide Array Sequence Analysis; Pyrroles; Simvastatin | 2006 |
Inhibitory effects of statins on human monocarboxylate transporter 4.
Topics: Animals; Atorvastatin; Basigin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lactic Acid; LLC-PK1 Cells; Lovastatin; Monocarboxylic Acid Transporters; Muscle Proteins; Pyridines; Pyrroles; Simvastatin; Swine; Transfection | 2006 |
Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes.
Topics: Amino Acid Chloromethyl Ketones; Antibodies; Atorvastatin; Caspase 1; CD28 Antigens; CD3 Complex; Cells, Cultured; Enzyme Activation; Heptanoic Acids; Humans; Inflammation; Interferon-gamma; Interleukin-1; Interleukin-12; Interleukin-18; Mevalonic Acid; Mitosis; Monocytes; Pyrroles; Simvastatin; Solubility; T-Lymphocytes | 2006 |
Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin | 2006 |
Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients.
Topics: Adolescent; Adult; Aged; Atorvastatin; Child; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Male; Middle Aged; Models, Biological; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
A case of cholesterol embolism confirmed by skin biopsy and successfully treated with statins and steroids.
Topics: Aged; Atorvastatin; Biopsy; Blue Toe Syndrome; Diagnosis, Differential; Embolism, Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Prednisolone; Pyrroles; Simvastatin; Skin; Skin Diseases, Vascular; Steroids | 2006 |
Effects of preoperative statin therapy on cytokines after cardiac surgery.
Topics: Aged; Anti-Inflammatory Agents; Atorvastatin; Cardiopulmonary Bypass; Coronary Artery Bypass; Female; Heart Arrest, Induced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-10; Interleukin-6; Male; Postoperative Complications; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors | 2006 |
High-dose statins and the IDEAL study.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2006 |
High-dose statins and the IDEAL study.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2006 |
High-dose statins and the IDEAL study.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2006 |
High-dose statins and the IDEAL study.
Topics: Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2006 |
Cholesterol distribution, not total levels, correlate with altered amyloid precursor protein processing in statin-treated mice.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anticholesteremic Agents; Atorvastatin; Cell Membrane; Central Nervous System; Cholesterol; Ergosterol; Heptanoic Acids; Lovastatin; Male; Mice; Peptide Fragments; Pyrroles; Simvastatin; Synaptosomes | 2006 |
Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Meta-Analysis as Topic; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Spain | 2006 |
Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome.
Topics: Atorvastatin; Cohort Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multiple Organ Failure; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Survival Rate | 2006 |
Influence of HMG-CoA-reductase inhibitors on the body fat status.
Topics: Adipose Tissue; Aged; Arterial Occlusive Diseases; Atorvastatin; Body Composition; Body Mass Index; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Simvastatin | 2006 |
Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia.
Topics: Adult; Aged; Aged, 80 and over; Animals; Annexins; Anticholesteremic Agents; Atorvastatin; Biomarkers; Calcium Channels, L-Type; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Middle Aged; Muscle Fibers, Skeletal; Muscle, Skeletal; Pravastatin; Pyrroles; Receptors, LDL; Simvastatin | 2006 |
Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cytokines; Dose-Response Relationship, Drug; Endarterectomy, Carotid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Inflammation; Macrophages; Peptide Hydrolases; Phenotype; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Brain; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2006 |
Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Pyrroles; Quebec; Registries; Retrospective Studies; Simvastatin | 2006 |
[For coronary disease patients is certain: the lower the LDL the better].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Odds Ratio; Pravastatin; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 2006 |
Growth inhibition of Candida species and Aspergillus fumigatus by statins.
Topics: Antifungal Agents; Aspergillus fumigatus; Atorvastatin; Candida; Cholesterol; Ergosterol; Growth Inhibitors; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Pyrroles; Simvastatin | 2006 |
Statins and cerebral vasomotor reactivity: implications for a new therapy?
Topics: Adult; Animals; Arginine; Atorvastatin; Brain Ischemia; Cerebrovascular Circulation; Clinical Trials, Phase II as Topic; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Intracranial Aneurysm; Mice; Middle Cerebral Artery; Nitric Oxide; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Simvastatin; Stroke; Subarachnoid Hemorrhage; Ultrasonography, Doppler, Transcranial; Vasodilation; Vasomotor System; Vasospasm, Intracranial | 2006 |
Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer.
Topics: Aged; Atorvastatin; Biopsy; Brachytherapy; Cause of Death; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease-Free Survival; Fatty Acids, Monounsaturated; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Neoplasm Staging; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Retrospective Studies; Simvastatin; Survival Analysis | 2006 |
Autoimmune hepatitis triggered by statins.
Topics: Atorvastatin; Female; Hepatitis, Autoimmune; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Simvastatin | 2006 |
Media report of rare rhabdomyolysis cases seems to have triggered reluctance among some New Zealanders to use statins.
Topics: Anticholesteremic Agents; Atorvastatin; Health Education; Health Knowledge, Attitudes, Practice; Heptanoic Acids; Humans; Hypercholesterolemia; Mass Media; New Zealand; Pyrroles; Rhabdomyolysis; Simvastatin | 2006 |
More on switching statins: comments from Pfizer.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Simvastatin | 2006 |
Usefulness of follow-up low-density lipoprotein cholesterol level as an independent predictor of changes of coronary atherosclerotic plaque size as determined by intravascular ultrasound analysis after statin (atorvastatin or simvastatin) therapy.
Topics: Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Databases as Topic; Elastic Tissue; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Pyrroles; Simvastatin; Tunica Media; Ultrasonography, Interventional | 2006 |
Statins induce differentiation and cell death in neurons and astroglia.
Topics: Animals; Animals, Newborn; Apoptosis; Astrocytes; Atorvastatin; Cell Communication; Cell Differentiation; Cell Shape; Cell Survival; Cells, Cultured; Central Nervous System; Cholesterol; Coculture Techniques; Diterpenes; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Neurons; Polyisoprenyl Phosphates; Pyrroles; Rats; Rats, Wistar; Receptors, LDL; Simvastatin; Up-Regulation | 2007 |
Arterial stiffness and Chlamydia pneumoniae infection in coronary artery disease. Is there a link?
Topics: Adult; Aged; Arteries; Atorvastatin; Chlamydia Infections; Chlamydophila pneumoniae; Constriction, Pathologic; Coronary Artery Disease; Diabetes Mellitus; Double-Blind Method; Female; Heptanoic Acids; Humans; Immunoglobulin A; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Smoking; Vascular Resistance | 2006 |
Toxicity of statins on rat skeletal muscle mitochondria.
Topics: Animals; Apoptosis; Atorvastatin; Cytochromes c; DNA Fragmentation; Fatty Acids; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Membrane Potentials; Mitochondria, Muscle; Mitochondrial Membranes; Muscle, Skeletal; Oxygen; Pravastatin; Pyridines; Pyrroles; Rats; Simvastatin | 2006 |
Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Drug Resistance; Female; Heptanoic Acids; Heterozygote; Humans; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Retrospective Studies; Risk Factors; Scavenger Receptors, Class E; Simvastatin; Thrombosis | 2007 |
Risk factors for rhabdomyolysis with simvastatin and atorvastatin.
Topics: Atorvastatin; Australia; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Rhabdomyolysis; Risk Factors; Simvastatin | 2006 |
Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: the National FINRISK Study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cohort Studies; Coronary Disease; Female; Finland; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Surveys and Questionnaires; Treatment Outcome | 2006 |
Differential effects of statins and alendronate on cholinesterases in serum and brain of rats.
Topics: Alendronate; Animals; Atorvastatin; Bone Density Conservation Agents; Brain; Butyrylcholinesterase; Cholinesterases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2007 |
Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cost-Benefit Analysis; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Patterns, Physicians'; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2006 |
Clinical characteristics and outcomes of Chinese patients with cholesterol crystal embolism after coronary intervention.
Topics: Acute Kidney Injury; Aged; Angioplasty, Balloon, Coronary; Arteriosclerosis; Atorvastatin; China; Coronary Angiography; Embolism, Cholesterol; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Prognosis; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Treatment Outcome | 2006 |
Risk factors for rhabdomyolysis with simvastatin and atorvastatin.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Rhabdomyolysis; Risk Factors; Simvastatin | 2006 |
The MEGA study.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2006 |
Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization.
Topics: Angioplasty, Balloon, Coronary; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Biopsy, Needle; Cells, Cultured; Chemokine CCL19; Chemokine CCL21; Chemokines, CC; Coronary Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Gene Expression Regulation; Heptanoic Acids; Humans; Immunohistochemistry; In Vitro Techniques; Leukocytes, Mononuclear; Mice; Mice, Transgenic; Prognosis; Pyrroles; Receptors, CCR7; Receptors, Chemokine; Reference Values; Risk Factors; RNA, Messenger; Sensitivity and Specificity; Simvastatin; Treatment Outcome | 2007 |
Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Pravastatin; Pyrroles; Simvastatin; Sterol Regulatory Element Binding Protein 1 | 2006 |
Probable statin-induced testicular pain.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pain; Pyrroles; Simvastatin; Testis | 2007 |
Cholesterol lowering in patients with CHD and metabolic syndrome.
Topics: Aged; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Male; Medical Audit; Middle Aged; Patient Readmission; Pyrroles; Simvastatin; United Kingdom | 2007 |
Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Family Practice; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Losartan; Male; Middle Aged; Patient Satisfaction; Pyrroles; Simvastatin; Tetrazoles; Treatment Outcome | 2007 |
Diabetes and residual risk of coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Heptanoic Acids; Humans; Insulin Resistance; Obesity; Pyrroles; Risk Factors; Simvastatin | 2007 |
Progressive myopathy with up-regulation of MHC-I associated with statin therapy.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Atorvastatin; Creatine Kinase; Female; Folic Acid Antagonists; Genes, MHC Class I; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Methotrexate; Middle Aged; Mitochondria, Muscle; Muscle Weakness; Muscular Diseases; Prednisolone; Pyrroles; Sarcolemma; Simvastatin; Up-Regulation | 2007 |
Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures.
Topics: Aged; Atorvastatin; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Collagen Type I; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Osteoblasts; Osteocalcin; Osteosarcoma; Pyrroles; Simvastatin; Transforming Growth Factor beta | 2007 |
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Diseases; Lovastatin; Niacin; Pravastatin; Prevalence; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2007 |
Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes.
Topics: Antifungal Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Synergism; Fluorobenzenes; Fungi; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Microbial Sensitivity Tests; Penicillium chrysogenum; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Spores, Fungal; Sulfonamides | 2007 |
Statins enhance circulating vitamin E.
Topics: Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Oxidative Stress; Pyrroles; Retrospective Studies; Simvastatin; Vitamin E | 2008 |
Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice.
Topics: Aged; Atorvastatin; Chi-Square Distribution; Coronary Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Treatment Outcome | 2007 |
Fluvastatin as co-medication in heart transplant recipients with elevated creatine-kinase.
Topics: Adult; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2007 |
Construction of atorvastatin dose-response relationships using data from a large population-based DNA biobank.
Topics: Aged, 80 and over; Algorithms; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cohort Studies; Databases, Nucleic Acid; Dose-Response Relationship, Drug; Drug Utilization Review; Female; Heptanoic Acids; Humans; Male; Pyrroles; Reproducibility of Results; Simvastatin; Treatment Outcome; Wisconsin | 2007 |
Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drugs, Generic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quality of Life; Simvastatin; Survival Rate; Time Factors | 2007 |
Use of maximum-dose simvastatin or atorvastatin in an ethnically diverse population.
Topics: Aged; Atorvastatin; California; Drug Interactions; Ethnicity; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Retrospective Studies; Simvastatin | 2007 |
Did a flawed study design affect the results of the VYTAL study?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Diabetes Mellitus, Type 2; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Multicenter Studies as Topic; Pyrroles; Random Allocation; Research Design; Simvastatin | 2007 |
Switching statins in Norway after new reimbursement policy: a nationwide prescription study.
Topics: Atorvastatin; Drug Costs; Drug Utilization; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Norway; Pyrroles; Reimbursement Mechanisms; Simvastatin | 2007 |
Effects of atorvastatin and simvastatin on atrial plateau currents.
Topics: Action Potentials; Animals; Atorvastatin; Cell Separation; CHO Cells; Cricetinae; Cricetulus; Heart Ventricles; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kv1.5 Potassium Channel; Male; Membrane Potentials; Mice; Myocytes, Cardiac; Pyrroles; Shal Potassium Channels; Simvastatin | 2007 |
Study highlights need for considered clinical approach to statin switching.
Topics: Atorvastatin; Cost Savings; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Practice Patterns, Physicians'; Pyrroles; Simvastatin | 2007 |
Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Brain Edema; Brain Injuries; Brain Ischemia; Cerebrovascular Circulation; Chemotaxis, Leukocyte; Cognition Disorders; Cytokines; Disease Models, Animal; Encephalitis; Endothelial Cells; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurons; Pyrroles; Recovery of Function; RNA, Messenger; Simvastatin; Treatment Outcome | 2007 |
Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Costs and Cost Analysis; Diabetes Mellitus; Drug Costs; Female; Heptanoic Acids; Humans; Male; Models, Theoretical; Pyrroles; Simvastatin; United States | 2007 |
Cost-effectiveness of high-dose atorvastatin compared with usual-dose simvastatin: less than IDEAL?
Topics: Atorvastatin; Coronary Artery Disease; Cost-Benefit Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin; Treatment Outcome | 2007 |
A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets.
Topics: Atorvastatin; Canada; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Economic; Pyrroles; Simvastatin | 2007 |
Therapeutic dose assessment of patient switching from atorvastatin to simvastatin.
Topics: Atorvastatin; Drugs, Generic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quality of Health Care; Retrospective Studies; Simvastatin; Therapeutic Equivalency; United States | 2007 |
Physiogenomic association of statin-related myalgia to serotonin receptors.
Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Genomics; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscular Diseases; Pain; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Receptors, Serotonin; Simvastatin | 2007 |
Reversal of memory deficits by Atorvastatin and Simvastatin in rats.
Topics: Alprazolam; Amnesia; Animals; Atorvastatin; Body Weight; Cholesterol; Dietary Fats; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Maze Learning; Memory; Pyrroles; Rats; Rats, Wistar; Reaction Time; Scopolamine; Simvastatin; Stimulation, Chemical | 2007 |
Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury.
Topics: Animals; Atorvastatin; Brain Injuries; Cell Proliferation; Dentate Gyrus; Dose-Response Relationship, Drug; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Maze Learning; Memory Disorders; Neovascularization, Physiologic; Nerve Degeneration; Nerve Regeneration; Neuronal Plasticity; Neurons; Neuroprotective Agents; Pyrroles; Rats; Rats, Wistar; Recovery of Function; Simvastatin; Stem Cells; Treatment Outcome | 2007 |
Effect of statin withdrawal on frequency of cardiac events after vascular surgery.
Topics: Aged; Atorvastatin; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Substance Withdrawal Syndrome; Troponin T; Vascular Surgical Procedures | 2007 |
Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease.
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Databases as Topic; Dementia; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Parkinson Disease; Proportional Hazards Models; Pyrroles; Simvastatin; United States; Veterans | 2007 |
P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Brain; Heptanoic Acids; Lactones; Liver; Lovastatin; Male; Mice; Mice, Inbred Strains; Mice, Knockout; Pravastatin; Pyrroles; Simvastatin | 2007 |
Atorvastatin decreases lipoprotein lipase and endothelial lipase expression in human THP-1 macrophages.
Topics: Animals; Atorvastatin; Cell Line; DNA-Binding Proteins; Dose-Response Relationship, Drug; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipase; Lipoprotein Lipase; Liver X Receptors; Macrophages; NF-kappa B; Orphan Nuclear Receptors; Polyisoprenyl Phosphates; Pyrroles; Receptors, Cytoplasmic and Nuclear; Sesquiterpenes; Simvastatin | 2007 |
On the factors modulating the effect of statins on malignant cell proliferation.
Topics: Annexin A5; Atorvastatin; Cell Division; Cell Line, Tumor; DNA Fragmentation; DNA, Neoplasm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; K562 Cells; Kinetics; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 2007 |
Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study.
Topics: Animals; Atorvastatin; Blood Pressure; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Echocardiography; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Male; Monocrotaline; Phosphorylation; Pulmonary Artery; Pyrroles; Rats; Rats, Sprague-Dawley; Ribosomal Protein S6 Kinases, 70-kDa; Simvastatin; Sirolimus | 2007 |
CYP2D6*4 polymorphism is associated with statin-induced muscle effects.
Topics: Alleles; Atorvastatin; Case-Control Studies; Cytochrome P-450 CYP2D6; Gene Frequency; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscles; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrroles; Simvastatin | 2007 |
Discontinuation of statin therapy and clinical outcome after ischemic stroke.
Topics: Aged; Atorvastatin; Brain Ischemia; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Simvastatin; Stroke; Substance Withdrawal Syndrome | 2007 |
Hydrophobic but not hydrophilic statins enhance phagocytosis and decrease apoptosis of human peripheral blood cells in vitro.
Topics: Adult; Apoptosis; Atorvastatin; Dose-Response Relationship, Drug; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Leukocytes; Lovastatin; Male; Middle Aged; Phagocytes; Phagocytosis; Pravastatin; Pyrroles; Simvastatin | 2008 |
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Managed Care Programs; Odds Ratio; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Adverse balance of nitric oxide/peroxynitrite in the dysfunctional endothelium can be reversed by statins.
Topics: Acetophenones; Atorvastatin; Calcimycin; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase Type III; Peroxynitrous Acid; Pyrroles; Simvastatin | 2007 |
Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
Topics: Atorvastatin; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pravastatin; Pyrroles; Saphenous Vein; Simvastatin | 2007 |
Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Databases, Factual; Drug Administration Schedule; Drug Prescriptions; Drug Utilization; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Norway; Patient Selection; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Sex Factors; Simvastatin; Tablets | 2007 |
Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Atorvastatin; Child; Child, Preschool; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Infant; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Rhabdomyolysis; Simvastatin; United States; United States Food and Drug Administration | 2008 |
Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cholesterol; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Losartan; Male; Pyrroles; Retrospective Studies; Simvastatin; Tetrazoles; Therapeutic Equivalency; Treatment Outcome | 2008 |
Disease modifying effect of statins in dextran sulfate sodium model of mouse colitis.
Topics: Animals; Apolipoprotein A-I; Atorvastatin; Colitis; Colon; Dextran Sulfate; Disease Models, Animal; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Mice; Occult Blood; Pyrroles; Simvastatin; Tumor Necrosis Factor-alpha | 2008 |
Class effects of statins in elderly patients with congestive heart failure: a population-based analysis.
Topics: Aged; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Pravastatin; Pyrroles; Simvastatin; Survival Analysis; Treatment Outcome | 2008 |
Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Contrast Media; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Length of Stay; Male; Middle Aged; Multivariate Analysis; Pravastatin; Preoperative Care; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Up-Regulation | 2008 |
Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro.
Topics: Acids; Atorvastatin; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Stability; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Indoles; Lactones; Microscopy, Fluorescence; Molecular Structure; Muscle Fibers, Skeletal; Muscle, Skeletal; Pravastatin; Pyrroles; Satellite Cells, Skeletal Muscle; Simvastatin; Structure-Activity Relationship | 2008 |
Determinants of CRP level in statin-treated patients.
Topics: Atorvastatin; Blood Pressure; C-Reactive Protein; Enzyme Inhibitors; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Logistic Models; Male; Metabolic Syndrome; Middle Aged; Pilot Projects; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Smoking; Sulfonamides | 2008 |
High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins.
Topics: Aged; Atorvastatin; Case-Control Studies; Cells, Cultured; Chemokine CCL2; Chemokine CXCL16; Chemokines, CXC; Coronary Artery Disease; Down-Regulation; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-8; Leukocytes, Mononuclear; Male; Middle Aged; Muscle, Smooth, Vascular; Pyrroles; Receptors, Scavenger; Simvastatin | 2008 |
LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases. Part 1. Separation of active components and classification of their interaction/degradation products.
Topics: Aspirin; Atenolol; Atorvastatin; Cardiovascular Agents; Chromatography, High Pressure Liquid; Drug Combinations; Drug Interactions; Drug Stability; Heptanoic Acids; Hydrochlorothiazide; Lisinopril; Pravastatin; Pyrroles; Simvastatin; Spectrometry, Mass, Electrospray Ionization | 2008 |
Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Topics: Atorvastatin; Cardiovascular Diseases; Databases, Factual; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Managed Care Programs; Middle Aged; Myocardial Revascularization; Outcome Assessment, Health Care; Primary Prevention; Proportional Hazards Models; Pyrroles; Simvastatin; United States | 2008 |
Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Managed Care Programs; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2008 |
Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program.
Topics: Adult; Aged; Alleles; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Decision Making; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Inpatients; Linear Models; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Predictive Value of Tests; Pyridines; Pyrroles; Simvastatin; Triglycerides | 2008 |
[Influence of statins on the antiplatelet effect of clopidogrel and on cardiovascular outcome in patients after coronary intervention].
Topics: Atorvastatin; Clopidogrel; Coronary Disease; Coronary Stenosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Simvastatin; Stents; Ticlopidine | 2008 |
Dose-related effect of statins on atrial fibrillation after cardiac surgery.
Topics: Aged; Aged, 80 and over; Aortic Valve; Atorvastatin; Atrial Fibrillation; Cohort Studies; Coronary Artery Bypass; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Heart Valve Prosthesis Implantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Postoperative Complications; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome | 2008 |
Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
Topics: Atorvastatin; Cohort Studies; Coronary Disease; Cost-Benefit Analysis; Finland; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Expectancy; Male; Markov Chains; Middle Aged; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Drugs, Generic; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters.
Topics: Aryldialkylphosphatase; Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipids; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Pyrroles; Simvastatin | 2008 |
CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin.
Topics: Alleles; Anticholesteremic Agents; Asian People; Atorvastatin; Cholesterol, LDL; Cytochrome P-450 CYP3A; Female; Gene Frequency; Heptanoic Acids; Humans; Male; Middle Aged; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Prospective Studies; Pyrroles; Simvastatin | 2008 |
Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Drug Utilization Review; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Simvastatin; Survival Analysis; United States | 2008 |
Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.
Topics: Adult; Aged; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Muscular Diseases; Pyrroles; Risk Management; Simvastatin | 2008 |
[Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Ezetimibe; Germany; Heptanoic Acids; Humans; Hypercholesterolemia; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2008 |
Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; Atorvastatin; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Membrane; Cell Proliferation; DNA Replication; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Membrane Potential, Mitochondrial; Necrosis; Oxidative Stress; Pyrroles; Reactive Oxygen Species; Simvastatin | 2008 |
Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways.
Topics: Angiotensin II; Atorvastatin; Cell Line; Cell Transdifferentiation; Connective Tissue Growth Factor; Epithelial Cells; Fibrosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Kidney Tubules, Proximal; Mitogen-Activated Protein Kinase Kinases; Phenotype; Protein Kinase Inhibitors; Pyrroles; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Simvastatin; Time Factors; Transfection | 2008 |
Statins activate GATA-6 and induce differentiated vascular smooth muscle cells.
Topics: Actins; Amino Acid Motifs; Atorvastatin; Cell Differentiation; Cell Proliferation; Diterpenes; DNA Replication; GATA6 Transcription Factor; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nucleic Acid Synthesis Inhibitors; Polyisoprenyl Phosphates; Pyrroles; Sesquiterpenes; Simvastatin; Transcription, Genetic | 2008 |
Intensive lipid intervention in the post-ENHANCE era.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; British Columbia; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2008 |
Impact of adherence to statins on chronic heart failure in primary prevention.
Topics: Aged; Atorvastatin; Case-Control Studies; Databases, Factual; Female; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2008 |
Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Insurance Claim Review; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors | 2008 |
A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in diabetic patients without prior cardiovascular disease.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus; Health Maintenance Organizations; Heptanoic Acids; Humans; Preferred Provider Organizations; Pyrroles; Simvastatin; Treatment Outcome; United States | 2008 |
Statins alone are ineffective in cerebral malaria but potentiate artesunate.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Atorvastatin; Disease Models, Animal; Drug Synergism; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Malaria, Cerebral; Malaria, Falciparum; Mice; Neuroprotective Agents; Pravastatin; Pyrroles; Simvastatin | 2008 |
Amelioration of human allograft arterial injury by atorvastatin or simvastatin correlates with reduction of interferon-gamma production by infiltrating T cells.
Topics: Adult; Animals; Arteries; Atorvastatin; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Leukocytes, Mononuclear; Lymphocyte Transfusion; Mice; Mice, SCID; Pyrroles; Simvastatin; T-Lymphocytes; Transplantation, Heterologous; Transplantation, Homologous | 2008 |
The influence of simvastatin, atorvastatin and high-cholesterol diet on acetylcholinesterase activity, amyloid beta and cholesterol synthesis in rat brain.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anticholesteremic Agents; Atorvastatin; Brain; Brain Chemistry; Cholesterol; Cholesterol, Dietary; Diet; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Male; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2009 |
Statins alter neutrophil migration by modulating cellular Rho activity--a potential mechanism for statins-mediated pleotropic effects?
Topics: Atorvastatin; Cells, Cultured; Chemotactic Factors; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; N-Formylmethionine Leucyl-Phenylalanine; Neutrophil Infiltration; Neutrophils; Polyisoprenyl Phosphates; Pravastatin; Pyrroles; rhoA GTP-Binding Protein; Simvastatin | 2009 |
The influence of statin medications on prostate-specific antigen levels.
Topics: Aged; Atorvastatin; Biomarkers, Tumor; Cholesterol, HDL; Cholesterol, LDL; Early Diagnosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Linear Models; Longitudinal Studies; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Risk Assessment; Simvastatin; Veterans | 2008 |
Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Lipid Metabolism; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2008 |
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.
Topics: Adult; Atorvastatin; Cohort Studies; Disease-Free Survival; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2008 |
Intensive lipid-lowering therapy for patients with aortic stenosis.
Topics: Aortic Valve Stenosis; Atorvastatin; Clinical Trials as Topic; Disease Progression; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated.
Topics: Adolescent; Adult; Atorvastatin; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Primary Prevention; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk; Simvastatin; United States | 2008 |
Cholesterol synthesis in central nervous system of rat is affected by simvastatin as well as by atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Biomarkers; Brain Chemistry; Central Nervous System; Cholesterol; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Male; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2008 |
Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes.
Topics: Adult; Aged; Atorvastatin; Biological Availability; Diabetes Mellitus, Type 2; Estradiol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Sex Hormone-Binding Globulin; Simvastatin; Testosterone | 2009 |
[Statin therapy and muscle disorders].
Topics: Atorvastatin; Biological Availability; Cytochrome P-450 Enzyme System; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Muscular Diseases; Pravastatin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
[Comment from the cardiologic viewpoint].
Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension.
Topics: Animals; Atorvastatin; Disease Models, Animal; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Male; Monocrotaline; Phosphodiesterase Inhibitors; Pravastatin; Pulmonary Artery; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2009 |
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy.
Topics: Animals; Atorvastatin; Azetidines; Brain; Capillary Permeability; Diet; Disease Models, Animal; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Maze Learning; Mice; Mice, Transgenic; Neurofibrillary Tangles; Pyrroles; Simvastatin; Spinal Cord; Tauopathies | 2009 |
Anti-atherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenase-1.
Topics: Animals; Aorta; Arginine; Atherosclerosis; Atorvastatin; Disease Models, Animal; Endothelium, Vascular; Enzyme Inhibitors; Heme Oxygenase-1; Hemin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Malondialdehyde; Metalloporphyrins; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Peroxynitrous Acid; Protoporphyrins; Pyrroles; Rabbits; Simvastatin; Time Factors | 2009 |
Preoperative statin use and infection after cardiac surgery: a cohort study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Chemoprevention; Cohort Studies; Female; Heptanoic Acids; Hospitals, University; Humans; Immunologic Factors; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Surgical Wound Infection; Thoracic Surgery; Treatment Outcome | 2009 |
ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin.
Topics: Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Female; Finland; Half-Life; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Polymorphism, Single Nucleotide; Pyrroles; Simvastatin | 2008 |
Comparison of UV and charged aerosol detection approach in pharmaceutical analysis of statins.
Topics: Aerosols; Atorvastatin; Chromatography, High Pressure Liquid; Equipment and Supplies; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pyrroles; Simvastatin; Tablets | 2009 |
Effect of statins on fibroblasts from human nasal polyps and turbinates.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Cell Division; Depression, Chemical; Drug Evaluation, Preclinical; Fatty Acids, Monounsaturated; Fibroblasts; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Nasal Polyps; Pyrroles; Simvastatin; Turbinates | 2008 |
Moving from A to Z: successful implementation of a statin switch program by a large physician group.
Topics: Atorvastatin; Cost Savings; Drugs, Generic; Fee-for-Service Plans; Female; Heptanoic Acids; Hospitals, Teaching; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Michigan; Middle Aged; Patient Selection; Pyrroles; Simvastatin | 2009 |
Comparison of atorvastatin and simvastatin in prevention of atrial fibrillation after successful cardioversion.
Topics: Aged; Anti-Arrhythmia Agents; Atorvastatin; Atrial Fibrillation; Electric Countershock; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Odds Ratio; Pyrroles; Retrospective Studies; Simvastatin; Treatment Outcome | 2009 |
Statin effects on LDL and HDL cholesterol in South Asian and white populations.
Topics: Anticholesteremic Agents; Asian People; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coronary Disease; Female; Heptanoic Acids; Humans; Linear Models; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides; White People | 2009 |
Statins normalize vascular lysyl oxidase down-regulation induced by proatherogenic risk factors.
Topics: Animals; Atherosclerosis; Atorvastatin; Capillary Permeability; Cattle; Cells, Cultured; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Down-Regulation; Endothelial Cells; Farnesol; Female; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Protein Kinase C; Protein Kinase Inhibitors; Protein-Lysine 6-Oxidase; Pyrroles; rho-Associated Kinases; rhoA GTP-Binding Protein; Risk Factors; RNA, Messenger; Simvastatin; Swine; Transfection; Tumor Necrosis Factor-alpha | 2009 |
Selective prescribing of simvastatin and atorvastatin by patient characteristics at treatment initiation over a 7-year period in Finland.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Drug Prescriptions; Female; Finland; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Patterns, Physicians'; Pyrroles; Simvastatin | 2009 |
Long-term statin therapy and CSF cholesterol levels: implications for Alzheimer's disease.
Topics: Adult; Aged; Alzheimer Disease; Apolipoproteins E; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Mutation; Pilot Projects; Presenilin-1; Pyrroles; Simvastatin | 2009 |
Ultra high performance liquid chromatography tandem mass spectrometric detection in clinical analysis of simvastatin and atorvastatin.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Chromatography, High Pressure Liquid; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Sensitivity and Specificity; Simvastatin; Tandem Mass Spectrometry | 2009 |
The expression of efflux and uptake transporters are regulated by statins in Caco-2 and HepG2 cells.
Topics: Animals; Atorvastatin; Caco-2 Cells; Cell Line, Tumor; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Pyrroles; RNA, Messenger; Simvastatin | 2009 |
Autocrine amplification loop in statin-induced apoptosis of human melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Atorvastatin; Autocrine Communication; Biological Factors; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Enzyme Activation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Melanoma; Pyridines; Pyrroles; Simvastatin; Time Factors | 2009 |
Fluvastatin inhibits expression of the chemokine MDC/CCL22 induced by interferon-gamma in HaCaT cells, a human keratinocyte cell line.
Topics: Atorvastatin; Cell Line; Chemokine CCL22; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interferon-gamma; Keratinocytes; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Pyrroles; Signal Transduction; Simvastatin; Th2 Cells | 2009 |
Simvastatin and atorvastatin improve neurological outcome after experimental intracerebral hemorrhage.
Topics: Animals; Apoptosis; Atorvastatin; Biomarkers; Brain; Brain Infarction; Bromodeoxyuridine; Cerebral Hemorrhage; Cytoprotection; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Doublecortin Domain Proteins; Doublecortin Protein; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microtubule-Associated Proteins; Nerve Degeneration; Neurogenesis; Neuronal Plasticity; Neuropeptides; Neuroprotective Agents; Pyrroles; Rats; Rats, Wistar; Regeneration; Simvastatin; Treatment Outcome | 2009 |
Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Atorvastatin; Azithromycin; Databases, Factual; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Rhabdomyolysis; Simvastatin | 2009 |
Comparison of the effects of simvastatin versus atorvastatin on oxidative stress in patients with type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2010 |
Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
Topics: Aged; Aged, 80 and over; Alleles; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cholesterol; Cohort Studies; Cytochrome P-450 CYP3A; Databases, Factual; Female; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Sex Factors; Simvastatin | 2010 |
[The ram and the oat bag].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Drug Prescriptions; Evidence-Based Medicine; Heptanoic Acids; Humans; Norway; Practice Patterns, Physicians'; Pyrroles; Simvastatin | 2009 |
Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Arterioles; Atorvastatin; Cytokines; Gemfibrozil; Heptanoic Acids; Inflammation; Male; Metabolic Syndrome; Microcirculation; Muscle, Skeletal; Nitric Oxide; Probucol; Pyrroles; Rats; Rats, Zucker; Simvastatin; Time Factors | 2009 |
Lack of robust neurologic benefits with simvastatin or atorvastatin treatment after acute thoracic spinal cord contusion injury.
Topics: Analysis of Variance; Animals; Atorvastatin; Benzenesulfonates; Dietary Sucrose; Disease Models, Animal; Drug Administration Routes; Ectodysplasins; Exploratory Behavior; Food, Formulated; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Motor Activity; Nervous System Diseases; Pain Measurement; Pain Threshold; Psychomotor Performance; Pyrroles; Rats; Rats, Sprague-Dawley; Sacrococcygeal Region; Simvastatin; Spinal Cord Injuries | 2010 |
Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability.
Topics: ADP Ribose Transferases; Angiogenesis Inhibitors; Atorvastatin; Botulinum Toxins; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Down-Regulation; Endothelial Cells; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 9; Mevalonic Acid; Neovascularization, Physiologic; Nitrobenzenes; Polyisoprenyl Phosphates; Pyrroles; rho GTP-Binding Proteins; RNA, Messenger; Simvastatin; Sulfonamides; Tetradecanoylphorbol Acetate; Tumor Necrosis Factor-alpha | 2010 |
Is initiation of atorvastatin for employees a good buy for employers?
Topics: Atorvastatin; Comparative Effectiveness Research; Health Benefit Plans, Employee; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin; United States | 2009 |
Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.
Topics: Adolescent; Adult; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Health Benefit Plans, Employee; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrroles; Simvastatin; United States | 2009 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Combined hyperlipidemia in patients with lysinuric protein intolerance.
Topics: Adolescent; Adult; Amino Acid Metabolism, Inborn Errors; Atorvastatin; Biomarkers; Child; Child, Preschool; Cholesterol; Cholesterol, HDL; Cystatin C; Disease Progression; Female; Finland; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors; Treatment Outcome; Triglycerides; Young Adult | 2010 |
LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
Topics: Adult; Aged; Atorvastatin; Case-Control Studies; Cholesterol, LDL; Cohort Studies; Databases, Factual; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Multivariate Analysis; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Simvastatin | 2010 |
Different effects of commonly prescribed statins on abdominal aortic aneurysm wall biology.
Topics: Aged; Aorta; Aortic Aneurysm, Abdominal; Atorvastatin; Biomarkers; Cathepsin A; Cathepsin B; Chi-Square Distribution; Cohort Studies; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Interleukins; Lymphotoxin-alpha; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Netherlands; Pravastatin; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Tumor Necrosis Factor-alpha; Vascular Surgical Procedures | 2010 |
Approach to the patient who is intolerant of statin therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Coronary Disease; Diltiazem; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Middle Aged; Pyrroles; Simvastatin | 2010 |
[Investigation of the in vitro antibacterial effects of statins].
Topics: Atorvastatin; Bacteria; Drug Resistance, Bacterial; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microbial Sensitivity Tests; Pyrroles; Simvastatin | 2010 |
The utility of observational studies in clinical decision making: lessons learned from statin trials.
Topics: Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Decision Making; Epidemiologic Studies; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Observation; Pyrroles; Simvastatin | 2010 |
Pitavastatin: the newest HMG-CoA reductase inhibitor.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Product Surveillance, Postmarketing; Pyrroles; Quinolines; Simvastatin | 2010 |
Early outcome of acute ischemic stroke in hyperlipidemic patients under atorvastatin versus simvastatin.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Medical Records; Middle Aged; Neuroprotective Agents; Pyrroles; Retrospective Studies; Severity of Illness Index; Simvastatin; Statistics as Topic; Stroke; Stroke Rehabilitation; Treatment Outcome | 2010 |
The inhibitory effect of statins on urinary 11-dehydrothromboxane levels.
Topics: Aged; Aspirin; Atorvastatin; Biomarkers; Blood Glucose; Blood Platelets; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Czech Republic; Down-Regulation; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Simvastatin; Thromboxane B2; Time Factors; Treatment Outcome; Triglycerides | 2010 |
Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement?
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Half-Life; Heptanoic Acids; Humans; Hypercholesterolemia; Lipid Metabolism; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2010 |
Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study.
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Databases, Factual; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Netherlands; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Simvastatin; Time Factors | 2010 |
Cytotoxicity of atorvastatin and simvastatin on primary rainbow trout (Oncorhynchus mykiss) hepatocytes.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cell Survival; Cells, Cultured; Female; Hepatocytes; Heptanoic Acids; Male; Oncorhynchus mykiss; Pyrroles; Simvastatin; Water Pollutants, Chemical | 2010 |
Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?
Topics: Acetyl-CoA Carboxylase; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Sectional Studies; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
State generic substitution laws can lower drug outlays under Medicaid.
Topics: Anticholesteremic Agents; Atorvastatin; Attitude to Health; Cost Savings; Drug Prescriptions; Drugs, Generic; Health Policy; Heptanoic Acids; Humans; Industry; Informed Consent; Medicaid; Patient Compliance; Prescription Fees; Program Evaluation; Pyrroles; Simvastatin; State Government; United States | 2010 |
Incomparable effectiveness--apples to apples?
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin | 2010 |
Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression.
Topics: Aspirin; Atorvastatin; Case-Control Studies; Confidence Intervals; Cytokines; Depressive Disorder, Major; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Middle Aged; Models, Psychological; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors | 2010 |
Comparative neuroprotective profile of statins in quinolinic acid induced neurotoxicity in rats.
Topics: Analysis of Variance; Animals; Atorvastatin; Behavior, Animal; Body Weight; Corpus Striatum; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Peroxidation; Male; Mitochondria; Motor Activity; Neuroprotective Agents; Neurotoxicity Syndromes; Nitrites; Oxidative Stress; Pyrroles; Quinolinic Acid; Rats; Rats, Wistar; Rotarod Performance Test; Simvastatin; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2011 |
Vascular recovery promoted by atorvastatin and simvastatin after experimental intracerebral hemorrhage: magnetic resonance imaging and histological study.
Topics: Animals; Atorvastatin; Blood-Brain Barrier; Brain Edema; Cerebral Hemorrhage; Cerebrovascular Circulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Magnetic Resonance Imaging; Neovascularization, Physiologic; Nerve Regeneration; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2011 |
Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Clarithromycin; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Heptanoic Acids; Humans; In Vitro Techniques; Ketoconazole; Microsomes, Liver; Models, Molecular; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Pyrroles; Recombinant Proteins; Simvastatin; Substrate Specificity; Ticlopidine | 2010 |
Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.
Topics: Absenteeism; Adult; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Cost-Benefit Analysis; Diabetes Mellitus; Drug Costs; Employment; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Risk; Simvastatin | 2011 |
Enhanced spectrophotometric determination of two antihyperlipidemic mixtures containing ezetimibe in pharmaceutical preparations.
Topics: Atorvastatin; Azetidines; Calibration; Drug Combinations; Drug Compounding; Drug Stability; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Heptanoic Acids; Hypolipidemic Agents; Molecular Structure; Pyrroles; Reproducibility of Results; Simvastatin; Solvents; Spectrophotometry, Ultraviolet; Tablets | 2011 |
Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells.
Topics: Absorption; Anticholesteremic Agents; Atorvastatin; ATP-Binding Cassette Transporters; Azetidines; Biological Transport; Cholesterol; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Gene Expression; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Lipid Metabolism; Male; Middle Aged; Orphan Nuclear Receptors; Pyrroles; RNA, Messenger; Simvastatin; Up-Regulation | 2010 |
Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial.
Topics: Aged; Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Statistics as Topic | 2011 |
Involvement of the p38 pathway in the differential induction of heme oxygenase-1 by statins in Neuro-2A cells exposed to lipopolysaccharide.
Topics: Animals; Atorvastatin; Blotting, Western; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cerebral Cortex; Dose-Response Relationship, Drug; Enzyme Induction; Fluorobenzenes; Heme Oxygenase-1; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iron; Iron Chelating Agents; Lipopolysaccharides; Mice; Neurons; p38 Mitogen-Activated Protein Kinases; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Rosuvastatin Calcium; Simvastatin; Structure-Activity Relationship; Sulfonamides | 2011 |
Statins alter intracellular calcium homeostasis in malignant hyperthermia susceptible individuals.
Topics: Animals; Atorvastatin; Biopsy; Calcium; Electric Stimulation; Female; Gemfibrozil; Genotype; Heptanoic Acids; Homeostasis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Isometric Contraction; Male; Malignant Hyperthermia; Muscle, Skeletal; Phenotype; Pyrroles; Rhabdomyolysis; Simvastatin; Swine; Time Factors | 2010 |
[On the current debate on lowering LDL cholesterol with ezetimibe].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Financing, Personal; Fluorobenzenes; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Myocardial Infarction; National Health Programs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides | 2010 |
[Pharmaco-economic optimization of cholesterol-lowering treatment with statins].
Topics: Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Goals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Spain; Sulfonamides | 2011 |
Use of ultra high performance liquid chromatography-tandem mass spectrometry to demonstrate decreased serum statin levels after extracorporeal LDL-cholesterol elimination.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Chromatography, High Pressure Liquid; Female; Hemofiltration; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Statistics, Nonparametric; Tandem Mass Spectrometry | 2011 |
Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-β-independent process.
Topics: Angiotensin II; Animals; Aorta; Atorvastatin; Blotting, Western; Cells, Cultured; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyrroles; Rats; Rats, Wistar; Signal Transduction; Simvastatin; Smad Proteins; Transforming Growth Factor beta; Vasoconstrictor Agents | 2010 |
Statin wars: efficacy vs. cost.
Topics: Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin | 2011 |
Use of high-intensity statin therapy with simvastatin 80 mg and atorvastatin 80 mg in primary care.
Topics: Adult; Aged; Atorvastatin; Body Mass Index; Cardiovascular Diseases; England; Family Practice; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Practice Patterns, Physicians'; Pyrroles; Quality of Health Care; Retrospective Studies; Simvastatin | 2011 |
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Topics: Adult; Aged; Atorvastatin; British Columbia; Case-Control Studies; Chi-Square Distribution; Female; Gene Frequency; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Netherlands; Odds Ratio; Organic Anion Transporters; Phenotype; Polymorphism, Single Nucleotide; Pyrroles; Risk Assessment; Risk Factors; Severity of Illness Index; Simvastatin | 2012 |
Paradoxical decrease in serum high-density lipoprotein cholesterol and lipid-lowering drugs.
Topics: Atorvastatin; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Pyrroles; Simvastatin | 2011 |
Statins utilisation pattern: a retrospective evaluation in a tertiary care hospital in Thailand.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Electronic Health Records; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Patterns, Physicians'; Pravastatin; Primary Prevention; Pyrroles; Retrospective Studies; Secondary Prevention; Simvastatin; Thailand | 2011 |
Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cohort Studies; Drug Costs; Drug Substitution; Drugs, Generic; Female; Finland; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Pyrroles; Registries; Simvastatin | 2012 |
ABCA1 and ABCG1 expressions are regulated by statins and ezetimibe in Caco-2 cells.
Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Azetidines; Caco-2 Cells; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Polymerase Chain Reaction; Pyrroles; RNA, Messenger; Simvastatin; Time Factors | 2011 |
Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells.
Topics: Atorvastatin; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pravastatin; Pyrroles; Simvastatin; Tetradecanoylphorbol Acetate; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Umbilical Veins | 2011 |
Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
Topics: Atorvastatin; Bayes Theorem; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Costs; Drug Prescriptions; Drugs, Generic; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Markov Chains; Medication Adherence; Models, Economic; Pyrimidines; Pyrroles; Quality Indicators, Health Care; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome | 2012 |
Statins regulate interleukin-1β-induced RANKL and osteoprotegerin production by human gingival fibroblasts.
Topics: Atorvastatin; Cell Culture Techniques; Cell Survival; Cells, Cultured; Coloring Agents; Culture Media, Serum-Free; Fibroblasts; Gingiva; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Osteoprotegerin; Pyrroles; RANK Ligand; Simvastatin; Temperature; Tetrazolium Salts; Thiazoles; Time Factors | 2011 |
Statin therapy is associated with decreased pulmonary vascular pressures in severe COPD.
Topics: Aged; Atorvastatin; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Pulmonary Wedge Pressure; Pyrroles; Regression Analysis; Simvastatin | 2011 |
Statins and prostate cancer diagnosis and grade in a veterans population.
Topics: Aged; Aged, 80 and over; Anticarcinogenic Agents; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Biomarkers, Tumor; Cholesterol; Confounding Factors, Epidemiologic; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lipids; Lovastatin; Male; Middle Aged; Multivariate Analysis; New England; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Risk Assessment; Severity of Illness Index; Simvastatin; Veterans | 2011 |
Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization.
Topics: Animals; Atorvastatin; Cholesterol; Crystallization; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Microscopy, Electron, Scanning; Plaque, Atherosclerotic; Pravastatin; Pyrroles; Rabbits; Simvastatin | 2011 |
Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Caco-2 Cells; DNA; Ezetimibe; Female; Hep G2 Cells; Heptanoic Acids; Humans; Hypercholesterolemia; Leukocytes, Mononuclear; Lipids; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; RNA, Messenger; Scavenger Receptors, Class B; Simvastatin | 2011 |
The beneficial effects of statin therapy may not apply to all forms of crescentic glomerulonephritis.
Topics: Animals; Atorvastatin; Disease Models, Animal; Glomerulonephritis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Rats; Rats, Inbred WKY; Simvastatin | 2011 |
Impact of HMG-CoA reductase inhibition on oxidant-induced injury in human retinal pigment epithelium cells.
Topics: Atorvastatin; Caspase 3; Cell Line; Cell Survival; Enzyme Activation; Epithelial Cells; Heptanoic Acids; Humans; Hydrogen Peroxide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; NADPH Oxidases; Oxidants; Oxidative Stress; Pyrroles; Retinal Pigment Epithelium; Simvastatin; Tumor Necrosis Factor-alpha | 2011 |
Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus--an observational study from the Swedish National Diabetes Register.
Topics: Adolescent; Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Statistical; Pyrimidines; Pyrroles; Registries; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Sweden; Treatment Outcome | 2011 |
Hip circumference is associated with high density lipoprotein cholesterol response following statin therapy in hypertensive subjects.
Topics: Aged; Atorvastatin; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Waist Circumference; Waist-Hip Ratio | 2011 |
[Retention behavior of statins in microemulsion liquid chromatography].
Topics: Atorvastatin; Chromatography, Liquid; Emulsions; Heptanoic Acids; Lovastatin; Models, Chemical; Pravastatin; Pyrroles; Simvastatin | 2011 |
Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Health Status Indicators; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Longitudinal Studies; Male; Middle Aged; Pyrroles; Simvastatin; Spain; Young Adult | 2011 |
Low-density lipoprotein cholesterol goal attainment among Malaysian dyslipidemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Logistic Models; Malaysia; Male; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Therapy and clinical trials: aggressive statin therapy versus combined and emerging approaches.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Clinical Trials as Topic; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Effects of simvastatin, atorvastatin, ezetimibe, and ezetimibe + simvastatin combination on the inflammatory process and on the liver metabolic changes of arthritic rats.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Leukocyte Count; Leukocytes; Liver; Liver Function Tests; Perfusion; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin | 2012 |
Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; United States | 2011 |
Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Atorvastatin; Chemical and Drug Induced Liver Injury; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Simvastatin; Sweden; Time Factors | 2012 |
Differential effects of atorvastatin treatment and withdrawal on pentylenetetrazol-induced seizures.
Topics: Animals; Anticonvulsants; Atorvastatin; Blood-Brain Barrier; Cerebral Cortex; Cholesterol; Convulsants; Electroencephalography; Heptanoic Acids; Male; Pentylenetetrazole; Pyrroles; Rats; Rats, Wistar; Seizures; Simvastatin | 2011 |
[Association of a polymorphic marker Trp719Arg of KIF6 gene with effects of atorvastatin and simvastatin in patients with early ischemic heart disease].
Topics: Age of Onset; Apolipoprotein A-I; Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypolipidemic Agents; Kinesins; Male; Middle Aged; Myocardial Ischemia; Pharmacogenetics; Polymorphism, Genetic; Pyrroles; Simvastatin; Treatment Outcome | 2011 |
Altered fibrin clot properties in patients with retinal vein occlusion.
Topics: C-Reactive Protein; Coronary Artery Disease; Female; Fenofibrate; Fibrin; Fibrinolysis; Heptanoic Acids; Homocysteine; Humans; Hypersensitivity, Immediate; Laser Coagulation; Lipoprotein(a); Male; Pyrroles; Retinal Vein; Retinal Vein Occlusion; Simvastatin; Tetrahydroisoquinolines; Thrombosis; Venous Thromboembolism; Venous Thrombosis | 2011 |
The value of atorvastatin over the product life cycle in the United States.
Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Utilization Review; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Economic; Pyrroles; Quality-Adjusted Life Years; Simvastatin; Time Factors; United States | 2011 |
Species-dependent sensitivity to contaminants: an approach using primary hepatocyte cultures with three marine fish species.
Topics: Animals; Atorvastatin; Cells, Cultured; Copper; Female; Fishes; Hepatocytes; Heptanoic Acids; Male; Pyrroles; Simvastatin; Species Specificity; Water Pollutants, Chemical | 2011 |
Pleiotropic effects of statins in distal human pulmonary artery smooth muscle cells.
Topics: Apoptosis; Atorvastatin; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Female; Genetic Pleiotropy; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pravastatin; Pulmonary Artery; Pyrroles; Simvastatin | 2011 |
Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Apolipoprotein B-100; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reference Values; Regression Analysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides; Young Adult | 2011 |
Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Atorvastatin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Esophageal Neoplasms; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; NF-kappa B; Pravastatin; Pyrroles; Simvastatin | 2011 |
Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Multivariate Analysis; Pyrroles; Regression Analysis; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; United States | 2011 |
Different statins produce highly divergent changes in gene expression profiles of human hepatoma cells: a pilot study.
Topics: Atorvastatin; Carcinoma, Hepatocellular; Computational Biology; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Profiling; Gene Expression Regulation; Genome, Human; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Metabolic Networks and Pathways; Mevalonic Acid; Oligonucleotide Array Sequence Analysis; Pilot Projects; Principal Component Analysis; Pyrroles; Simvastatin | 2011 |
Statins lower calcium-induced oxidative stress in isolated mitochondria.
Topics: Animals; Atorvastatin; Calcium; Cytochromes c; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lipid Peroxidation; Membrane Potential, Mitochondrial; Mitochondria, Liver; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Nitric Oxide Synthase; Oxidative Stress; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin | 2012 |
Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Association Studies; Haplotypes; Heptanoic Acids; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Single Nucleotide; Proportional Hazards Models; Pyrroles; Simvastatin | 2013 |
Statin use in COPD patients is associated with a reduction in mortality: a national cohort study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medical Record Linkage; Middle Aged; New Zealand; Pulmonary Disease, Chronic Obstructive; Pyrroles; Simvastatin; Treatment Outcome | 2012 |
Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population.
Topics: Age Factors; Aged; Atorvastatin; Cohort Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Databases, Factual; Drug Interactions; Enzyme Inhibitors; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Patterns, Physicians'; Primary Health Care; Pyrroles; Retrospective Studies; Simvastatin; United Kingdom | 2012 |
Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland.
Topics: Atorvastatin; Drugs, Generic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Omeprazole; Practice Patterns, Physicians'; Proton Pump Inhibitors; Pyrroles; Scotland; Simvastatin | 2012 |
Simvastatin and atorvastatin attenuate VCAM-1 and uPAR expression on human endothelial cells and platelet surface expression of CD40 ligand.
Topics: Anti-Inflammatory Agents; Atorvastatin; Biomarkers; Blood Platelets; CD40 Ligand; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Lipopolysaccharides; Matrix Metalloproteinase 14; P-Selectin; Platelet Activation; Pyrroles; Receptors, Urokinase Plasminogen Activator; Simvastatin; Thrombin; Vascular Cell Adhesion Molecule-1 | 2012 |
Statins for COPD: a challenge to conventional beliefs?
Topics: Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pulmonary Disease, Chronic Obstructive; Pyrroles; Simvastatin | 2012 |
Pravastatin and simvastatin improves acetylsalicylic acid-mediated in vitro blood platelet inhibition.
Topics: Adult; Aspirin; Atorvastatin; Blood Platelets; Cholesterol; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Young Adult | 2012 |
Statin use and the risk of Clostridium difficile in academic medical centres.
Topics: Academic Medical Centers; Adult; Age Distribution; Aged; Aged, 80 and over; Atorvastatin; Case-Control Studies; Clostridioides difficile; Clostridium Infections; Confidence Intervals; Cross Infection; Databases, Factual; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Logistic Models; Male; Middle Aged; Odds Ratio; Pyrroles; Reference Values; Risk Assessment; Sex Distribution; Simvastatin; United States; Young Adult | 2012 |
[Statin-ezetimibe combination in hyperlipidemia treatment].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Simvastatin | 2012 |
Long-term outcome after statin treatment in routine clinical practice: results from a prospective PCI cohort study.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Cohort Studies; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Survival Rate | 2012 |
Fate and transport of atorvastatin and simvastatin drugs during conventional wastewater treatment.
Topics: Atorvastatin; Biomass; Biotransformation; Heptanoic Acids; Models, Statistical; Molecular Weight; Pyrroles; Reproducibility of Results; Sewage; Simvastatin; Waste Disposal, Fluid; Water Pollutants, Chemical | 2012 |
Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin.
Topics: Anti-Bacterial Agents; Atorvastatin; Drug Resistance, Multiple, Bacterial; Fluorobenzenes; Gram-Negative Bacteria; Gram-Positive Bacteria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microbial Sensitivity Tests; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Cholesteryl ester transfer protein and ATP-binding cassette transporter A1 genotype alter the atorvastatin and simvastatin efficacy: time for genotype-guided therapy?
Topics: Aged; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Biomarkers; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Female; Gene Frequency; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Patient Selection; Phenotype; Polymorphism, Genetic; Precision Medicine; Pyrroles; Simvastatin; Treatment Outcome | 2013 |
Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis--guidelines vs. reality.
Topics: Atherosclerosis; Atorvastatin; Cholesterol, LDL; Decision Making; Diet, Fat-Restricted; Diet, Reducing; Dose-Response Relationship, Drug; Female; Health Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Middle Aged; Patient Compliance; Poland; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Rural Population; Secondary Prevention; Simvastatin; Urban Population | 2012 |
Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cholesterol; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Metabolism; Liver Neoplasms; Lovastatin; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tumor Suppressor Protein p53 | 2012 |
Discontinuation of statin therapy due to muscular side effects: a survey in real life.
Topics: Adult; Aged; Atorvastatin; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Motor Activity; Muscle Cramp; Muscle Weakness; Muscle, Skeletal; Musculoskeletal Diseases; Pain; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2013 |
Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Netherlands; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms.
Topics: Amphetamine; Analysis of Variance; Animals; Atorvastatin; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Glutathione; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Malondialdehyde; Mitochondria; Motor Activity; NADH Dehydrogenase; Nitrites; Oxidopamine; Parkinsonian Disorders; Pyrroles; Rats; Rats, Wistar; Simvastatin; Tetrazolium Salts; Thiazoles; Tumor Necrosis Factor-alpha | 2012 |
Atorvastatin and simvastatin, but not pravastatin, up-regulate LPS-induced MMP-9 expression in macrophages by regulating phosphorylation of ERK and CREB.
Topics: Animals; Atorvastatin; Calcium; Cell Line; Cyclic AMP Response Element-Binding Protein; Extracellular Signal-Regulated MAP Kinases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Macrophages; Matrix Metalloproteinase 9; Mice; Microglia; Phosphorylation; Polyisoprenyl Phosphates; Pravastatin; Pyrroles; Signal Transduction; Simvastatin; Up-Regulation | 2012 |
Statins affect the presentation of endothelial chemokines by targeting to multivesicular bodies.
Topics: Atorvastatin; Cell Compartmentation; Chemokine CXCL1; Chemokines; E-Selectin; Endocytosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-1beta; Intracellular Space; Multivesicular Bodies; Pravastatin; Prenylation; Pyrroles; Simvastatin; Solubility; Subcellular Fractions; Tetraspanin 30 | 2012 |
The evaluation of analgesic effects of simvastatin, pravastatin and atorvastatin in hot plate test.
Topics: Analgesics; Animals; Atorvastatin; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred BALB C; Naloxone; NG-Nitroarginine Methyl Ester; Pravastatin; Pyrroles; Simvastatin | 2012 |
A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Topics: Atorvastatin; Databases, Factual; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tendons; United States; United States Food and Drug Administration | 2012 |
The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins.
Topics: Animals; Atorvastatin; Cell Communication; Disease Models, Animal; Endothelial Cells; Gene Expression; Hepatic Stellate Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Portal; Kruppel-Like Transcription Factors; Liver; Liver Circulation; Liver Cirrhosis, Experimental; Lovastatin; Male; Paracrine Communication; Pyrroles; Rats; Rats, Wistar; Simvastatin; Stress, Mechanical | 2013 |
Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study.
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Atrial Fibrillation; Chi-Square Distribution; Comorbidity; Denmark; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Myocardial Infarction; Polypharmacy; Pravastatin; Propensity Score; Proportional Hazards Models; Pyrroles; Registries; Retrospective Studies; Risk Factors; Sex Factors; Simvastatin; Time Factors; Treatment Outcome | 2014 |
Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Iceland; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reimbursement Mechanisms; Rosuvastatin Calcium; Simvastatin; Social Security; Sulfonamides; Treatment Outcome | 2012 |
Comments on "CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women".
Topics: Cytochrome P-450 CYP3A; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin | 2012 |
Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Pilot Projects; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Pyrroles; Retrospective Studies; Sex Factors; Simvastatin; Triglycerides | 2012 |
Use of secondary preventive medications in patients with atherosclerotic disease in urban China: a cross-sectional study of 16, 860 patients.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Cerebrovascular Disorders; Coronary Artery Disease; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Peripheral Vascular Diseases; Pyrroles; Secondary Prevention; Simvastatin | 2012 |
Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Topics: Adult; Aged; Analysis of Variance; Asian People; Atorvastatin; Biomarkers; Chi-Square Distribution; China; Cholesterol, HDL; Cholesterol, LDL; Cytochrome P-450 CYP3A; Female; Gene Frequency; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Pharmacogenetics; Phenotype; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 2013 |
Lipid-lowering pharmacotherapy in Central and Eastern European countries in cardiovascular prevention: self-reported prescription patterns of primary care physicians.
Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cross-Sectional Studies; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Europe; Female; Health Care Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Physicians, Primary Care; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Risk; Secondary Care; Self Report; Simvastatin | 2013 |
CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control.
Topics: Aged; Atorvastatin; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Female; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pyrroles; Simvastatin | 2013 |
Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin: biochemical regulatory mechanisms.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Blood Platelets; Calcium; Collagen; Cyclooxygenase 1; Drug Combinations; Drug Synergism; Heptanoic Acids; Humans; Mitogen-Activated Protein Kinases; Phospholipase A2 Inhibitors; Phospholipases A2; Phosphorylation; Platelet Aggregation; Pravastatin; Pyrroles; Simvastatin; Thromboxane A2; Thromboxane-A Synthase | 2013 |
The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study.
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Pyrroles; Simvastatin; Treatment Outcome; Vitamin D | 2013 |
Factors associated with statin selection among privately insured commercial and Medicare patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Drug Interactions; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insurance, Health; Male; Medicare; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sex Factors; Simvastatin; Sulfonamides; United States; Young Adult | 2013 |
HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway.
Topics: Acetylcysteine; Acyl Coenzyme A; Animals; Antioxidants; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; DNA Fragmentation; Extracellular Signal-Regulated MAP Kinases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lymphoma; Membrane Potential, Mitochondrial; Mevalonic Acid; Mice; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Reactive Oxygen Species; Signal Transduction; Simvastatin | 2013 |
Statin treatment and diabetes.
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin | 2013 |
How to balance cardiometabolic benefits and risks of statins.
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin | 2013 |
Reply: To PMID 23219296.
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin | 2013 |
Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats.
Topics: Animals; Atorvastatin; Behavior, Animal; Brain; Cognition Disorders; Cyclooxygenase 2 Inhibitors; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Heptanoic Acids; Huntington Disease; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Malonates; Neurons; Neuroprotective Agents; Nootropic Agents; Oxidative Stress; Pyrroles; Rats; Rats, Wistar; Simvastatin; Sulfones | 2013 |
Standards of statin usage in Poland in high-risk patients: 3ST-POL study results.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticholesteremic Agents; Atorvastatin; Cardiology; Cardiovascular Diseases; Cohort Studies; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Utilization; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Outpatients; Patient Compliance; Poland; Population Surveillance; Primary Health Care; Pyrroles; Simvastatin; Surveys and Questionnaires; Treatment Failure | 2013 |
Multilevel analysis of the influence of patients' and general practitioners' characteristics on patented versus multiple-sourced statin prescribing in France.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus; Drug Prescriptions; Drugs, Generic; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; France; General Practitioners; Heart Diseases; Heptanoic Acids; Humans; Indoles; Lipid Metabolism Disorders; Male; Middle Aged; Models, Statistical; Practice Patterns, Physicians'; Pravastatin; Prescription Drugs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2013 |
Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
Topics: Adult; Atorvastatin; Costs and Cost Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Managed Care Programs; Models, Economic; Myocardial Infarction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; United States | 2013 |
Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Cardiovascular System; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Longitudinal Studies; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk; Simvastatin; Treatment Outcome; Young Adult | 2013 |
Exploratory analysis on the use of statins with or without n-3 PUFA and major events in patients discharged for acute myocardial infarction: an observational retrospective study.
Topics: Aged; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Heptanoic Acids; Humans; Kaplan-Meier Estimate; Male; Matched-Pair Analysis; Middle Aged; Myocardial Infarction; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Simvastatin; Treatment Outcome | 2013 |
Effect of statins with α-tricalcium phosphate on proliferation, differentiation, and mineralization of human dental pulp cells.
Topics: Adolescent; Adult; Alkaline Phosphatase; Aluminum Compounds; Atorvastatin; Biocompatible Materials; Biomarkers; Bone Morphogenetic Protein 2; Calcification, Physiologic; Calcium Compounds; Calcium Phosphates; Cell Adhesion; Cell Differentiation; Cell Proliferation; Dental Pulp; Dentin; Drug Combinations; Extracellular Matrix Proteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Odontoblasts; Osteogenesis; Osteonectin; Oxides; Phosphoproteins; Pyrroles; Sialoglycoproteins; Silicates; Simvastatin; Young Adult | 2013 |
Risk of incident diabetes among patients treated with statins: population based study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury.
Topics: Animals; Atorvastatin; Biomarkers; Endotoxins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lung Injury; Male; Mice; Mice, Inbred C57BL; Oxidation-Reduction; Pravastatin; Pyrroles; Simvastatin | 2013 |
Mechanisms of the statins cytotoxicity in freshly isolated rat hepatocytes.
Topics: Animals; Atorvastatin; Cell Death; Cell Survival; Glutathione; Glutathione Disulfide; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lovastatin; Male; Membrane Potential, Mitochondrial; Pyrroles; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Simvastatin | 2013 |
[Statins after drug discontinuation are usually well tolerated].
Topics: Atorvastatin; Cardiovascular Diseases; Cohort Studies; Drug Substitution; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Retreatment; Retrospective Studies; Simvastatin | 2013 |
HMG-CoA reductase inhibitors, simvastatin and atorvastatin, downregulate ABCG1-mediated cholesterol efflux in human macrophages.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Biotinylation; Blotting, Western; Cell Separation; Cells, Cultured; CHO Cells; Cholesterol; Cricetinae; Cricetulus; Down-Regulation; Heptanoic Acids; Humans; Hydrocarbons, Fluorinated; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indicators and Reagents; Lipoproteins, LDL; Liver X Receptors; Macrophages; Orphan Nuclear Receptors; Plasmids; Pyrroles; Real-Time Polymerase Chain Reaction; Simvastatin; Sulfonamides; Transfection | 2013 |
ACP Journal Club. Meta-analysis: Atorvastatin reduces CV events and increases new-onset diabetes in patients with coronary disease.
Topics: Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin | 2013 |
Synergistic effect of combined treatment with gamma-tocotrienol and statin on human malignant mesothelioma cells.
Topics: Apoptosis; Atorvastatin; Caspase 3; Cell Line, Tumor; Cell Proliferation; Chromans; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Enzyme Activation; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mesothelioma; Metabolic Networks and Pathways; Mevalonic Acid; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Simvastatin; Vitamin E | 2013 |
Evidence based policy decisions through a Bayesian approach: the case of a statin appraisal in The Netherlands.
Topics: Atorvastatin; Bayes Theorem; Decision Making; Drug and Narcotic Control; Evidence-Based Medicine; Heptanoic Acids; Humans; Hypolipidemic Agents; Insurance, Health, Reimbursement; Netherlands; Practice Patterns, Physicians'; Pyrroles; Simvastatin | 2013 |
Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.
Topics: Animals; Atorvastatin; Caspase 3; Cell Line; Cell Proliferation; Cell Shape; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Heptanoic Acids; Humans; Lymphangioleiomyomatosis; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Simvastatin; Sirolimus; TOR Serine-Threonine Kinases; Transfection; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2013 |
Prevalence and types of persistent dyslipidemia in patients treated with statins.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Croatia; Cross-Sectional Studies; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prevalence; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2013 |
Long-term use of statins reduces the risk of hospitalization for dementia.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Case-Control Studies; Dementia; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Italy; Logistic Models; Male; Middle Aged; Pravastatin; Pyrroles; Risk; Simvastatin; Time Factors | 2013 |
Characterization of statin dose response in electronic medical records.
Topics: Algorithms; Alleles; Atorvastatin; Cholesterol, LDL; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Electronic Health Records; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Lipids; Phenotype; Polymorphism, Single Nucleotide; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2014 |
The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase.
Topics: Atorvastatin; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Fungal Proteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Isoenzymes; Mevalonic Acid; Organisms, Genetically Modified; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Saccharomyces cerevisiae; Simvastatin; Sterols; Sulfonamides; Terpenes | 2013 |
Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein.
Topics: Adolescent; Adult; Aged; Animals; Atorvastatin; Biological Availability; Heptanoic Acids; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Mice; Mice, Knockout; Middle Aged; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Pravastatin; Pyrroles; Simvastatin; Solute Carrier Organic Anion Transporter Family Member 1B3; Tissue Distribution; Young Adult | 2014 |
Influence of PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms on the lipid-lowering efficacy and safety of statin therapy.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Anticholesteremic Agents; Atorvastatin; Constitutive Androstane Receptor; Dyslipidemias; Female; Genotype; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; PPAR alpha; Pregnane X Receptor; Pyrroles; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Retinoid X Receptor alpha; Risk Factors; Simvastatin; Treatment Outcome | 2013 |
Low level of inflammatory marker in hyperhomocysteinemic patients on statin therapy.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Case-Control Studies; Cells, Cultured; Chemokines; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperhomocysteinemia; Inflammation Mediators; Leukocytes, Mononuclear; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Young Adult | 2014 |
Exploring Leishmania donovani 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) as a potential drug target by biochemical, biophysical and inhibition studies.
Topics: Amino Acid Sequence; Atorvastatin; Cholesterol; Cloning, Molecular; DNA, Protozoan; Drug Delivery Systems; Ergosterol; Gene Expression Regulation, Enzymologic; Genes, Protozoan; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leishmania donovani; Molecular Sequence Data; Open Reading Frames; Protein Structure, Secondary; Pyrroles; Recombinant Proteins; Resveratrol; Sequence Analysis, DNA; Simvastatin; Stilbenes | 2014 |
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Cholesterol, LDL; Databases, Factual; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Managed Care Programs; Middle Aged; Multivariate Analysis; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; United States | 2013 |
Effects of HMG-CoA reductase inhibitors on learning and memory in the guinea pig.
Topics: Amnesia; Animals; Atorvastatin; Behavior, Animal; Guinea Pigs; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Long-Term Potentiation; Male; Maze Learning; Memory; Pyrroles; Simvastatin; Synaptic Transmission | 2014 |
Effects of simvaglyzin and atorvaglyzin on the expression of 3-hydroxy-3-methyl-glutaryl-CoA reductase in rat liver.
Topics: Animals; Atorvastatin; Gene Expression; Glycyrrhizic Acid; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Microsomes, Liver; Pyrroles; Rats; Rats, Wistar; RNA, Messenger; Simvastatin | 2013 |
Comparison of effects of different statins on growth and steroidogenesis of rat ovarian theca-interstitial cells.
Topics: Animals; Atorvastatin; Cell Proliferation; Cells, Cultured; Female; Gonadal Steroid Hormones; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Metabolic Networks and Pathways; Ovary; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Theca Cells | 2014 |
Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cohort Studies; Cytochrome P-450 CYP3A; Female; Gene Frequency; Genetic Association Studies; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; NADPH-Ferrihemoprotein Reductase; Polymorphism, Single Nucleotide; Pyrroles; Simvastatin | 2014 |
Long-term follow-up on the effect of combined therapy of bile acids and statins in the treatment of cerebrotendinous xanthomatosis: a case report.
Topics: Adult; Atorvastatin; Chenodeoxycholic Acid; Cognition; Drug Therapy, Combination; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neuropsychological Tests; Pyridines; Pyrroles; Simvastatin; Treatment Outcome; Xanthomatosis, Cerebrotendinous | 2014 |
Daily administration of atorvastatin and simvastatin for one week improves cardiac function in type 1 diabetic rats.
Topics: Animals; Atorvastatin; Blood Glucose; Cardiac Output; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Administration Schedule; Heart; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Ventricular Function, Left | 2014 |
Oxidative stress and inflammation are differentially affected by atorvastatin, pravastatin, rosuvastatin, and simvastatin on lungs from mice exposed to cigarette smoke.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Inhalation Exposure; Lung; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Smoking; Sulfonamides | 2014 |
Statin treatment is associated with reduction in serum levels of receptor activator of NF-κB ligand and neutrophil activation in patients with severe carotid stenosis.
Topics: Aged; Atherosclerosis; Atorvastatin; Carotid Stenosis; Cohort Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Middle Aged; Neutrophil Activation; Neutrophils; NF-kappa B; Osteopontin; Osteoprotegerin; Pyrimidines; Pyrroles; RANK Ligand; Risk Factors; RNA, Messenger; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2014 |
No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
Topics: Adult; Aged; Alleles; Atorvastatin; Cholesterol, LDL; Drug Administration Schedule; Female; Gene Frequency; Gene-Environment Interaction; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Pyrroles; Simvastatin | 2014 |
Frequency and evolution of thin-capped fibroatheromas in left main coronary artery as assessed by serial virtual histology intravascular ultrasound analysis.
Topics: Aged; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Phenotype; Plaque, Atherosclerotic; Pyrroles; Quinolines; Registries; Retrospective Studies; Simvastatin; Ultrasonography, Interventional | 2014 |
LDL cholesterol variability in patients with Type 2 diabetes taking atorvastatin and simvastatin: a comparison of two formulae for LDL-C estimation.
Topics: Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Drug Monitoring; Half-Life; Heptanoic Acids; Humans; Hypolipidemic Agents; Immunoassay; Prospective Studies; Pyrroles; Simvastatin; Triglycerides | 2015 |
Statin-induced impairment of monocyte migration is gender-related.
Topics: Atherosclerosis; Atorvastatin; Cell Movement; Female; Healthy Volunteers; Heptanoic Acids; Humans; Inflammation; Lipopolysaccharides; Male; Monocytes; Pyrroles; Sex Characteristics; Simvastatin; Tumor Necrosis Factor-alpha | 2014 |
[Renoprotective efficacy of different doses of statins in experimental acute renal failure].
Topics: Acute Kidney Injury; Administration, Topical; Animals; Atorvastatin; Creatine Kinase; Diuresis; Glomerular Filtration Rate; Glycerol; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Lovastatin; Pyrroles; Rats; Rhabdomyolysis; Simvastatin; Stomach; Urodynamics | 2014 |
The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials.
Topics: Adult; Ambulatory Care; Anticholesteremic Agents; Atorvastatin; Databases, Factual; Electronic Health Records; Evaluation Studies as Topic; Feasibility Studies; Female; General Practitioners; Heptanoic Acids; Humans; Male; Middle Aged; Patient Selection; Pragmatic Clinical Trials as Topic; Pyrroles; Simvastatin | 2014 |
Statins increase rifampin mycobactericidal effect.
Topics: Animals; Antitubercular Agents; Atorvastatin; Cell Line; Drug Synergism; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leprosy; Macrophages; Mice; Mice, Inbred BALB C; Mycobacterium leprae; Mycobacterium tuberculosis; Pyrroles; Rifampin; Simvastatin | 2014 |
Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comorbidity; Computer Simulation; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus; Drug Costs; Drug Substitution; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Style; Lipoproteins, LDL; Medicare; Models, Cardiovascular; Nuclear Magnetic Resonance, Biomolecular; Pyrroles; Quality-Adjusted Life Years; Risk; Risk Reduction Behavior; Simvastatin; Treatment Outcome; United States | 2014 |
Evaluation of sexual dimorphism in the efficacy and safety of simvastatin/atorvastatin therapy in a southern Brazilian cohort.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Brazil; Cholesterol; Creatine Kinase; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Myalgia; Prospective Studies; Pyrroles; Sex Factors; Simvastatin | 2014 |
Statin use in Australian children: a retrospective audit of four pediatric hospitals.
Topics: Adolescent; Atorvastatin; Australia; Child; Child, Preschool; Drug Utilization Review; Fluorobenzenes; Heptanoic Acids; Hospitals, Pediatric; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant; Kidney Diseases; Organ Transplantation; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2014 |
Possible association of ABCB1:c.3435T>C polymorphism with high-density-lipoprotein-cholesterol response to statin treatment--a pilot study.
Topics: Aged; Alleles; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; Cholesterol, HDL; Female; Genotype; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Multivariate Analysis; Pilot Projects; Polymorphism, Genetic; Pyrroles; RNA, Messenger; Simvastatin; Triglycerides | 2014 |
Inhibition of protein geranylgeranylation specifically interferes with CD40-dependent B cell activation, resulting in a reduced capacity to induce T cell immunity.
Topics: Antigen Presentation; Atorvastatin; B-Lymphocytes; CD40 Antigens; Dendritic Cells; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Lymphocyte Activation; Mevalonic Acid; Primary Cell Culture; Protein Prenylation; Pyrroles; Signal Transduction; Simvastatin; T-Lymphocytes; Transcriptome | 2014 |
Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Topics: Aged; Atorvastatin; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2015 |
Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.
Topics: Aged; Aged, 80 and over; Atorvastatin; Brazil; Cardiovascular Diseases; Cost-Benefit Analysis; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Economic; National Health Programs; Primary Prevention; Pyrimidines; Pyrroles; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides | 2015 |
Statin use and risk of depression: a Swedish national cohort study.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cohort Studies; Depression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Population Surveillance; Pyrroles; Risk Factors; Simvastatin; Sweden | 2014 |
Role of microRNAs 221/222 on statin induced nitric oxide release in human endothelial cells.
Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cell Survival; Cells, Cultured; Down-Regulation; Endothelium, Vascular; Ezetimibe; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Luminescence; MicroRNAs; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Real-Time Polymerase Chain Reaction; Simvastatin | 2015 |
Liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma.
Topics: Adult; Aged; Atorvastatin; Calibration; Chromatography, Liquid; Heptanoic Acids; Humans; Lovastatin; Middle Aged; Pyrroles; Quality Control; Reproducibility of Results; Simvastatin; Tandem Mass Spectrometry | 2015 |
Trends in statin consumption and cardiovascular mortality in Croatia 2004-2012.
Topics: Adolescent; Adult; Atorvastatin; Cardiovascular Diseases; Child; Child, Preschool; Croatia; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant; Infant, Newborn; Middle Aged; Practice Patterns, Physicians'; Pyrroles; Simvastatin; Young Adult | 2014 |
Switching from high-efficacy lipid-lowering therapies [atorvastatin or rosuvastatin] to simvastatin and the results on low-density lipoprotein cholesterol level.
Topics: Atorvastatin; Drugs, Essential; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Thailand | 2015 |
Achievement of LDL-cholesterol goal with statins after an st segment elevation myocardial infarction.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Cohort Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Thailand; Treatment Outcome | 2015 |
Lovastatin-Mediated Changes in Human Tendon Cells.
Topics: Atorvastatin; Cholesterol; Cytoskeleton; Gap Junctions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pyrroles; Simvastatin; Tendons | 2015 |
Relief of photoallergy: atorvastatin replacing simvastatin.
Topics: Atorvastatin; Dermatitis, Photoallergic; Drug Eruptions; Drug Substitution; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Tests; Male; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2015 |
Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Primary Prevention; Pyrroles; Quinolines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin | 2020 |
SLCO1B1*5 Allele Is Associated With Atorvastatin Discontinuation and Adverse Muscle Symptoms in the Context of Routine Care.
Topics: Alleles; Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Muscles; Polymorphism, Single Nucleotide; Pyrroles; Simvastatin | 2022 |
Effects of Simvastatin on the Metabolism of Vonoprazan in Rats Both in vitro and in vivo.
Topics: Animals; Chromatography, Liquid; Drug Interactions; Microsomes, Liver; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Sulfonamides; Tandem Mass Spectrometry | 2022 |
Drug Eruption From Atorvastatin: With Initial Misdiagnosis of
Topics: Aged; Atorvastatin; Drug Eruptions; Drug Substitution; Exanthema; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin; Tinea cruris | 2023 |
Some pleiotropic effects of statins on hepatocellular carcinoma cells: Comparative study on atorvastatin, rosuvastatin and simvastatin.
Topics: Atorvastatin; Carcinoma, Hepatocellular; Fluorobenzenes; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Pyrimidines; Pyrroles; Reactive Oxygen Species; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2023 |